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ABSTRACT 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease 
characterized by the loss of the motor neurons. One consistent 
neuropathological feature of ALS patients and models of the disease is the 
formation of proteinaceous inclusion bodies; for this reason, alterations in the 
proteolytic ubiquitin-proteasome pathway (UPP) have been suggested to be 
implicated. 
The purpose of this thesis was to analyze the role of the UPP in ALS 
pathogenesis studying the G93A mouse model. The activity of UPP was 
evaluated in G93A mice carrying the Ub076V_GFP reporter protein for 
proteasomal functionality. Furthermore, the expression of different 
constitutive proteasome and immunoproteasome subunits was measured 
during disease progression. 
In symptomatic G93A lumbar spinal cord, a mild increase of Ub076V_GFP 
protein, but not of its transcript, was found in the motor neuronal population 
and was partly associated with high levels of ubiquitin and perikarial presence 
of phosphorylated neurofllam.ents. At the end stage, the increase of the 
reporter protein was prevalent in other neurons besides motor neurons, but 
also the mRNA levels were augmented. 
Constitutive catalytic subunits of the 20S proteasome were reduced in end 
stage G93A lumbar spinal cord, while an increase of their inducible 
counterparts and a decrease of the non-catalytic as subunit were evident at 
the symptomatic phase. Components of 19S and 11 S complexes were 
significantly reduced prior to symptom onset. The changes in proteasome 
composition were accompanied by a substantial increase of glial markers and 
TNFa. 
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-Altogether, these data suggest that a subtle dysfunction of the ubiquitin-
proteasome pathway occurs in the spinal cord of a mouse model of ALS in a 
phase in which the frrst signs of motor impairment are detectable. This pairs 
with alterations in the transcriptional rate of various proteasome subunits, 
resulting in a decrease of constitutive proteasome and an increase of 
immunoproteasome. 
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The existence of clinical conditions characterized by progressive muscular 
weakness and wasting became clearly recognized by the mid 19th century. In 
1869 the famous French neurobiologist and physician Jean-Martin Charcot, 
studying the pathological features of this syndrome, described the 
characteristic alterations of the corticospinal tract and the loss of motor 
neurons and proposed the term amyotrophic lateral sclerosis (ALS). 
"Amyotrophic" refers to the muscle atrophy, weakness and fasciculation that 
derive from the degeneration of the motor neurons, whereas "lateral sclerosis" 
refers to the hardness to palpation of the lateral columns of the spinal cord in 
autopsy specimens, where gliosis follows degeneration of the corticospinal 
tracts. 
The term motor neuron disease (MND) is commonly used in the United 
Kingdom to indicate the ALS syndrome. In the United States, ALS is often 
known as Lou Gehrig's disease after the great baseball player who developed 
this disorder in the 1930s. 
Nowadays, amyotrophic lateral sclerosis is defmed as a progressive and fatal 
neurodegenerative disease resulting from the selective degeneration of upper 
motor neurons (UMN) in the motor cortex and lower motor neurons (LMN) in 
the brain stem and in the spinal cord (Fig. 1.1). When the motor neurons die, 
the nervous system becomes unable to initiate and control muscle movements. 
Because muscles no longer receive the input they need in order to function, 
they gradually weaken and deteriorate, producing deep atrophy. 
ALS is the most frequent of the motor neuron disorders, representing 85-90% 
of cases of this kind of pathologies. The majority of ALS patients present a 
sporadic form (sporadic ALS, sALS) but in 5-10% of cases the disease is 
inherited (familial ALS, fALS). 
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Regrettably, at the moment, no primary therapy for this disorder is available 
and the only drug approved for its treatment (riluzole) only slightly promotes 
survival; therefore symptomatic measures are the mainstay of management of 
ALS. 
Motor cortex 
Spinal cord 
Oroph nno aI 
motor 
neurone 
Medulla 
CeN1CClI 
"pon"l r.tlm 
Th()(3C1C 
5plnalcord 
lumbar 
spinal cord 
Figure 1.1 The human motor system. Adapted from Rowland L.P. and Shneider NA, N. Eng!. J. Med., 2001. 
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1.1 CLINICAL PHENOTYPE OF AMYOTROPHIC LATERAL 
SCLEROSIS 
By defmition, the features of ALS are signs and symptoms of lower motor 
neuron dysfunction associated with upper motor neuron dysfunction. LMN 
involvement determines weakness and fatigue, associated to progressive 
muscular atrophy, fasciculation (muscular twitching and shaking of 
contiguous groups of muscle fibers) and fibrillation (muscular twitching and 
shaking involving individual muscle fibers acting without coordination), 
reduced muscle tone and absence of tendon reflex. UMN involvement causes 
weakness, incoordination, stiffness and slowing of movement, with spasticity 
(persistent contraction of muscle), increased tendon reflexes, clonus 
(alternating contractions and relaxations) and extensor plantar responses. 
ALS probably begins a long time before its clinical manifestations, given that a 
substantial number of motor neurons can be lost before any clinical signs 
develop. In fact, several studies on animal models have shown that motor 
neuron dysfunction precedes the onset of symptoms and that compensatory 
reinnervation from nearby motor neurons permits a good maintenance of the 
motor function, although with an enlargement of motor units, until more than 
50% of motor units have been lost; at this point symptoms appear and the 
number of motor units declines rapidly (Cote et al., 1993; Kennel et al., 1996). 
No neuropathological, neurophysiological or biochemical markers are yet 
available to identify a patient as potentially susceptible for ALS prior to 
symptom onset. 
The different extent and localization of motor system involvement determines 
various early clinical features in different patients but ultimately, as the 
25 
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disorder progresses, the clinical expression of ALS is quite uniform, with 
extreme muscular wasting, spasticity and paralysis. 
At the onset, ALS presents with lower motor neuron involvement, upper motor 
neuron involvement or bulbar involvement. Limb onset is the most frequent, 
and is found in 75-80% of cases, while bulbar onset is evidenced in only 20-
25%. The most common initial presentation of ALS is focal asymmetric distal 
weakness and muscular atrophy. For example, the patient may present 
himself with a history of unexpected tripping, dragging of a foot and ultimately 
more diffuse weakness of the leg. Difficulty with buttoning clothes, turning 
keys in doors or simply poor coordination while performing fme movements 
are the symptoms of involvement of upper limbs. Bulbar motor neuron 
degeneration leads to difficulty in swallowing (dysphagia) and speaking or 
forming words (dysarthria), associated to fasciculation of the tongue. Bulbar 
signs are often closely related to respiratory deficits, due to the involvement of 
diaphragmatic muscular weakness. This leads to a poor prognosis and to a 
shorter life expectancy. 
With the progression of the illness, the disease spreads to contiguous muscle 
segments. The progressive loss of motor function results in increasing 
disability and paralysis, ultimately leading to a bed-bound state. 
Recent fmdings have revealed that the selectivity of ALS for the motor system 
is not absolute. In fact, some reports describe cognitive impairment in a 
subgroup of ALS patients. A battery of neuropsychological tests has shown a 
cognitive impairment in about 30% of ALS patients, ranging from mild 
impairment to frontotemporal lobar degeneration (FI'LD). The main symptoms 
are executive dysfunction with deficits in verbal and non-verbal fluency and 
concept formation (Lomen-Hoerth et aI., 2003; Kilani et aI., 2004; Abrahams et 
aI., 2005; Schreiber et aI., 2005; Rippon et aI., 2006). However, in the majority 
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of the cases, the rate of cognitive decline is very slow as compared to the 
devasting motor deterioration. 
Respiratory deficits, due to the progressive atrophy of respiratory muscles, 
appear during the progression of the disease. When respiratory muscle activity 
is insufficient, patients need to use mechanised ventilatory support. 
Respiratory failure fmally leads to the death of almost all ALS patients without 
mechanised assistance. 
In 50% of cases the death occurs within three years from diagnosis. 
1.2 DIAGNOSIS OF AMYOTROPHIC LATERAL SCLEROSIS 
Diagnosis of ALS is often critical, since many different clinical conditions may 
resemble this disease. To date, no test or specific marker can provide a 
definitive diagnosis of ALS; thus, it is primarily based on the symptoms and 
signs that the physician observes in the patient and on a series of tests to rule 
out other diseases. 
Criteria for clinical and pathological diagnosis have been defined during the 
ALS meeting held in EI Escorial, Spain, in 1994 and updated at Airlie House, 
Virginia, four years later. 
Based on these criteria, the diagnosis of ALS requires the presence of: 
1) evidence of LMN degeneration by clinical, electrophysiological or 
neuropathological examination, 
2) evidence of UMN degeneration by clinical examination, and 
3) progressive spread of symptoms or signs within a region or to other 
regions, as determined by history or examination, 
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together with the absence of: 
1) e1ectrophysiological and pathological evidence of other disease 
processes that might explain the signs of LMN and/ or UMN 
degeneration, and 
2) neuroimaging evidence of other disease processes that might explain 
the observed clinical and electrophysiological signs. 
As shown in table 1.1, the EI Escorial scale classifies the probability of a 
patient having ALS according to the degree of clinical certainty in relation to 
other pathologies. It includes four degrees of certainty for the diagnosis of ALS. 
A careful history, physical and neurological examination must search for 
clinical evidence of UMN and LMN signs in four regions (brainstem, cervical, 
thoracic or lumbosacral spinal cord) of the central nervous system (eNS). 
LEVEL OF CERTAINTY CHARACTERISTIC FEATURES 
UMN and LMN signs together in one region; or 
Clinically Possible ALS 
UMN signs in two or more regions; or 
UMN and LMN signs in two regions with no UMN signs 
rostral to LMN signs 
Clinically Probable -
UMN and LMN dysfunction in only one region; or 
UMN signs alone are present in one region, and LMN 
Laboratory supported 
signs defined by electromyography criteria are present 
ALS 
in at least two regions 
Clinically Probable UMN and LMN signs in at least two regions with some 
ALS UMN signs rostral to LMN signs 
Clinically Definite ALS .. UMN as well as LMN signs in three regions. 
Table 1.1: El Escorial scale for ALS diagnosis 
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1.3 EPIDEMIOLOGY OF AMYOTROPHIC LATERAL SCLEROSIS 
ALS is considered as a rare disease: it occurs in about 1-3 people per 100,000 
per year with a prevalence (number of surviving patients at any given time) of 
about 5-7 per 100,000. However, its personal and socioeconomic impact is 
greater and it has been calculated that its lifetime risk is approximately 1 in 
1000 (McGuire et al., 1996; Mitsumoto et al., 1998). The frequency of ALS 
appears to have been rising moderately over the past 50 years. Although this 
rise may indicate the increasing effect of some unidentified exogenous factors, 
more probably it simply reflects the greater life expectancy of the population, 
which allows longer survival of a subpopulation susceptible to ALS. 
The average survival for sporadic ALS patients is approximately 3-5 years after 
the frrst symptoms. Onset of ALS in patients younger than 50 years of age is 
generally associated with a longer survival. 
The incidence of ALS increases with age (Kurtzke, 1991), with a peak 
occurring between 55 and 75 years of age; therefore, aging is the most 
significant risk factor. 
ALS occurs predominantly in males, with a male to female ratio of 1.4 to 2.5; 
however, with increasing of age, this difference tends to diminish (Kurtzke, 
1991). 
Environmental risk factors are inconsistently reported in ALS; this may reflect 
a complex interaction between several environmental risk factors and specific 
genetic susceptibilities. 
People of all races and ethnic backgrounds are affected by ALS and, with the 
exception of specific endemic areas in the Western Pacific, its worldwide 
frequency is uniform. Four geographic areas with a high prevalence 
(approximately 100-150 fold higher than the other regions) of ALS are 
described (Kurland and Molgaard, 1982; Oyanagi and Wada, 1999): 
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• Guam and Rota islands 
• 2 areas in the Kii peninsula 
• Irian Jaya (Indonesia) 
• Area of the Gulf of Carpentaria (North Australia) 
Western Pacific ALS is considered a distinct disease because it is often 
associated to Parkinsonism dementia, with pathological alterations resembling 
Alzheimer's disease (neurofibrillary tangles). This syndrome is not considered 
further in this thesis. 
Although familial ALS is almost indistinguishable from the sporadic form in 
terms of clinical phenotype, some features differentiate it from an 
epidemiological point of view (Mitsumoto et al., 1998). The average onset of 
fALS cases is approximately 47 years, a decade earlier than the sporadic type, 
and the mean survival is shorter; moreover, it occurs equally in males and 
females. Finally, in fALS, symptoms more frequently begin in the lower 
extremities compared to sporadic ALS. 
1.4 NEUROPATHOLOGY OF AMYOTROPHIC LATERAL SCLEROSIS 
Immunohistochemical and ultrastructural studies performed on post mortem 
tissues of ALS patients have helped to describe better the neuropathology of 
the disease. However, post-mortem examinations are conducted on tissues 
representing the fmal stage of the pathology; thus the alterations observed 
reflect a very advanced state of neuronal degeneration and give little 
information about the triggering events causing the cell death. It is also true 
that patients have different degrees of neuronal degeneration in various areas 
of their central nervous system; for example, many patients with aggressive 
form of bulbar onset ALS at the time of death often have relatively spared 
motor neurons in the spinal cord. 
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1.4.1 Motor system pathology 
The major pathological features of ALS are: 
I. Upper motor neuron abnormalities 
II. Myelin pallor in the corticospinal tracts 
III. Reduction in both size and number of lower motor neurons in the spinal 
ventral horns and in the bulbar nuclei. 
I. UIIN involvement 
Upper motor neurons are defmed as the neurons, localized in the motor 
cortex, that exert supranuclear control over lower motor neurons. 
The degree of degeneration observable at autopsy in the motor cortex of ALS 
patients is quite variable and may not be always evident, even in the presence 
of clear upper motor neuron signs. In the most severely affected cases, an 
evident loss of giant Betz cells in cortical layer 5, associated with an extensive 
astrogliosis and microgliosis, is reported. Since there are not good markers to 
distinguish upper motor neurons and other pyramidal cell types in the cortex, 
the identification of the Betz cell is often based on morphological and size 
criteria. Neuron cell bodies appear atrophied (Kiernan and Hudson, 1991), 
with shorter fragmented dendrites (Hammer et al., 1979). Intracellular 
alterations are rarely identified in the spared Betz cells in classical ALS; 
occasionally, ubiquitinated neurofllament inclusions are reported. 
Pathological changes are rarely evident in somatosensory cortex, prefrontal 
cortex and premotor areas (Kiernan and Hudson, 1991). 
II. Corticospinal tract alterations 
Axonal degeneration of the descending corticospinal tract results in clear 
demyelination of the tract. As a consequence, the spinal cord of ALS cases 
shows a pallor with myelin stain. Corticospinal fibers also show marked 
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axonal swelling and spheroids (Chou, 1992). An extensive gliosis is present, 
causing the typical sclerosis of lateral spinal cord tracts. 
m. LIIN involvement 
Loss of large motor neurons localized in the lower brain stem and in the spinal 
cord is clearly observed at autopsy. Shrinkage and atrophy of the cell body 
precede neuronal death (Kiernan and Hudson, 1991); the phenomenon is 
associated with alterations of axon and dendrite structures, which become 
thinner (Nakano and Hirano, 1987). 
Certain motor neuron groups, such as those controlling eye movements and 
the Onuf's nucleus of the sacral spinal cord (that regulates the pelvic floor 
musculature) are largely spared by the disease. 
The remaining motor neurons present several abnormalities, listed below. 
Ubiquitinated inclusions 
Ubiquitin-positive inclusions are found very frequently in the susceptible LMN 
groups of the spinal cord and brainstem of most cases and are defmed as 
skein-like inclusions or Lewy body-like accumulations. The frrst are a specific 
hallmark of ALS whereas Lewy body-like inclusions are found also in other 
disorders. Both inclusions probably represent two different morphological 
stages of protein aggregation, from diffuse filamentous forms to dense and 
compact inclusions. Besides phosphorylated neurofllaments and ubiquitin, 
Lewy body-like inclusions also contain cyc1in-dependent kinase 5 (CDKS) 
(Nakamura et al., 1997); dorfm, a RING fmger-type E3 ubiquitin ligase, has 
also been found (Hishikawa et al., 2003). More recently, the nuclear factor 
TDP-43 (TAR-DNA-binding protein 43) has been identified as a major 
component of ubiquitinated inclusions in sporadic ALS cases (Neumann et al., 
2006); TDP-43 is thought to function as a regulator of transcription and 
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alternative splicing (Buratti and Baralie, 2001; Buratti et al., 2004; Mercado et 
al.,2005). 
Ubiquitin-positive inclusions are localized both in normal appearing motor 
neurons and in some shrunken cells. 
Bunina bodies 
Bunina bodies are described as smali, eosinophilic, irregularly shaped 
inclusions localized in the soma of motor neurons; probably they have a 
lysosomal derivation (Sasaki and Maruyama, 1993). At the ultrastructural 
analysis, they appear like electron-dense, amorphous structures surrounded 
by vesicles, endoplasmic reticulum (ER) fragments, lipofuscin granules and are 
shown to contain cystatin C. 
Bunina bodies are reported to be present in 30-50% of cases; since they are 
not described in other disorders, they seem to be specific for ALS. Their 
pathogenesis and their relationship to neurodegeneration have not yet been 
unravelled. 
Hyaline conglomerate inclusions 
Hyaline conglomerate inclusions consist of large aggregates of phosphorylated 
and non phosphorylated neuromaments associated with other "entrapped" 
cytoplasmic proteins and organelles (Schochet et al., 1969; Leigh et al., 1989; 
Sasaki and Maruyama, 1991). They have been identified in sporadic and 
familial ALS; however, they seem to be less specific for this pathology, since 
they have been found in other neurological disorders (Sobue et al., 1990). 
Globules and spheroids 
Phosphorylated neuromaments are also found packed in axonal swellings in 
the anterior horns of ALS patients (Corbo and Hays, 1992; Toyoshima et aI., 
1998). 
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Spheroids are larger and tend to be localized in proximal axons and dendrites, 
while globules are smaller and usually are more peripheral in the ventral horn. 
Both are presumed to represent focal abnormalities of axonal cytoskeletal 
regulation with a failure of axonal transport. 
Diffuse somatic phosphorylation ofneurofilaments 
Diffuse accumulation of phosphorylated neuromaments has been observed in 
the perikarya of motor neurons, especially in sporadic ALS (Hirano et al., 
1984). 
Golgi fragmentation 
Both upper and lower motor neurons of ALS cases show signs of 
fragmentation of the Golgi apparatus, that is dispersed into numerous small 
isolated elements (Mourelatos et al., 1994; Fujita and Okamoto, 2005). 
Mitochondrial alterations 
In recent years, morphological alterations of mitochondria in the motor 
neurons of ALS patients have been observed. These include dense 
conglomerates of aggregates, dark mitochondria, swelling and vacuolization 
(Hirano et al., 1984; Swerdlow et al., 1998). 
VI. Involvement of other cell types 
Remarkable morphological and neurochemical evidence demonstrates the 
proliferation and activation of the microglial and astrocytic populations in the 
areas characterized by motor neuronal loss (Kawamata et al., 1992). 
The concept of selective motor neuronal death has been challenged by studies 
reporting the loss of small neurons in the spinal cord of ALS cases (Oyanagi et 
al., 1989; Raynor and Shefner, 1994). In a recent report by Stephens and 
colleagues, the morphometric examination of the lumbar spinal cord of 
sporadic ALS patients revealed a substantial loss of ventral interneurons in 
addition to motor neurons. Therefore, the interneuronal population may 
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degenerate to a similar extent and contemporary with the motor neuronal one 
(Stephens et al., 2006). 
1.4.2 Non-motor system pathology 
Autopsy examination revealed in some ALS patients alterations in extra-motor 
regions of the eNS, such as in the sensory system (Hudson, 1981), substantia 
nigra and hippocampus (Wharton, 2003). 
1.4.3 Non-eNS pathology 
Profound atrophy of the skeletal muscles is one of the earliest pathological 
changes in ALS patients (Mitsumoto et al., 1998). Other alterations are 
reported in the skin, in which the collagen cross-linking results altered (Kolde 
et al., 1996). 
1.5 GENETICS OF AMYOTROPHIC LATERAL SCLEROSIS 
ALS is considered a multifactorial disease, with a complex interaction between 
genetic and environmental factors. 
As already explained, in 90-95% of ALS cases, there is no apparent genetic 
linkage (sporadic ALS), but in the remaining 5-10% the disease is inherited 
(familial ALS); the transmission is, in most cases, dominant, with rare cases of 
recessive inheritance. 
1.5.1 Mendelian genetics of ALS 
SO far, as shown in table 1.2, five mendelian gene defects have been reported 
to cause ALS (Pasinelli and Brown, 2006). 
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Genomic 
fALS type Gene Clinical features 
region 
Mendelian genes 
ALS l SOD1 21q22 
Autosomal dominant; typical ALS 
ALS2 ALS2 2q33 
Autosomal recessive; juvenile onset, 
slowly progressive form 
ALS4 SETX 9q34 
Autosomal dominant; juvenile onset, 
slowly progressive non-fatal form 
ALS8 VAPB 20q13 
Autosomal dominant; heterogeneous 
disease phenotype 
Autosomal dominant; adult onset, slowly 
ALS Dynactin 2p13 progressive form with vocal cord 
paralysis 
Autosomal dominant, frontotemporal 
FTDP Tau 17q21 dementia and parkinsonism with some 
amyotrophy 
Mendelian loci 
Autosomal dominant 
ALS3 Unknown 18q21 
ALSS Unknown 1Sq12-21 
Autosomal recessive; juvenile onset, 
slowly progressive 
Autosomal dominant 
ALS6 Unknown 16q12 
Autosomal dominant 
ALS7 Unknown 20p13 
Autosomal dominant; ALS associated 
ALS-FTD Unknown 9q21-22 
with frontotemporal dementia (FTD) 
Unknown 
Autosomal dominant; ALS associated 
ALS-FTD 9p 
with frontotemporal dementia 
Table 1.2: Mendelian genetics of ALS 
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The protein products of these mutated genes are: 
• ALSI: Cu,Zn superoxide dismutase (SODI): 
In 1993, Rosen and colleagues reported that mutations in the gene coding 
for the soluble, cytoplasmic enzyme CU,Zn superoxide dismutase (SOD1) 
were associated with a subset of familial ALS patients (Rosen et al., 1993). 
This is the most common form of inherited ALS, accounting for about 20% 
of all familial ALS forms and corresponding to 2-3% of all ALS cases. 
SOD1 is a 153 amino acid, cytoplasmic homodimer that converts 
superoxide, produced as a by-product of oxidative phosphorylation, to 
oxygen and hydrogen peroxide; it is very abundant, representing up to 2% 
of the soluble proteins of the brain. 
To date, more than 125 mutations have been identified in SODI gene and 
are localized in all the five exons, with no region of the polypeptide 
escaping from disease-causing mutations; 114 of them result in amino acid 
substitution and are known to cause the disease, whereas six silent 
mutations and five intronic variants do not. Although most mutations are 
missense, 12 are nonsense or deletion mutations that produce a truncated 
protein (Andersen et al., 2003). Fig. 1.2 shows human SOD1 three-
dimensional structure and some mutations that cause ALS. All mutations 
are associated with autosomal dominant fALS, except for D90A and D96N, 
which can cause both dominant and recessive ALS (Andersen et al., 1995; 
Robberecht et al., 1996; Orrell, 2000). The most frequent SOD1 mutation is 
A4V. 
Penetrance, clinical manifestations, age of onset, disease progression and 
survival vary greatly among specific mutations. For example, A4V and A4T 
are associated with an aggressive fALS type, (Aksoy et al., 2003), while slow 
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progression over 10-15 years is reported for mutations such as G37R, 
D90A, G93C and G93V (Arisato et al., 2003). 
It was initially proposed that the toxicity of mutated SOD1 was associated 
with the loss of superoxide dismutase activity. However, most mutated 
SOD1 forms appear to fully retain their enzymatic property. The creation of 
transgenic mice expressing SOD 1 with some of the mutations found in the 
human patients, which develop a motor syndrome similar to human ALS, 
showed that the catalytic activity is unchanged or elevated (Gurney et al., 
1994; Ripps et al., 1995; Wong, 1995; Bruijn et al ., 1997). Furthermore, 
SOD 1 knockout mice do not develop spontaneous motor neuron disease 
(Reaume et al. , 1996). The conclusion is that SOD1 mutants acquire one or 
more toxic properties, irrespective of the amount of superoxide dismutase 
activity that each of them retains. 
H~ 
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Figure 1.2 Position of some SOD1 mutations in the three-dimensional structure of human SOD1 . 
• ALS2: alsin 
A new gene linked to a rare, recessively inherited form of ALS characterized 
by juvenile onset and slow progression has been identified in 2001 (Hadano 
et al., 2001; Yang et al., 2001); ALS2 variant is distinguished by the 
predominance of spasticity of facial and limb muscles. The ALS2 gene is 
38 
Ciapter 1: OVerall introtf'uaion 
localized to chromosome 2 and encodes a 184 KDa protein named alsin. 
Alsin is ubiquitously expressed and is abundant in neurons, where it is 
localized to the cytosolic portion of the endosomal membrane. The amino-
terminal region of alsin contains sequence motifs that are characteristic of 
guanine exchange factors (GEFs), involved in the recycling of a specific 
small G protein from its GOP-bound state to its GTP-state. The carboxy-
terminal half of alsin contains two further domains, which are similar to 
those of the Rho G-protein family that modulates dynamic actin assembly. 
The function of alsin is not fully understood, but it is known that it acts as 
exchange factor for the small GTPase Rab5a in vitro (Otomo et al., 2003; 
Topp et al., 2004), suggesting a possible involvement in the organization of 
the cytoskeleton and in vesicle trafficking. In addition, alsin can interact 
with the small Rho GTPase Rac1 (Topp et al., 2004; Tudor et al., 2005). 
Interestingly, alsin is also able to bind specifically to different mutant 
variants of SODI through the RhoGEF domain (Kanekura et al., 2004) and, 
in a cell culture paradigm, it has been shown to suppress mutant SOOl 
toxicity. 
All the disease-causing alsin truncation mutations are highly unstable 
(Hadano et al., 2001); this has led to the hypothesis that the disease is 
caused by loss of activity of the protein. 
• ALS4: 8enat8ldD. (SETX) 
The gene encode a 303 KDa protein that contains a DNA/RNA helicase 
domain with strong homology to human RENT 1 and IGHMBP2, two 
proteins known to have roles in RNA processing (Chen et al., 2004). 
Missense mutations in SETX cause an autosomal dominant, juvenile onset 
motor neuron disease with very slow progression of distal limb atrophy and 
motor neuron loss; the lifespan is not reduced. 
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• ALBS: vesicle-associated membrane proteiD B (V APB) 
VAPB gene encodes a ubiquitously expressed homodimer, which belongs to 
a family of intracellular vesicle-associated/membrane-bound proteins that 
can associate with microtubules and are presumed to regulate vesicle 
transport. In particular, VAPB has been shown to act during the transport 
through the endoplasmic reticulum, Golgi apparatus and secretion. The 
P56S mutation dramatically disrupts the sub-cellular distribution of VAPB 
and induces the formation of intracellular protein aggregates (Nishimura et 
al.,2004). 
• DynactiD 
This protein is a component of the dynein complex, implicated in the 
retrograde axonal transport of organelles and proteins. Dominantly 
transmitted mutations cause an adult onset, slowly progressive atypical 
motor neuron disorder with vocal cord paresis. The mutations appear to 
affect the binding of the dynactin-dynein motor to microtubules. 
• FTDP: Tau 
Tau is a member of the microtubule-associated protein family, which has 
the principal functions of stabilizing microtubules and promoting their 
assembly by binding to tubulin. In addition, tau is likely to regulate motor 
protein-mediated transport of vesicles and organelles along the 
microtubules by modulating their stability (Sato-Harada et al., 1996; 
Ebneth et al., 1998). In frontotemporal dementia with parkinsonism 
(Fl'DP), the mutation of tau gene affects the alternative splicing of exon 10, 
resulting in an excess of four repeat tau isoforms; this may cause a 
reduced binding of tau to microtubules in axons. No pure ALS case has 
been associated with tau mutations. 
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Although all these forms have in common the degeneration of motor neurons, 
only ALS 1 represents the classic late-onset neurodegenerative disease with 
selective death of upper and lower motor neurons. 
Besides these genes, other loci linked to ALS have been identified and are 
reported in table 1.2. 
1.5.2 Susceptibility genes 
Susceptibility genes are defmed as genes that can potentially contribute to the 
development of ALS; in other words, mutations in these genes may lead to ALS 
interacting with other genetic or environmental risk factors. 
Among the genetic alterations that may confer a higher predisposition to the 
development of ALS, have been described mitochondrial DNA micro deletions 
encoding for cytochrome-C oxidase (Borthwick et al., 1999), RNA processing 
errors in the glutamate transporter EAAT2 (Excitatory Amino Acid 
Transporter) (Lin et al., 1998), an abnormal copy number of the survival motor 
neuron gene (Corcia et al., 2002) and gene deletions of the chromosome 5q13-
linked neuronal apoptosis inhibitory protein gene (Jackson et al., 1996). An 
increased frequency of the cytochrome P450 debrisoquine hydroxylase 
CYP2D6(B) allele, encoding a cytochrome P450 mono oxygenase involved in 
drug metabolism and associated with a "poor metabolizer" phenotype, has 
been also reported (Siddons et al., 1996). Frequently, these alterations were 
described in only few cases or the results of different studies are conflicting. 
Some evidence suggests that vascular endothelial growth factor (VEGF) acts as 
a modifier of ALS in both human and mice. In a study conducted by 
Oosthuyse et al., ALS-like symptoms and neuropathology were observed in 
mice bearing a targeted deletion that eliminates the ability of VEGF gene to 
respond to tissue hypoxia (Oosthuyse et al., 2001). These mice show a normal 
baseline expression of VEGF, but have a pronounced deficit in the ability to 
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induce it in response to hypoxia. The motor deficits appear between 5 and 7 
months of age and gradually progress; various classical features of ALS are 
observed, such as accumulation of neuromaments in the motor neurons, 
degeneration of motor axons and muscle atrophy. As regards to the human 
pathology, in a large European study three single nucleotide polymorphisms in 
the promoter region of the VEGF gene have been associated with an overall 
1.B-fold increased risk of developing ALS. The promoter variants in the VEGF 
gene in these patients coincided with reduced levels of plasma VEGF 
(Lambrechts et al., 2003). 
Also neuromament variants are probable modifying risk factors in sporadic 
ALS and may modulate disease expression. A set of small in-frame deletions or 
insertions in the repetitive tail domain of the large neuromament subunit NF-
H has been identified in about 1% of 1,300 sporadic ALS patients examined 
(Al-Chalabi et al., 1999). Although the known neuromament sequence variants 
are not responsible by themselves for producing disease with high penetrance, 
it is likely that they are at least important risk factors for apparently sporadic 
disease. 
The studies that link sALS to particular genetic variants so far known account 
only for a small number of the total cases; the causes could be a complex 
pattern of inheritance with very low penetrance, a high degree of heterogeneity 
and/ or the existence of environmental factors predisposing to ALS. In 
conclusion, high genetic heterogeneity and complex interactions between 
genetic and environmental factors are the main obstacles in the process of 
fmding new ALS genetic determinants. 
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1.6 EXPERIMENTAL MODELS OF AMYOTROPHIC LATERAL 
SCLEROSIS 
One of the major breakthroughs in the field of ALS research derives from the 
development of animal models of disease, that proved useful both for the study 
of pathogenetic mechanisms and to test potential pharmacological 
approaches. 
Histopathological studies performed on post-mortem tissues obtained from 
ALS patients at autopsy may give important information about the status of 
motor neurons and other cells involved in the pathology at the final stage of 
the disease, but they provide a poor contribution to the understanding of the 
pathogenic mechanisms. Thus, the study of experimental models of ALS is 
useful to investigate the triggering events occurring earlier in the pathology. 
Nowadays, many models of motor neuron degeneration have been discovered 
or developed. However, even if some of them are associated with gene 
mutations found in human ALS or considered risk factors for the disease, they 
recapitulate only some of the features of the human disease. 
Nevertheless, these models may provide useful insights in deciphering the 
mechanisms of selective motor neuron degeneration as potential therapy 
targets. 
1.6.1 Spontaneous models of ALS 
Mice carrying naturally occurring mutations on identified or unidentified 
genes provide animal models of motor system impairment. 
I. MND mouse 
MND (motor neuron degeneration) is a spontaneous, dominant mutation 
localized to chromosome 8 in the coding region of the gene e1n8, belonging to 
the family of neuronal ceroid lipofuscinose-related genes (Ranta et al., 1999). 
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MND mice exhibit an adult-onset, progressive deterioration of motor function 
with spastic paralysis moving from caudal to cranial spinal cord levels. They 
undergo a premature death at 10-12 months (Messer et al., 1987). However, 
the number of choline acetyl transferase (ChAT) immuno-positive lumbar 
motor neurons is not different from normal mice (Mennini et al., 2002). 
Neuropathological hallmarks are inclusion bodies containing ubiquitin, 
mitochondrial alterations, lipofuscin accumulation and neurofilament 
abnormalities. However, the presence of abnormal autofluorescent cytoplasmic 
inclusions rich in lipofuscin found in neurons, as well as in many other 
somatic organs, makes these animals a useful model for human neuronal 
ceroid lipofuscinosis rather than for ALS (Bronson et al., 1993). 
II. PMN mouse 
PMN (paralyse natural mutant) mice carry a recessive mutation on 
chromosome 13, (Brunialti et al., 1995). Two groups identified the PMN 
mutation as a Trp to Gly substitution at the last residue of the tubulin-specific 
chaperone protein (Bommel et al., 2002; Martin et al., 2002), that is essential 
for the proper tubulin assembly and for the maintenance of microtubules in 
motor axons. Distal axonopathy with paralysis of the limbs and muscular 
atrophy are the most relevant clinical signs, while motor neuron cell bodies 
and proximal axons are relatively preserved (Schmalbruch et al., 1991). 
Symptomatic phase begins at 2 weeks of age and evolves rapidly to death. 
m. Wasted mouse 
It carries a recessive mutation on chromosome 2, in the gene coding for the 
translational elongation factor eEF1A2 (Chambers et al., 1998). 
The symptom onset is around 2 weeks of age and the progression is very fast, 
leading to death within a month. Spinal and brain stem motor neurons are 
lost, while UMN are not affected (Doble and Kennel, 2000). 
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IV. Wobbler mouse 
The wobbler mouse represents another model of motor neuron disease 
(Mitsumoto and Bradley, 1982). It shows a progressive forelimb weakness and 
atrophy, accompanied by a marked decrease of muscular strength and motor 
ability; the symptoms are associated with proximal axonal degeneration and 
vacuolar changes within the motor neurons of the cervical spinal cord with 
little involvement of the brain. 
In this case, the autosomal recessive genetic defect responsible for this 
syndrome has been mapped on chromosome 11 and it has recently been 
identified as a missense mutation in a Vacuolar Vesicular Protein Sorting (Vps 
54) involved in the transport of vesicles from late endosomes to Golgi 
apparatus (Schmitt-John et al., 2005). 
V. lOID mouse 
Mice showing neuromuscular degeneration, with autosomal recessive 
mutation localized on the gene coding for the ATPase/DNA helicase have been 
described (Cook et al., 1995; Cox et al., 1998). Called NMD (neuromuscular 
degeneration) mice, they present rapidly progressive hind limb weakness and 
motor neuron cell body degeneration and have a life span that range from 2 to 
20 weeks. 
1.6.2 Artificial models of ALS 
The discovery of mutations linked with fALS has made possible the 
development of etiological models of the disease. 
I. SODl mutant mice 
To obtain transgenic mice, exogenous genes are introduced by microinjection 
of purified DNA in the male pronucleus of fertilized mouse eggs. The 
integration of foreign DNA is random, with multiple copies of DNA usually 
integrating at a single site. Using the above described technology, several 
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transgenic mouse strains were created by the introduction of the sequence 
coding for human mutant SOD 1 under the control of a promoter that enables 
ubiquitous expression of the transgene (Shibata, 2001). Investigators have 
generated different lines over-expressing human SOD 1 with G93A, G37R or 
G85R mutations (Dal Canto and Gurney, 1994; Wong, 1995), or mouse SOD1 
with G86R mutation (Ripps et al., 1995). These animals develop a phenotype 
that closely resembles ALS, with an adult onset progressive motor paralysis, 
muscle wasting and reduced lifespan. Pathological changes mainly consist of 
depletion of motor neurons in the spinal cord, atrophy, gliosis, axonal swelling 
and presence of ubiquitin-positive inclusions. By contrast, mice over-
expressing wild type SOD 1 remain clinically normal, although some changes 
have been reported at two years of age (Jaarsma et al., 2000). 
Transgenic mice carrying 23 copies of human SOD 1 with Gly93Ala mutation 
(G93A mice) are considered the standard model of ALS in therapeutic studies 
(Bendotti and Carri, 2004). The model develops a motor system disease 
prevalently affecting lower motor neurons. Ultrastructural and microscopical 
analysis reveals that the earliest pathological sign in these mice is the 
vacuolization of large neurons in the anterior horns of the spinal cord 
(Bendotti 2001); it has been hypothesized that these vacuoles originate from 
the dilation of rough endoplasmic reticulum and from degenerating 
mitochondria. At the end stage, motor neuronal depletion is evident and 
hyaline, filamentous inclusions immuno-positive for ubiquitin and 
neurofllaments are present in some of the surviving neurons (Gurney et al., 
1994; Migheli et al., 1999). 
Transgenic mice expressing low levels of SOD1 G37R mutant show a motor 
disease restricted to lower motor neurons, whereas higher copy number 
causes more severe abnormalities and affects a variety of other neuronal 
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populations. The most obvious cellular abnormality is the presence in axons 
and dendrites of membrane-bounded vacuoles, which appear to be derived 
from degenerating mitochondria (Wong, 1995). 
Transgene expression of mutant human SODI G85R or its murine 
counterpart G86R develops a very aggressive pathology with a rapid 
progression to paralysis and death within two weeks from the first symptoms. 
In G85R mice, motor neurons and astrocytes present inclusions immuno-
positive for ubiquitin and SOD 1 as the most relevant pathological feature 
(8ruijn et al., 1997). 
Differences on disease progression and survival in various SOD 1 mutant mice 
depend on the mutation and the copy number of the transgene. The age of 
onset, the duration and several pathological features also vary in dependence 
of the mouse strain in which the mutation is expressed; this background effect 
suggests the existence of strong modifying genetic factors. 
More recently, the transgenic technology has also permitted the creation of 
transgenic rats expressing the G93A mutant. In this model, the onset of the 
disease occurs early and the progression is very rapid. Pathological 
abnormalities are similar to those observed in the mouse model; vacuolization 
and gliosis are evident before clinical onset and before motor neuron death in 
the spinal cord and brainstem (Howland et al., 2002). 
D. LOA mice 
Recently, Ahmad-Annuar and colleagues have described another mutant 
mouse model of motor neuron disease, the legs-at-odd-angles (LOA) mutant. 
In these mice, mutations in the cytoplasmic dynein heavy chain gene cause 
motor neuron degeneration. Mice exhibiting the LOA phenotype suffer 
progressive loss of locomotor function and homozygous animals have neuronal 
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inclusion bodies that are positive for SOD 1, CDK5, neuromaments and 
ubiquitin (Ahmad-Annuar et al., 2003). 
m. ALS2 mice 
ALS2 knock out mice have been obtained recently by two groups (Hadano et 
al., 2006; Lai et al., 2006). The study of their phenotype revealed a mild motor 
dysfunction characterized by age-dependent deficits in motor coordination, 
slow progressive loss of cerebellar Purkinjie cells, reduction in ventral motor 
axons, astrogliosis and evidence of deficits in endosome trafficking (Hadano et 
al., 2006; Lai et aI., 2006). 
IV. Tau mice 
Different transgenic mouse models over-expressing various human tau 
isoforms have been generated (Ishihara et aI., 1999; Spittaels et al., 1999; 
Lewis et al., 2000; Santacruz et al., 2005) 
These mice acquire an age-dependent eNS pathology, similar to FTDP, and 
show axonal degeneration in brain and spinal cord, progressive motor 
disturbance and behavioural impairment. 
1.7 PATHOGENETIC HYPOTHESES IN AMYOTROPHIC LATERAL 
SCLEROSIS 
To date, the mechanisms underlining the motor neuron death in ALS still 
remain unknown; this is true also for fALS cases, in which single gene 
mutations have been identified. In fact, most of the current knowledge on 
disease mechanisms in ALS has come from the study of the effect of SOD 1 
mutations, but even in this defmed genetic subgroup the pathways of 
degeneration appear to be complex and multifactorial; indeed, mutations in 
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SOD 1 provoke motor neuron disease through the acquisition of one or more 
toxic properties. 
Studies performed on human ALS autopsy samples or on SODI mutant mice 
have suggested the involvement of various processes as possible triggers or 
secondary events in ALS pathology. Thus, most researchers consider ALS as a 
multifactorial disease in which a complex interplay between multiple 
mechanisms including genetic factors, oxidative stress, excitotoxicity, protein 
aggregation, damage to mitochondria and axonal transport determines the 
motor neuronal death. 
Because the clinical and pathological proflles of sporadic and familial ALS are 
similar, it can be predicted that insight from studies on ALS-causing gene 
mutations apply also to sporadic ALS. 
1.7.1 Oxidative damage 
The role of oxidative stress as primary or secondary event in the pathogenesis 
of ALS still remains controversial. Increase in markers of oxidative damage has 
been reported in human patients affected by both sporadic and inherited 
forms of ALS (Beal et al., 1997; Ferrante et al., 1997; Liu et al., 1999) and in 
transgenic mouse models of the disease (Ferrante et al., 1997; Andrus et al., 
1998). However, in other studies, no significant differences in markers of 
oxidative damage were found (Shaw et al., 1995; Bruijn et al., 1997). 
Concerning the ALS form linked to SOD 1 mutation, some studies suggested 
that a possible source of oxidative insult may be represented by the gain of 
toxic function of mutated SODI (Cleveland and Rothstein, 2001): it has been 
hypothesized that the mutation of SOD 1 alters the enzyme activity through 
aberrant copper catalysis or improper metal binding. Mutant SODI may 
accept abnormal substrates such as peroxynitrite, provoking aberrant tyrosine 
nitration and numerous toxic events (Beckman et al., 1993), or hydrogen 
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peroxide (Wiedau-Pazos et al., 1996). In the latter case, the use of hydrogen 
peroxide as substrate might produce the extraordinarily reactive hydroxyl 
radical (OR), leading to a cascade of peroxidation (Wiedau-Pazos et al., 1996). 
Another hypothesis suggests that SOD 1 mutations may reduce the zinc 
bound, allowing a rapid reduction of Cu2+ to Cu 1+. The reduced SOD1 mutant 
would then run the normal catalytic step backwards, converting oxygen to 
superoxide; the superoxide so produced would react with nitric oxide 
producing peroxynitrite, which would promote intracellular damage, including 
protein nitration (Estevez et al., 1999). 
Several experiments have raised questions as to whether the toxicity of mutant 
SOD 1 can be explained by copper-dependent oxidative mechanisms. 
In G85R mice, genetic manipulation of the levels of wild type SOD 1 did not 
affect the age of onset, the survival or the rate of progression (Bruijn et al., 
1998); by contrast, the forced expression of high levels of wild type SOD1 in 
G93A, L126Z and A4V mice accelerates the onset of the disease (Jaarsma et 
al., 2000; Deng et al., 2006). 
SOD 1 with mutation of the four histidines that bound copper into the active 
site, that losses the dismutase activity, also develop motor neuron disease 
(Wang et al., 2003). Moreover, transgenic mice with the knock out of the gene 
encoding the copper chaperone normally required for the insertion of copper 
into SOD1 (CCS), possess only minute levels of SOD1-bound copper and have 
drastically reduced dismutation activity, but still develop motor neuron 
disease (Subramaniam et al., 2002). On the contrary, CCS over-expression in 
G93A mice produces severe mitochondrial pathology and strongly accelerates 
disease course (Son et al., 2007). 
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1.7.2 Mitochondrial dysfunction 
Mitochondrial alteration is an attractive candidate for involvement in ALS 
pathogenesis because of its occurrence at the pre-symptomatic stage in SOD 1 
mutant mice (Bendotti et al., 2001; Jung et al., 2002) and in cultured cells 
expressing the mutant protein (Carri et al., 1997; Beal et al., 2000). 
Interestingly, mitochondrial abnormalities have also been observed in motor 
axon terminals of muscle biopsies from patients with early-diagnosed sporadic 
ALS (Siklos et al., 1996; Beal et al., 2000) and in proximal axons (Hirano et al., 
1984) and in anterior horns of the spinal cord in sALS patients (Sasaki and 
Iwata, 1996). 
Observations on the function of mitochondria have produced evidence 
consistent with the morphological data: biochemical studies have highlighted 
defects in the activity of the respiratory chain complex IV in sALS spinal motor 
neurons (Borthwick et al., 1999) and in complexes I and IV in spinal cord and 
brainstem homogenates of G93A mice (Browne et al., 1998). 
Recent studies have indicated that mutant SOD 1 could directly damage 
mitochondria. The presence of SOD 1 in mitochondria of eukaryotic cells has 
been conflrmed by several groups using a variety of experimental approaches. 
In particular, using immuno-gold electron microscopy, it has been 
demonstrated that both wild type and mutant SOD 1 localize in the 
mitochondria of motor neurons in the spinal cord of transgenic mice (J aarsma 
et al., 2001; Higgins et al., 2002). 
Liu and colleagues proposed that mutant SOD 1 progressively accumulates 
and aggregates on the mitochondrial outer membrane, altering the protein 
translocation machinery of the organelle (Uu et al., 2004). It has also been 
hypothesized that mutant SOD 1 aggregates could damage the mitochondrion 
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through abnormal interaction with mitochondrial proteins such as Bcl-2 
(Pasinelli et al., 2004). 
1.7.3 Alterations of cytoskeleton and axonal transport 
The idea that cytoskeleton abnormalities may play a role in ALS pathology 
arises from early reports of neurofIlament accumulations in the cell bodies and 
proximal axons of motor neurons of both sporadic and familial ALS (Hirano et 
al., 1984). Subsequently, it has been shown that in mice the over-expression 
of NF-H or NF-L subunits causes the selective degeneration and death of 
motor neurons (Cote et al., 1993; Xu et al., 1993). However, it has not yet been 
clarified whether neurofIlament disorganization represents a secondary 
product of pathological processes or whether it directly contributes to the 
death of the motor neurons. Other studies on transgenic mice have 
demonstrated that neurofIlament content and organization strongly influence 
the disease induced by mutant SOD1 (Couillard-Despres et al., 1998; 
Williamson et al., 1998; Couillard-Despres et al., 2000; Kong and Xu, 2000). 
In particular, eliminating neurofIlaments by deletion of the NF-L subunit 
increases the survival of SOD 1 mutant mice, while enhancing the expression 
of the NF-L or NF-H subunits slows SOD1 mutant-mediated disease. The 
protective effects of increased NF-H content in perikarya may be due to the 
ability of neurofIlaments to "buffer" against a cascade of aberrant and harmful 
events in the cell body (Couillard-Despres et al., 1998). 
Another intermediate fIlament protein, peripherin, may be implicated in motor 
neuron degeneration. In fact, mice that over-express peripherin develop a late 
onset motor neuron degeneration and show disruption of neurofilament 
assembly (Beaulieu et al., 1999). On the other hand, alteration of peripherin 
levels in SOD 1 mutant mice does not modify the disease course (Lariviere et 
al.,2003). 
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In neurons, the transport of molecules and organelles is dictated by the highly 
polarized anatomy of these cells: axonal proteins are synthesized in the cell 
body and must be transported in an anterograde manner along the axons and 
dendrites to reach synapses, whereas substances such as peripherally located 
trophic factors must be transported centrally from the synaptic regions by 
retrograde transport. The molecular motors for anterograde and retrograde 
transport are kinesin and the dynein-dynactin complex, respectively. 
Several factors indicate that defects in axonal transport might contribute to 
the degeneration of motor neurons in ALS. First, anterograde transport is 
slowed in G93A and G37R transgenic mice prior to disease onset and the 
deficit are exacerbated as the disease progresses (Zhang et al., 1997; Borchelt 
et al., 1998; Williamson et al., 1999). Also retrograde transport is disrupted in 
SOD1 mutant mice (Murakami et al., 2001). 
Several authors suggest that the aggregation of neurofllaments in proximal 
axons (spheroids) might physically compromise the transport apparatus 
(Sasaki and Iwata, 1996). Diminution of retrograde transport in ALS mice has 
been attributed to the mis-localization and disruption of dynein function 
(Ligon et al., 2005). In two lines of mice (LOA and eRA) point mutations in the 
dynein heavy chain impair motor neuron functionality and viability (Witherden 
et al., 2002; Hafezparast et al., 2003). Finally, aberrant vesicular sorting, 
which is relevant to successful axonal transport, has been implicated in the 
wobbler mouse. 
1.7.4 Excitotoxicity 
Glutamate-induced excitotoxicity is considered another major mechanism that 
may contribute to the aetiology of ALS. An over-stimulation of neuronal 
glutamate receptors can cause neuron death by increasing the cytosolic free 
calcium and activating the death cascades. This phenomenon may be 
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exacerbated by the regulation of the activity or of the subunit composition of 
glutamatergic receptors, which can render them more permeable to Ca2+ and 
Zn2+. Glutamate transporters play an important role in preventing an aberrant 
activation of these receptors, removing glutamate from the synaptic cleft. 
Thus, changes in the equilibrium of this system may result in harmful events 
to the motor neurons in ALS. 
The first indication of an involvement of glutamate-mediated excitotoxicity in 
ALS arose from studies showing increased levels of glutamate in the plasma 
(Plaitakis and Caroscio, 1987) and in the cerebrospinal fluid of a subset of ALS 
patients (Rothstein et al., 1990; Shaw et al., 1995). 
Furthermore, several line of evidence point out an involvement of the most 
abundant astrocytic glutamate transporter EAAT2. In fact, in animal models of 
ALS, there are changes in EAAT2 levels and activity in the spinal cord 
(Alexander et al., 2000; Bendotti et al., 2001), and its expression has been 
found impaired also in ALS patients (Fray et al., 1998). 
It is likely that the regulation of the expression of calcium-permeable AMPA 
(a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors is related 
to motor neuron degeneration in ALS patients and in SOD 1 mutant mice. 
Indeed, motor neurons probably have a greater proportion of calcium-
permeable AMPA receptors and the relative abundance of their subunits might 
change during the progression of the disease. 
1.7.5 Inflammation 
An increasing body of evidence suggests the involvement of inflammatory 
processes in ALS. Accumulation of reactive microglia and astrocytes has been 
documented in the spinal cord and in the motor cortex of ALS patients and 
animal models of the disease (Kawamata et al., 1992; Hall et al., 1998). A 
broad spectrum up-regulation of pro-inflammatory genes, such as COX-2 
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(Cyclooxygenase 2), NOS (nitric oxide synthase) and cytokines, for example 
TNFa., is reported in the spinal cord of G93A mice (Hensley et al., 2002). 
1.7.6 Non cell-autonomous death 
In recent years, various fmdings have emerged indicating that the cross-talk 
between neurons and non-neuronal cells may be crucial for the induction of 
motor neuronal death. 
Experiments with transgenic mice have shown that the specific expression of 
mutant SOD1 in motor neurons or glia fails to trigger motor neuron 
degeneration (Gong et al., 2000; Pramatarova et al., 2001); however, as a 
major drawback of these experimental paradigms, the levels of SOD 1 may 
have been below the threshold necessary to provoke disease. Transgenic mice 
possessing SOD1 G37R cDNA under the prion gene promoter express mutant 
SOD1 in neurons, astrocytes and muscles, but not in the macrophage lineage, 
and develop motor neuron disease (Wang et al., 2005), thus indicating that the 
presence of the mutant protein in the motor neuron/muscle circuit, along with 
supporting astrocytes, is sufficient to induce the disease. 
In an elegant work using chimeric mice with mixed population of cells 
expressing either endogenous or transgenic mutant SOD1, it has been 
demonstrated that the toxicity to motor neurons requires damage from mutant 
SOD1 acting within non-neuronal cells. In fact, motor neurons expressing 
mutant SOD1 did not degenerate if they were surrounded by wild type glia; 
reciprocally, wild type motor neurons surrounded by SOD1 mutated glia 
showed ubiquitin-positive inclusions (Clement et al., 2003). The importance of 
microglia for the pathological processes has been unravelled by recent new 
studies. Experiments with deletable transgenes has demonstrated that the 
lack of mutant SOD 1 only in microglia and peripheral macrophages does not 
change the onset of the disease, but increases the survival (Boillee et al., 
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2006); the deletion of mutant SOD1 only within motor neurons extend survival 
by delaying the onset and the early phase of disease progression. The role of 
microglia was confIrmed, using a different approach, by Beers et al., who 
established that the presence of G93A only in microglia is not capable of 
inducing motor neuron disease, while in G93A mice the substitution of 
mutated microglia with the wild type one significantly slowed the motor neuron 
loss, prolonging the disease duration and the survival (Beers et al., 2006). 
Also the role of astrocytes in ALS has recently been highlighted: experiments 
in co-culture systems provided evidence that astrocytes expressing mutant 
SOD 1 are able to cause the death of both wild type and mutant motor neurons 
(Di Giorgio et al., 2007; Nagai et al., 2007). 
1.7.7 Protein aggregation 
Many neurodegenerative disorders have in common the sequestration of 
aberrant proteins into inclusions and amyotrophic lateral sclerosis does not 
represent an exception. As already described in the section 1.4.1, one of the 
most relevant pathological features of ALS cases, as well as of SOD 1 mutant 
mice, is the formation of proteinaceous inclusions in the motor neurons and 
sometimes in the surrounding astrocytes (Migheli et al., 1990; Bruijn et al., 
1997; Kato et al., 1999). These inclusions are composed of different proteins, 
such as SOD 1, ubiquitin, domn, neurofllaments, peripherin and p38 MAPK; 
additionally, chaperones and proteasome subunits may also be sequestered 
(Watanabe et al., 2001; Strong et al., 2005). 
Given that ubiquitin-containing aggregates are a frequent feature both in 
sporadic and familial cases, this could link the mechanisms of the two forms 
of ALS. As regards to fALS cases linked to SOD1 mutations, one major 
pathogenetic hypothesis concerns the idea that mutant SOD 1 becomes 
56 
C~ter 1: OVerall intrwfuction 
unfolded and prone to aggregate; this theory has been deeply analyzed, with 
various experimental approaches, in in vivo and in vitro models. 
I. Structural characteristics of wUd type SOD! 
The evolution of aerobic organisms that can survive in oxygen-rich 
environments requires an effective defence against reactive oxygen species 
(ROS). The superoxide dismutase enzymes are the first line of antioxidant 
defence against ROS, and particularly superoxide anion radicals, since they 
catalyze the reaction of dismutation of the superoxide anion, in which two 
molecules of superoxide are turned into molecular oxygen and hydrogen 
peroxide. Each eUkaryotic cell has several types of SODs: mitochondrial SOD 
(SOD2), cytosolic SOD (SOD1) and extracellular SOD (SOD3). 
In humans, SOD 1 gene has been localized to chromosome 21. The protein is a 
ubiquitously expressed homodimer with a molecular mass of about 32 KDa; 
the two subunits are held together primarily with hydrophobic contacts 
(Tainer et al., 1982). 
The secondary structural elements of SOD1 are illustrated in Fig. 1.3. From a 
structural point of view, SOD1 is part of the immunoglobulin-fold family 
(Richardson et al., 1976) and each monomer consists primarily of an eight-
stranded J3-barrel with two large loops, the so-called "electrostatic loop" and 
the "metal-binding" loop (residues 49-84) (Tainer et al., 1982). The latter 
region contains the residues necessary for binding one copper, which plays a 
catalytic role, and one zinc, with a structural function (Rodriguez et al., 2005). 
The Cu2+ and Zn2+ ions are coordinated in close proximity (Strange et al., 
2003). 
Human SOD1 contains four cystidine residues; of these, Cys57 and Cys146 
form an intersubunit disulphide bond, whose presence is quite unexpected in 
a cytosolic enzyme localized in the reducing environment of the cytoplasm. It 
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is therefore evident that SOD 1 displays a complex folding and maturation 
pathway; indeed, to acquire their [mal structure, newly translated molecules 
have to undergo at least four steps: copper insertion, zinc insertion, disulfide 
formation and dimerization. 
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Figure 1.3 Secondary structural elements of human S001. The ~-strands are shown as blue arrows and the 
short a-helix as a cylinder. The Zn-coordinating residues are shown as grey spheres and the Cu-coordinating 
residues as green spheres. The disulfide bond between Cys 57 and Cys 146 is indicated with a broken line. The 
two large loops (IV and VII) are coloured red. Adapted from B.F. Shaw, J.S. Valentine, Trends Biochem. Sci. 
2007. 
SOD 1 is one of the most stable proteins known and remains active under a 
broad range of harsh denaturing conditions (Forman and Fridovich, 1973; 
Lepock et al., 1985). Its stability seems to be linked to its structural 
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characteristics, in particular the metal coordination and the presence of the 
disulfide bond. The maintenance of the disulfide linkage is critical both for the 
dimeric and the monomeric stability, since its reduction weakens the dimeric 
interactions and increases the proportion of denaturated and potentially 
aggregation-prone species (Furukawa and O'Halloran, 200S). Also the 
dimerization, reducing the solvent accessible surface area, contributes to 
render the molecule stable (Goodsell and Olson, 2000). 
Although originally thought to be a cytosolic protein, recently SOD 1 has been 
localized also in other cell compartments such as nucleus, mitochondria and 
microsomes (Keller et al., 1991; Crapo et al., 1992). 
D. Mutant SOD! alterations and aggregation 
In the last decade, more than one hundred mutations of SOD 1 linked to ALS 
have been discovered. These mutations are localized in all the regions of the 
primary sequence and in all the functional domains of the protein. The various 
mutants can differ for some features, for example the catalytic activity, the net 
charge and the metal affmity. For this reason, it has been difficult to describe 
precisely the properties that distinguish the mutant proteins from the wild 
type one. 
Based on their biophysical characteristics, SOD 1 mutants have been divided 
into two groups (Hayward et al., 2002): 
1. wild type-like mutants, with a metal content similar to wild type and 
structural perturbations in the region of the mutation (for example G93A) 
2. metal-binding region mutants, that are deficient in zinc and/or copper. 
Different studies have tried to fmd the alterations shared by the pathological 
mutants that could be responsible for the acquired toxicity. An increasing body 
of observations suggests that the ALS disease mechanism is coupled to 
destabilization or misfolding of the SOD 1 structure, manifested ultimately by 
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the presence of cellular inclusions. Actually, SODI mutants display a general 
structural instability (Lindberg et al., 2002) and result to be less thermostable 
than the wild type enzyme (Rodriguez et al., 2002). In this regard, particularly 
important is the increased sensitivity to the reduction of the disulfide bond, 
given its role in maintaining the integrity of the dimeric structure (Lindberg et 
al., 2002; Tiwari and Hayward, 2003); indeed, disulfide reduction was shown 
to prevent dimerization, increasing the presence of instable monomers 
(Lindberg et al., 2004). Also demetallation leads to structural destabilization of 
SOD1 mutants (Lindberg et al., 2002). 
Particular attention has been focused on the monomeric apo protein as a 
precursor state for noxious gain of function (Rakhit et al., 2004). Some studies 
suggest that SOD1 mutations perturb the folding pathway of the protein by 
destabilizing the precursor monomers or weaken the dimer interface; the 
result is a shift of the folding eqUilibrium toward poorly structured monomers 
(Lindberg et al., 2005). Furthermore, in an in vitro model of reticulocyte 
extracts, it has been shown that different fALS-associated mutations are 
significantly impaired in their ability to fold to a native-like dimeric state; this 
delayed folding should be expected to increase the fraction of instable folding 
intermediates (Bruns and Kopito, 2007). Conversely, the SOD1 monomer can 
be produced from the native heterodimer in a variety of ways, all of which 
involve disulfide reduction and demetallation (Tiwari and Hayward, 2003; 
Arnesano et al., 2004; Furukawa and O'Halloran, 2005). 
Another characteristic that could promote aggregation of mutant SODI is the 
decrease of the net negative charge of the polypeptide observed in several ALS-
associated mutations; this phenomenon is further exacerbated in 
environments that are more acidic than the cytosol, such as mitochondria and 
the trans-Golgi network (Lindberg et al., 2005). 
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SOD 1 misfolding could also be the result of its oxidation: when treated with 
mild oxidation systems, mutant SOD 1 display greater aggregation propensity 
than wild type (Rakhit et al., 2002). 
Generalizing, the mutation can determine both local perturbations of the 
secondary, tertiary or quaternary structure and the loss of metal ion binding; 
the common result is a destabilization of the enzyme that leads to non-native 
interactions with itself, or other proteins, and aggregation. 
Many in vitro and in vivo data support this hypothesis. 
In cell cultures, studies have shown that, in contrast to the stable wild type 
protein, the mutant one oligomerizes to form small pore-like structures 
(Chung et al., 2003; Ray et al., 2004; Matsumoto et al., 2005; Matsumoto et 
al., 2006). Inclusions of SOD1 are found in primary cultured motor neurons 
expressing several different SOD 1 mutations; the formation of such inclusions 
correlates with loss of viability (Durham et al., 1997). 
Analyzing the clinical course of familial ALS cases, it has been reported a 
correlation between protein aggregation and clinical phenotype: mutations 
that cause a more severe disease have a shorter half-life and are more likely to 
form aggregates (Lindberg et al., 2005; Sato et al., 2005). 
As regards to SOD 1 mutant mice, the formation of large inclusion bodies is a 
relatively late event in the disease progression. In a time course 
immunohistochemical study in the spinal cord of G93A mice, aggregates 
appeared progressively in dendrites, periaxonal processes of oligodendrocytes 
and neuronal and astrocytic perikarya (Stieber et al., 2000). Conversely, the 
presence of insoluble complexes of SOD 1 much smaller than the visible 
inclusions has been detected much earlier during disease progression. 
Johnston et al. showed that the aggregation of SOD 1 into insoluble high 
molecular weight species is an early event occurring in G93A mice (Johnston 
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et al., 2000) and their abundance increases as the disease progresses. Using 
another approach, accumulation of mutant SOD 1 complexes that can be 
trapped by cellulose acetate filtration was confirmed in brain and spinal cord 
of SOD 1 mutant mice; although expressed to the same level in non-nervous 
tissues, mutant SOD 1 was not found in high molecular weight structures 
(Wang et al., 2002). 
SOD 1 species with reduced disulfide bond are detected in the mouse model 
and their concentration is considerably higher in the eNS compared to the 
peripheral tissues (Jonsson et al., 2006). Moreover, a significant fraction of 
insoluble SOD1 aggregates found in the symptomatic spinal cord contains 
multimers cross-linked via uncorrected intermolecular disulfide bonds. These 
data suggest that the formation of insoluble aggregates of mutant SOD 1 may 
derive from the formation of incorrect disulfide cross-linking of immature 
misfolded proteins (Deng et al., 2006). 
m. Potential toxicity of SODl aggregates 
The role of proteinaceous aggregates in ALS pathogenesis remains 
controversial; however, although large inclusion bodies may not themselves be 
toxic, they are at least a sign that something is wrong in the cell with respect 
to the stability and solubility of the mutant protein. Aggregate formation could 
be a primary event in the disease pathogenesis and underlie neurotoxicity. 
Otherwise, aggregation could occur secondary to the primary neurotoxic event: 
indeed, it has been hypothesized that inclusions could be the ultimate product 
of a cellular defence mechanism that occurs when the burden of misfolded or 
damaged protein exceeds the capacity of the protein degradation machinery to 
eliminate them. Finally, the formation of inclusion bodies may act as a cellular 
defence mechanism in the attempt to actively reduce the concentration of 
smaller, more toxic aggregates (Ross and Poirier, 2005). Actually, whether the 
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[mal protein aggregates are themselves toxic, or whether some soluble 
precursors are the major toxic species, is a hotly debated sUbject. 
Considerable data implicates smaller aggregates and oligomers as the primary 
cytotoxic agent in many diseases associated with protein aggregation (Lashuel 
et al., 2002; Ross and Poirier, 2005) . 
Various hypotheses have been proposed regarding the citotoxicity of SOD1 
aggregates, including the disruption of axonal transport (Stokin et al., 2005), 
the aberrant binding of apoptosis regulators (Pasinelli et al., 2004; Tomik et 
al., 2005), perturbations in mitochondrial function and calcium homeostasis 
(Hervias et al., 2006; Sumi et al., 2006) and inhibition or overload of the 
ubiquitin-proteasome pathway (Cleveland and Rothstein, 2001). Consistent 
with the latter hypothesis, accumulation of ubiquitinated aggregates have 
been detected in SOD1 mutant mice (Stieber et al., 2000; Watanabe et al., 
2001; Bendotti et al., 2004). Since one of the roles of ubiquitin is to label and 
target misfolded and no more active proteins to the proteasome machinery, it 
has been hypothesized that proteasome activity could be inhibited by SOD 1, 
leading to accumulation of aberrantly folded forms of SOD1 and other proteins 
(Cleveland and Rothstein, 2001). 
The possible involvement of dysfunctions of the ubiquitin-proteasome pathway 
in ALS has been the focus of this thesis; for this reason, the constitution and 
the physiological and pathological roles of the ubiquitin-proteasome pathway 
are discussed in the next chapter. 
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CHAPTER II 
THE USIQUITIN-PROTEASOME 
PATHWAY 
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In the last decades, a major breakthrough in cell biology has been the 
discovery that protein turnover is a highly regulated process orchestrated by 
the ubiquitin-proteasome pathway (UPP). The pioneering research of Rose, 
Hersko and Ciechanover during the early '80s led to the discovery of the 
ubiquitin-mediated protein degradation and was awarded with the Nobel prize 
in chemistry in 2004. Nowadays, UPP is known as a versatile mechanism that 
plays a vital role in a great variety of cellular functions. For example, UPP 
controls the temporal and spatial inactivation of key proteins that regulate 
processes such as cell cycle progression, apoptosis, transcription and 
development; moreover it is involved in the immune response, since it 
generates the majority of the peptides presented by MHC I (major 
histocompatibility complex class I) (Goldberg et al., 2002), and is responsible 
for the clearance of aberrant proteins in the cellular environment. Finally, 
there are many non-proteolytic functions associated with UPP, such as DNA 
repair, membrane transport, chromatin-remodelling, transcription and 
signalling pathways (Ferdous et al., 2001; Gillette et al., 2001; Krogan et al., 
2004). 
The dual function of UPP as a sentinel of protein quality control and as a 
regulator of vital cellular processes places the system in a delicate position. 
This situation may be particularly relevant under conditions that cause a 
rapid accumulation of misfolded and damaged proteins. 
As shown in figure 2.1, the degradation of a protein via the ubiquitin-
proteasome pathway involves two steps: 
1. the substrate is tagged by the covalent attachment of multiple ubiquitin 
molecules; 
2. the tagged protein is degraded by the 26S proteasome . 
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Figure 2.1 The ubiquitin- and proteasome-dependent system of protein degradation. E1 , E2 and E3 enzymes 
cooperate to tag the target protein with a poly-ubiquitin chain. Poly-ubiquitinated substrates can then be 
destroyed by 26S proteasome. Adapted from Wojcik C., Oi Napoli M., Stroke 2004. 
2. 1 USIQUITIN 
Ubiquitin (Ub) is a small protein of 76 amino acids expressed m all the 
eukaryotic cells and it was the flrst protein discovered to be covalently 
attached to other proteins by an isopeptide bond (Goldknopf and Busch, 
1977). Protein modification by ubiquitin can be mediated either by the 
attachment of a single ubiquitin (mono-ubiquitination) or a poly-ubiquitin 
chain (poly-ubiquitination), in which a new ubiquitin is conjugated to the 
preceding ubiquitin molecule; the latter modiflcation was shown to serve as a 
signal that targets proteins for degradation (Ciechanover et aI., 1980a; 
Ciechanover et al., 1980b; Hershko et aI., 1980; Wilkinson and Rose, 1980) . 
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Beyond its role in protein degradation, ubiquitin is increasingly recognized to 
be a key post-translational modification that regulates target protein 
localization and activity in processes such as endocytosis, signal transduction, 
chromatin remodelling and DNA repair (Schnell and Hicke, 2003; Welchman et 
al., 2005); many of these functions are controlled by mono-ubiquitination or 
by the formation of non-canonical ubiquitin chains (Pickart and Eddins, 2004; 
Hicke, 2001). 
2.2 UBIQUITINATION 
Ubiquitination refers to the post-translational modification of a protein by the 
covalent attachment of one or more ubiquitin monomers. Conjugation of 
ubiquitin to the protein substrate proceeds via a three-step cascade 
mechanism: 
1. initially, E1 enzyme activates ubiquitin; 
2. the activated ubiquitin is transferred to a Cys residue of one of the 
several E2 enzymes; 
3. [mally, the concerted action of E2 and E3 results in the attachment of 
ubiquitin to the substrate. 
The ubiquitin molecule is generally transferred to an E-NH2 group of an 
internal lysine residue in the substrate to generate the isopeptide bond with 
the C-terminal glycine of the ubiquitin (Gly76). 
Once the fIrst ubiquitin is attached to the substrate, its internal Lys residues 
can become the acceptor for a new ubiquitination cycle and, through 
successive rounds of ubiquitination, the poly-ubiquitin chain is formed; since 
ubiquitin has several Lys residues, several linkages could occur that would 
result in chains with different structures and functions (Peng et al., 2003). 
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Most commonly, poly-ubiquitin chains are linked through Lys 48 as canonical 
signal for proteolysis. 
2.2.1 E1: the Ubiquitin-Activating Enzyme 
E1 activates ubiquitin, via a two-step ATP-dependent reaction, to generate a 
high-energy linkage between the C-terminal carboxyl group of the ubiquitin 
and the thiol group of a cysteine residue within the catalytic site of El. In 
mammals, El exists as two isoforms, resulting from alternative translation 
initiation sites (Cook and Chock, 1992; Handley-Gearhart et al., 1994). 
2.2.2 E2: the Ubiquitin-Conjugating Enzymes 
E2s catalyze the covalent attachment of ubiquitin to the target proteins, or, 
when acting along with HECT-domain E3s, the transfer of the activated 
ubiquitin moiety to a high-energy E3-ubiquitin intermediate. More than 30 
different E2s have been described in higher organisms. All E2 enzymes share a 
catalytic core domain, that contains the ubiquitin-binding Cys residue, and 
are distinguished by the presence of a UBC (ubiquitin conjugating) domain 
required for binding distinct E3s. Typically, each E2 interacts with a number 
of ligases, thus being involved in targeting numerous substrates. 
2.2.3 E3: the Ubiquitin-Protein Ligase 
E3s, which are responsible for the specific recognition of the multitude of 
substrates of the ubiquitin system, are the least defined components of the 
pathway and display the greatest variety. The mechanism by which E2s and 
E3s mediate the ubiquitination varies for different E3s. 
E3s belong to two main sub-families: 
1. HECT-domain E3s: E3 accepts the ubiquitin transferred from E2 by 
forming another high-energy bond; ubiquitin is then transported to the 
ligase-bound substrate. HECT-domain proteins are characterized by a C-
terminal domain that contains the conserved Cys residue to which the 
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ubiquitin is transferred from E2 (Scheffner et al., 1995). The NH2-terminal 
domain, which varies among the different HECT -domain proteins, is 
probably involved in specific substrate recognition. 
2. RING-finger domain E3s: RING-fmger E3s act as scaffolds to bring 
together the E2 and the substrate, allowing the efficient transfer of 
ubiquitin from E2 to the substrate (Lorick et al., 1999; Tyers and Willems, 
1999; Jackson et al., 2000; Joazeiro and Weissman, 2000). RING-finger 
domain is a small domain characterized by a pattern of conserved Cys and 
His residues that form a cross-brace structure and bind Zn2+; it is involved 
in the interaction between E2 and E3. 
An additional subset of E3s, termed E4s, serves as a scaffold to aid in the 
transfer of ubiquitin from E2 to a previously conjugated ubiquitin moiety, in 
effect elongating poly-ubiquitin chains. From a structural point of view, this 
family of protein is characterized by a modified version of the RING-fmger 
motif, named U-box (Hatakeyama and Nakayama, 2003). It is still a debated 
subject whether E4 proteins have intrinsic E3 activity and should be 
considered a subfamily of E3 enzymes. 
The specificity of the ubiquitin-proteasome system is largely determined at the 
E3 level, since the substrates must be specifically recognized by an 
appropriate E3 as a prerequisite to their ubiquitination. In most cases, 
however, substrates are not recognized in a constitutive manner. In some 
instances, the E3 must be "switched on" by undergoing post-translational 
modifications to yield an active form that recognizes the substrate; in other 
cases, it is the substrate that must undergo a certain change that renders it 
susceptible for recognition. These phenomena are essential for an accurate 
spatial and temporal regulation of the substrate fate. 
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2.2.4 DUB: Deubiquitinating Enzymes 
Deubiquitinating enzymes (DUBs) are an heterogeneous and not fully 
characterized group of proteins that catalyzes the cleavage of ubiquitin 
moieties after the glycine 76. Their activity plays an important role for UPP 
functionality; for example, DUBs maintain the free ubiquitin pool in the cell by 
processing ubiquitin precursors and recycling ubiquitin from poly-
ubiquitinated substrates. 
2.3 THE PROTEASOME 
The 268 proteasome is a large, multicataIytic protease that degrades poly-
ubiquitinated proteins to small peptides. As shown in Fig. 2.2, it is composed 
of two sub-complexes: a 208 core particle, that carries the catalytic activity, 
and a 198 regulatory particle. One or two regulatory particles attach to the 
surface of the outer a-rings of the 208 to form the 268 proteasome 
holoenzyme. 
2.3.1 The 20S particle 
The 208 core particle is a barrel-shaped structure composed of four stacked 
rings, two identical outer a-rings and two identicaI inner l3-rings. Each ring is 
composed of seven distinct subunits; in the two f3-rings, three of the seven 
subunits have the threonine-protease activity, meaning that each proteasome 
has six (three different) proteolytic active sites (Lowe et al., 1995; Groll et al., 
1997). The protease active sites face an inner cavity, termed proteolytic 
chamber, that can be accessed through a narrow channel formed by the a-
rings (Groll et aI., 2000; Kohler et aI., 2001). Indeed, the NH2 termini of the a-
subunits obstruct the access to the proteolytic chamber, suggesting that the 
proteasome channel is gated (Groll et aI., 1997; Groll et aI., 2000). 
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Overall, the 20S can cleave peptide bonds after any amino acid. However, each 
of the three active sites preferentially cleaves after different amino acids: PI 
(post-glutamil peptide hydrolase) cleaves after acidic amino acids, P2 (trypsin-
like) cuts after basic amino acids, while p5 (chymotrypsin-like) hydrolyzes the 
peptide bond after hydrophobic residues (Dick et al., 1998). The rules that 
govern the cleavage rate of the same peptide bond can be significantly altered 
when put into the context of the primary structure of the polypeptide 
(Holzhutter et al., 1999). 
2.3.2 The 195 particle 
The 19S regulatory particle is composed of at least 18 different subunits and 
can assemble at either end of the 20S core particle to form the 26S 
proteasome. 
The 19S itself can be further dissected into two multisubunit substructures: 
the lid and the base (Glickman et al., 1998). The base is connected to the (l 
subunits of the 20S by a ring formed by six ATPase subunits (named Rpt 1-6 
in S. Cerevisiae); two additional components of the base are the non-ATPase 
subunits Rnpl and Rnp2 (Davy et al., 2001; Fu et al., 2001). The lid contains 
nine of the remaining non-ATPase subunits (Rpn3, -5, -6, -7, -8, -9, -10, -11, -
12) and can be released from the proteasome or rebound under certain 
conditions. The role of the lid is still unclear, although it is necessary for the 
proper degradation of poly-ubi qui tina ted proteins (Glickman et al., 1998). 
The 19S complex serves multiple roles in regulating proteasomal activity. 
First, it is responsible for the recognition of the substrates that should be 
degraded; in particular, Rnpl0 and Rpt 5 subunits have been shown to bind 
poly-ubiquitinated chains (Young et al., 1998; Hofmann and Falquet, 2001). 
The subsequent removal of the poly-ubiquitin chain from the substrate is 
mediated by subunits that display a de-ubiquitinating activity (Verma et al., 
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2002; Yao and Cohen, 2002). A second function of 198 is to open an orifice in 
the a-ring, allowing the substrate to enter into the proteolytic chamber. In 
addition, because a folded protein would not be able to fit through the narrow 
proteasomal channel, it is assumed that the 198 particle unfolds substrates 
and inserts them into the 208 channel. Both the channel opening function and 
the unfolding of the substrate require energy, and therefore are probably 
mediated by the ATPase subunits. 
It is well known that the 268 complex is responsible for the clearance of the 
bulk of cellular ubiquitinated proteins. However, the 208 particle constitutes a 
major portion of the total amount of the proteasome present in cells and it has 
recently emerged that it is able to degrade some proteins in a ubiquitin-
independent manner (Orlowski and Wilk, 2003). Natural unfolded, damaged, 
misfolded and oxidized proteins are all susceptible to degradation by the 208 
proteasome. It is probable that the delivery of such proteins to the 208 
proteasome is mediated by the exposure of hydrophobic patches (Inai and 
Nishikimi, 2002; 8hringarpure et al., 2003). 
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Figure 2.2 The subunit composition of 268 proteasome. The different 198 subunits are indicated using the 
nomenclature of S. Cerevisiae 26S proteasome. Rnp: regulatory particle non-ATPase; Rtp: regulatory particle 
ATPase. Adapted from Pickart and Cohen, Nat. Rev. Mol. Cell. BioI. , 2004 
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2.3.3 Proteasome plasticity 
I. The immuDoproteasome 
An important function of protein breakdown in mammalian cells is to generate 
the peptides that are presented in association with MHC class I molecules to 
the immune system, and in particular to the T cell receptor of cytotoxic CD8+ 
T cells. Each antigenic peptide is bound by an MHC I molecule; MHC genes 
are highly polymorphic, with several hundred alleles and each allele binds a 
unique set of peptides with an average length of 8-10 amino acids. 
Cells display intracellular antigens, from both self proteins and intracellular 
pathogens, at the cell surface to distinguish between infected and uninfected 
cells. Peptide fragments derived form self proteins are usually ignored by the 
host immune system, whereas epitopes derived from foreign or mutated self-
antigens trigger a cytotoxic T cell response. MHC I plays also an important role 
as ligand for the receptor of natural killer cells, thereby controlling the 
functional state of these lymphocytes (Moretta et al., 2004; Lanier, 2005; 
Parham, 2005). 
The clearest evidence that most antigentic peptides are generated by the 
proteasome was the fInding that inhibitors of proteasome reduce or prevent 
antigenic presentation (Rock et al., 1994). 
During infections, the release of the cytokine IFNy (interferon y), a critical 
antiviral mediator in the CNS (Komatsu et al., 1996), optimizes the antigen 
presentation by the replacement of the proteolytically active ~-subunits with 
alternative, so-called LMP or ~i, subunits. ~li/LMP2 replaces its constitutive 
f31-homolog, f35i/LMP7 replaces ~5, and ~2i/LMPI0 (or MECL-I) replaces f32 
(Bochtler et al., 1999). Since the proteasome complex with inducible subunits 
is more prone to generate peptides suitable for the antigen presentation, it is 
often referred to as "immunoproteasome". Indeed, experiments with small 
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flu orogenic substrates have shown that immunoproteasome has a greater 
capability to cleave after hydrophobic and basic amino acids, and lower to 
cleave after acidic ones. This tendency should enhance the production of 
peptides able to bind MHC molecules (Van Kaer et al., 1994). 
Another molecule able to elicit changes in proteasomal composition is the pro-
inflammatory cytokine TNFa. (tumor necrosis factor a.) (Hallermalm et al., 
2001). 
O. 118 regulatory particle 
IFNy induces also the up-regulation of PA28a. and PA28P, which form an 
heptameric ring (0.3134) known as 118 regulatory particle, or PA28 (8chwarz et 
al., 2000). 8imilarly to 198, 118 can assemble with the 208 core particle and 
is believed to open the a. gate; on the other hand, 118 does not have ATPase 
activity or ubiquitin-binding sites. The precise role of 118 in MHC I 
presentation is still not well understood. It is known that it is able to greatly 
stimulate the ability of 208 to hydrolyze small peptides (Ma et al., 1992). lIS 
can also associate with 268 particles containing one 198 cap to generate 
hybrid 198-208-118 (Cascio et al., 2002); these hybrid complexes generate a 
distinct set of peptide products, that presumably exit from the 11 S-bound end. 
10. Post-translational modiftcatioDs 
Besides the shift from constitutive proteasome to immunoproteasome, other 
and more subtle modifications can regulate the catalytic activity of the 
proteasome. In fact, western blot analysis demonstrated that frequently 
proteasome inhibition is not associated with a decrease of proteasome levels 
(Keller et al., 2000a; Keller et al., 2000c); therefore, it appears that post-
translational modifications can play an important role. For example, it has 
been shown that, under severe stress conditions, 268 dissociates into 198 and 
208 components causing a rapid decrease in cellular proteolysis. In addition, 
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various 198 and 208 subunits can be phosphorylated; it is thought that 
phosphorylation plays a positive role in proteasome function, favouring its 
assembly and stability. The subunits can also be modified by glycosylation at 
the same residues as phosphorylation, with antagonistic outcomes. 
In vitro experiments demonstrated that mild oxidative stress inactivates the 
268 proteasome, whereas the 208 one seems to be more resistant (8hang and 
Taylor, 1995; Jahngen-Hodge et al., 1997; Grune et al., 1998; Grune, 2000). 
2.3.4 Proteasome biogenesis 
All the different proteasome subunits of the 20S catalytic core are usually 
synthesized in stochiometric amounts. 208 is formed following a sophisticated 
biogenesis pathway; the 3 J3-catalytic subunits are synthesized as inactive 
precursors and are activated by intramolecular proteolysis after the 
incorporation into 208 (Chen and Hochstrasser, 1996; Ditzel et al., 1998). The 
assembly is a multistep process that occurs via the formation of precursor 
complexes and requires accessory proteins to promote maturation steps. 
Among these various factors, a fundamental role is played by POMP 
(proteasome maturation protein), that is directly associated with proteasome 
precursors and is degraded as a f11"st substrate when the 20S is fully 
assembled and activated (Ramos et al., 1998; Burri et al., 2000; Witt et al., 
2000). POMP transcript levels are increased after IFNy treatment (Burri et al., 
2000) and the interaction between POMP and LMP7 is thought to accelerate 
immunoproteasome biogenesis (Heink et al., 2005); indeed, in POMP-depleted 
cells, a decrease of MHC I surface expression is found. 
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2.4 THE USIQUITIN-PROTEASOME PATHWAY IN 
NEURODEGENERATIVE DISEASES 
Accumulation of ubiquitin conjugates and inclusion bodies has been reported 
in a broad array of chronic neurodegenerative diseases, such as the 
neurofibrillary tangles of Alzheimer's disease (AD), Lewy bodies in Parkinson's 
disease (PD), Bunina bodies in ALS and nuclear inclusions in polyglutamine-
extension disorders (Poli-Q diseases, for example Huntington's disease, 
spinocerebellar ataxia and spinal bulbar muscular atrophy). Since the 
pathogenetic significance of these aggregates has remained still mysterious, 
the appearance of inclusion bodies has emerged as a cornmon but poorly 
understood mechanistic theme in neurodegenerative disorders (Fig. 2.3). 
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Figure 2.3 The involvement of the ubiquitin-proteasome pathway in neurodegenerative diseases. The figure 
describes different aspects related to protein misfolding and neurodegeneration: the triggers that can cause the 
accumulation of misfolded proteins, the primary responses to their accumUlation and the types of 
neuropathological protein depOSits that can be found in the patients. Adapted from Ciechanover A. , Brundin P., 
Neuron 2003. 
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It has been suggested that alterations in UPP functionality can be involved in 
this phenomenon. In fact, the proteins that accumulate in neurons are 
apparently tagged for degradation, but amass rather than be destroyed. 
Therefore, an important, unanswered question is why UPP fails to destroy 
aggregation-prone proteins and allows their accumulation over time. Bence 
and co-worker (Bence et al., 2001) demonstrated that UPP function is directly 
impaired by protein aggregates. Following their hypothesis, the proteasome 
could become engaged by ubiquitinated aggregates that can neither unfold nor 
degrade, and would thus be unavailable for degrading other substrates. 
Indeed, proteasome subunits co-localize in inclusion bodies associated with 
neurodegenerative diseases (Kwak et al., 1991; Cummings et al., 1998; 
Seilhean et al., 2004). A decline in UPP activity would result in increased 
production of aggregated proteins, that, in turn, would lead to a further 
decline of UPP function, determining a feed-back mechanism. Such 
phenomenon is more dramatic in post-mitotic cells, possibly explaining the 
vulnerability of neurons (Sitte et al., 2000). 
The failure of UPP can occur at different levels, for example it could derive 
from a decrease of proteasome catalytic activity, a mis-regulation of 
ubiquitinating enzymes, a mis-regulation of the delivery of the substrates to 
the proteasome, or alterations in the activity of 19S particle. It is important to 
highlight that even subtle perturbations of the UPP could compromise the 
neurons by rendering them more susceptible to other stresses. 
The strongest support for the possibility that UPP has a primary role in the 
pathogenesis of neurodegenerative diseases comes from mutations in UPP 
components that provoke disease insurgence. In fact, mutation in the E3-
ligase parkin causes an early onset parkinsonism in humans (Kitada et al., 
1998). Ubiquitin carboxy-terminal hydrolase-l (UCHL1) is a neuron-specific 
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deubiquitinating enzyme that also displays a secondary dimerization-
dependent ubiquitin-ligase activity. A point mutation affecting the ligase 
activity of UCHLI has been linked to Parkinson's disease (Liu et al., 2002), 
while an internal deletion in the same gene is responsible for murine gracile 
axonal dystrophy, which is characterized by axonal degeneration and 
formation of spheroids in nerve terminals (8aigoh et al., 1999). 
There is also indirect evidence implicating UPP in neurodegeneration. 
Decreased proteasome activity seems to be a feature that characterizes many 
cell models in which aggregates are formed, for example in vitro models of 
Parkinson's disease (Rideout et al., 2001; Tofaris et al., 2001; Liu et al., 2002), 
ofprion disease (Ma and Lindquist, 2001; Yedidia et al., 2001; Ma et al., 2002) 
and Poli-Q diseases (Jana et al., 2001; Chan et al., 2002). Additionally, Af3 
oligomers, as well as prion oligomers, were shown to inhibit proteasome 
function (Kristiansen et al., 2007; Tseng et al., 2007). Not always, these in vitro 
fmdings mirror the in vivo situation. For example, in some poli-Q disease 
mouse models, proteasome impairment was not detected at the symptomatic 
stage (Diaz-Hernandez et al., 2003; Bowman et al., 2005). On the other hand, 
a direct relationship between prion neuropathology and a dysfunction of the 
UPP was demonstrated in prion-infected mice (Kristiansen et al., 2007). 
Analyses of AD and PD human brain showed modest decrease of proteolytic 
activity of the proteasome (Keller and Markesbery, 2000; McNaught and 
Jenner, 2001) and 208 complex isolated from AD brain revealed post-
translational modifications such as acetylation and dephosphorylation 
(Gillardon et al., 2007). 
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CHAPTER III 
AIM 
OF THE THESIS 
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The purpose of this thesis is to study in depth the role of the ubiquitin-
proteasome pathway in the pathogenesis of amyotrophic lateral sclerosis, 
analysing the mice transgenic for human SOD 1 with G93A mutation. 
As a fIrst objective, I have evaluated the time course of ubiquitinated protein 
accumulation in the spinal cord of G93A mice during disease progression. 
Then, the activity of the ubiquitin-proteasome pathway has been monitored by 
cross-breeding G93A mice with a mouse model that expresses a protein 
reporter of UPP activity. 
Another aim of the study is the investigation of the shift from constitutive 
proteasome to immunoproteasome in the mechanisms that lead to motor 
neuron degeneration. Therefore I examined the levels of the transcripts for 
constitutive and inducible proteasome subunits in the spinal cord of G93A 
mice at different stages of disease progression. 
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In this chapter are provided the general procedures adopted in the 
experiments described in this thesis. When necessary, further methodological 
details are given for specific experiments before the presentation of the results. 
4.1 MOUSE MODELS 
Procedures involving animals and their care were conducted in according to 
the institutional guidelines, that are in compliance with national (D.L. no. 116, 
G.V. suppl. 40, Feb. 18, 1992, Circolare No.8, G.U., 14 luglio 1994) and 
international laws and policies (EEC Council Directive 86/609, OJ L 358, I 
DEC.12, 1987; NIH Guide for the Care and use of Laboratory Animals, U.S. 
National Research Council, 1996). The animals were housed under standard 
conditions (22 ± 1°C, 60% relative humidity, 12 hour light/dark schedule), 3-4 
per cage, with free access to food (Altromin, MT, Rieper) and water. 
4.1.1 G93A transgenic mice 
Transgenic mice expressing about 20 copies of mutant human SOD1 with a 
Gly93Ala substitution (G93A mice) were originally obtained from Jackson 
Laboratories (B6SJL-TgNSOD-I-G93A-1Gur); the line is hemizygous for the 
transgene. Male G93A mice were repeatedly backcrossed with non transgenic 
female C57BL/6 mice, obtaining transgenic mice on the homogeneous 
C57BL/6 genetic background. These mice develop the frrst signs of 
neuropathology at the motor neuronal level around one month of age, while 
the frrst symptoms of muscular dysfunction appear around three months of 
age, with tremors and a progressive reduction in the extension reflex of the 
hind limbs, when the mice are raised by the tail. At about four months of age, 
the mice start to show a progressive muscular weakness, revealed by the 
increasing difficulty in staying on a rotating bar and by a reduction in stride 
length on an inclined ramp. At this stage, about 50% of motor neurons of the 
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lumbar spinal cord are lost and two months later these mice die (Ciavarro et 
al.,2003). 
Mitochondrial vacuolisation and swelling are among the earliest events and 
are accompanied by a decreased function of the mitochondria. Later, but still 
at the asymptomatic stage, G93A mice show signs of cytoskeletal 
disorganization in the motor neurons, with the accumulation of 
phosphorylated neuromaments in the perykaria (Tortarolo et al., 2003). 
Reactive gliosis, which involves hypertrophy and the activation of astrocytes 
and the proliferation and activation of microglia, is detectable with the 
degeneration of motor neurons and becomes prominent when the cell loss is 
remarkable (Tortarolo et al., 2003; Veglianese et al., 2006). 
For the present study, female mice have been sacrificed at 12, 16 and 22-23 
weeks of age, corresponding respectively to pre-symptomatic, early 
symptomatic and end stage of the progression of the motor dysfunction. Age-
matched non transgenic littermates (NTg mice) and, for some experiments, 
transgenic mice expressing wild type human SOD 1 (WT SOD 1 mice) have been 
used as controls. 
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Figure 4.1 The disease progression in G93A mouse model. 
4.1.2 UbG76V_GFP transgenic mice 
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UbG76V-GFP mice are available in our laboratory thanks to a collaboration with 
Dr. Dantuma (Dept. Cell and Molecular Biology, Karolinska Institute, 
Stockholm, Sweden) , who generated them. 
This model is based on the constitutive expression of the UbG76v-GFP reporter 
protein for the activity of the ubiquitin-proteasome pathway (see section 5 .1.4), 
that was selected because its short half-life and low toxicity in cell cultures . 
The transgene is expressed from a chicken ~-actin promoter with a 
cytomegalovirus (CMV) immediate early enhancer, which normally gives high 
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constitutive expression in all the tissues (Sato-Harada et al., 1996). Two 
mouse strains, named UbG76V-GFP1 (GFPl) and UbG76v-GFP2 (GFP2) were 
generated with the reporter construct and were characterized by the presence 
of the transcript in all the examined tissues (Lindsten et al., 2003); both lines 
are hemizygous for the transgene. Degradation of the substrate was so 
efficient that inhibition of the UPP was required in order to detect the reporter 
protein. For the maintenance of these lines, GFPl or GFP2 males were bred 
with C57BL/6 (NTg) females. 
4.1.3 Double transgenic mice 
Since G93A females are sterile, to obtain double transgenic GFPG93A mice 
G93A males and GFPl or GFP2 females were cross-bred. Both G93A and GFP 
mice are derived from the same strain C57BL/6, thus minimizing the 
confounding effects of different genetic backgrounds. The genotyping of the 
litters was conducted by polymerase chain reaction (PCR) on DNA extracted 
from tail biopsies. In the experiments, double transgenic mice were evaluated 
in comparison with single transgenic and non transgenic littermates. 
4.1.4 Mouse genotyping 
I. DNA extraction 
Tail biopsies were treated with 0.1 llg/111 of Proteinase K (Promega 
Corporation, Madison, WI, USA) over-night at 55°C for tissue digestion. Total 
genomic DNA extraction was performed using Wizard genomic DNA 
purification kit (Promega). Nuclei lysis and protein precipitation were carried 
out according to manufacturer's instructions; DNA was precipitated by adding 
40 111 (10 % of volume) of sodium acetate 3M, pH 5 and 1 ml of cold ethanol. 
The pellet was dried at room temperature, then resuspended in 100 pI of 
distilled water; samples were then incubated for 1 h at 65°C to allow complete 
resuspension. DNA concentration was measured by spectrophotomer 
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(Eppendorf International, Hamburg, Germany) and samples were diluted to 
reach the [mal concentration of 50 ng/pl. 
D. PeR screening 
The conditions for qualitative PCR experiments were established using GoTaq 
(Promega). 50 ng of DNA from each animal were used as a substrate for the 
PCR reaction, in a mix containing IX PCR buffer, GoTaq (0.25 U), deoxyNTPs 
(250 pM each), specific forward and reverse primers (0.5 pM each) in a [mal 
volume of 10 pl. All the reagents were purchased by Promega, except for 
primers that were synthesized by Invitrogen (Invitrogen Corporation, 
Carlsbard, CA, USA). 
The thermocycling profIle used for amplification is reported below: 
1. 94°C for 2 min 
2. 94°C for 45 sec 
T annealing for 45 sec 
72°C for 1 min 
3. 72°C for 10 min 
For 34 cycles 
PCRs were performed in a MJ thermocycler (distributed by Bio-rad laboratorie, 
Hercules, CA, USA). Amplicons were resolved in agarose gel usually containing 
1.5% of agarose, 2pg/ml ethidium bromide in Tris-Acetate-EDTA (40 mM Tris, 
0.35% vol/vol acid acetic, 1 mM EDTA). 
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In the table 4 .1 are reported the primer sequences and their annealing 
temperatures. 
Gene 
I 
Forward 15'->3') 
I 
Reverse (5' 3') 
SODI CATCAGCCCTAATCCATCTGA CGCGACTAACAATCAAAGTGA 
GFP ACCACATGAAGCAGCACGACT CTTGTACAGCTCGTCCATGC 
Table 4.1: Primer sequences for SODI and GFP genotyping. 
4.2 IMMUNOHISTOCHEMISTRY 
4.2.1 Tissue obtainment 
T 
annealing 
56 °C 
58°C 
Mice were anesthetized with Equithesin (1% Phenobarbital, 4% chloral 
hydrate) and transcardially perfused with 20 m1 of phosphate buffered saline 
(PBS, phosphate buffer O.OIM, 0.9% NaCl) followed by 50 ml of 4% para-
formaldehyde solution in PBS. Brains and spinal cords were rapidly removed, 
post-flxed in flXative for 2 h, transferred to 20% sucrose solution in PBS 
overnight, then to 30% sucrose solution until they sank, and fmally frozen in 
2-methylbutane at -45°C and conserved at -80°C until the experiments. 
Before freezing, spinal cord was divided in cervical, thoracic and lumbar 
segments and included in OCT (Tissue-tek, Sakura Finetek, Torrance, CA, 
USA) . 
Tissues were cut on a cryostat at -20°C to obtain sections of 30 pm. The brain 
was sectioned in the sagittal plane, whereas the spinal cord in the coronal 
plane. The lumbar level of the spinal cord was chosen for the experiments, 
because the hind legs of G93A mice are affected earlier and more severely 
compared to the forelegs . 
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Figure 4.2 The mouse central nervous system. 
4.2.2 Diaminobenzidine immunostaining 
Free floating sections were treated for 10 min with 1 % hydrogen peroxide in 
PBS O.OlM to inhibit endogenous peroxidases, blocked in PBS containing 
normal goat serum (NGS) and Triton X- 100 at the appropriate concentration 
for 60 min at room temperature (RT) and then incubated overnight at 4 °C with 
the primary antibody diluted in PBS containing NGS and Triton X- 100. The 
following day, after three washing in PBS 0.01 M, sections were incubated with 
biotinylated secondary antibody (1 :200, Vectastain kit, Vector Laboratories, 
Burlingame, CA, US) for 1 h , washed and incubated in avidine-biotin-
peroxidase solution (Vectastain kit, Vector Laboratories). Immunostaining was 
revealed by the reaction with 3'-3-diaminobenzidine tetrahydrochloride (DAB, 
10 mg/20 ml in TBS + 6 pl hydrogen peroxide 30%). Subsequently, sections 
were washed, dried and mounted on poly-L-Iysine coated slides, dehydrated 
through graded alcohols, fIxed in xylene and coverslipped using DPX 
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mountant (BDH, Poole, UK). Control sections were incubated without the 
primary antibody. 
4.2.3 Indirect immunofluorescence 
Free-floating sections were treated for 1 h with a blocking solution composed 
of NGS and Triton X-100 at the appropriate concentration in PBS. 
Subsequently, the sections were incubated overnight at 4 D C with the primary 
antibody diluted in PBS containing NGS and Triton X-100. Then, after three 
washes in PBS, samples were treated for 1 h with the appropriate secondary 
antibody conjugated to fluorochromes with various wavelengths (Alexa 488, 
546 and 647, Molecular Probes, Invitrogen), diluted 1:500 in PBS added with 
NGS 2%. Finally, sections were mounted on slides and coverslipped with 
Fluorsave (Calbiochem, Notthingam, UK). 
Control sections were incubated without the primary antibody. 
4.2.4 Amplified immunofluorescence by tyramide 
Sections were pre-treated for 10 min with hydrogen peroxide 1% in PBS. 
Blocking was performed for 1 h at RT with NGS and Triton X-100 at 
appropriate concentration in PBS. Subsequently, samples were probed 
overnight at 4°C with the primary antibody, diluted in PBS containing NGS 
and Triton X-100. The following day, after three washes in PBS, sections were 
incubated with biotinylated secondary antibody (1 :200, Vectastain kit, Vector 
Laboratories) for 1 hour, washed with TNT (TBS 0.1 M; Triton 0.05%) and 
incubated with for 90 min in TNB (TBS 0.1 M, Blocking reagent 0.5%). 
Subsequently, the sections were again washed with TNT and treated with 
streptavidin (1:100, Perkin Elmer, Waltham, MA, USA) in TNB for 30 min, 
washed with TNT and incubated for 10 min with tyramide conjugated with Cy5 
fluorochrome (1:500, Perkin Elmer) in amplification diluent provided by the 
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kit. Processed sections were mounted on slides and coverslipped with 
Fluorsave. 
The amplification technique was utilized to detect faint signal or reveal two 
antibodies of the same specie on the same section, taking advantage of the 
sensibility of this technique for one of the antibodies. In the latter case, it was 
verified that, in the established conditions, no direct reaction was detectable 
between the secondary fluorescent antibody and the primary antibody 
amplified with tyramide procedure. 
In each immunohistochemical experiment, some of the sections were 
processed without the primary antibody, in order to verify the specificity of the 
staining. 
4.2.5 Image analysis 
Sections immunolabelled with diaminobenzidine were examined under an 
Olympus BX61 light microscope. Images were collected with a camera, using 
AnaliSYS software (Soft Imaging Systems, ver. 3.2). 
Fluorescence-labelled sections were analyzed under an Olympus Fluoview 
laser scanning confocal microscope, using three lasers: Ar with a 488 nm 
emission line to acquire Alexa 488 signal, He-Ne green laser with a 546 
emission line to acquire Alexa 546 signal and He-Ne red laser with a 647 
emission line to acquire Cy5 signal. Analysis in double or triple staining was 
made by sequential scanning in order to avoid cross talk between the 
channels. 
For some immunohistochemical experiments, with the aim to obtain 
quantitative data, co-localization studies were performed on serial sections (1 
every 10 sections, for a total of 10 sections for animal) from the spinal cord. 
Samples were examined under an Olympus BX61 light microscope and images 
of the dorsal and ventral spinal cord were collected with a camera, using 
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AnaliSYS software (Soft Imaging Systems, ver. 3.2); cells that resulted stained 
for one or both of the analyzed markers were recorded. 
4.3 CELL CULTURES 
4.3.1. Culture Preparation 
Primary spinal neurons were prepared from 14-day-old mouse embryos 
deriving from the cross-breeding of GFP2 males with NTg females; genotyping 
of the embryos was performed by PCR as described above (paragraph 4.1.4) 
using the DNA extracted from the liver. 
Spinal cords were isolated by dissection and the meninges were removed. The 
tissue was then mechanically dissociated using a ftre-polished glass Pasteur 
pipette in phosphate-buffered saline (PBS, Ca2+ and Mg2+ free) supplemented 
with glucose (33 mM). The cell suspension was layered onto a 4% BSA 
cushion, centrifuged at 1000 rpm for 10 min, and the cells from the pellet 
were resuspended in culture medium composed of Neurobasal (Gibco, 
Invitrogen) supplemented with 10% inactivated horse serum, 16.5 mM 
glucose, 1 ng/ml BDNF, 2 mM glutamine, 100 J.lg/ml streptomycin and 60 
J.lg/ml penicillin. A mixture of hormones and salts composed of insulin 
(25 J,lg/ml), transferrin (100 J.lg/ml), putrescine (60 l-lM), progesterone (20 nM) 
and sodium selenate (30 nM) was also added to the culture medium. In order 
to improve neuronal viability and resistance, neurons from GFP2 embryos 
were plated into wells previously coated with a layer of confluent non-
transgenic astrocytes; the growth of Ub076V_GFP glial cells was minimized by 
adding to the culture medium the anti-mitotic drug Ara-c. 
Cells were cultured at 37°C in a humidifted atmosphere of 95% air and 5% 
C02 and were used after 5-6 days in vitro. 
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4.3.2 Treatment with proteasome inhibitor 
Proteasome inhibition was obtained adding to the medium the drug MG 132. 
Actually, primary neurons resulted to be very sensitive to proteasome 
inhibition and the administration of MG 132 in concentration suitable for 
overnight treatment in cell lines demonstrated to be toxic. For this reason, 
experiments were done with decreasing quantities of MG 132 and shorter 
periods of treatment; the best range was chosen to be in 0.5-4.5 11M for 6 
hours of incubation. 
At the end of the treatment, cells were rinsed in PBS, fIXed with 4% para-
formaldehyde in PBS for 30 min at RT and labelled by immunofluorescence 
techniques as already described. 
4.4 BEHAVIOURAL ANALYSES 
Starting from the age of 84 days, mice were tested once a week for motor 
behavioural deficits using the grid test. Animals were posed on a horizontal 
grid and supported until they grabbed the grid with both their fore and hind 
paws; the grid was then inverted so that the mice were allowed to hung upside 
down. At this point, time was started for a maximum of 90 sec. The time (sec) 
at which the animal fell from the grid was recorded. Animals performed three 
trials with at least 5 min of rest among them; the time of the best trial was 
considered for the statistical analysis. Body weight of each animal was 
recorded before the test. 
Mice at the end stage of the disease that were unable to right themselves 
within 30 sec after being placed on one side were euthanized by a high dose of 
anaesthetic; the age of death was recorded as time of survival. 
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For the statistical analyses, the results from each group of animals at each 
test session were expressed as mean ± standard error (S.E.). Missing data, due 
to death of animals, were taken into account in the statistic analysis as 
follows: when an animal died, its performance was considered equal to the last 
recorded value for all subsequent test sessions, until the death of the last 
animal of the group. The patterns in the progression of motor deficits and body 
weight were evaluated by a repeated measure two-way ANOVA. The survival of 
G93A and GFPlG93A mice was analyzed by the log-rank test. All the 
statistical analyses were done using Prism 4 for Windows, version 4.03 
(GraphPad Software Inc.). 
4.5 WESTERN BLOT 
Western blot experiments were performed in collaboration with Dr. C. 
Maynard and Dr. N. Dantuma (Dept. Cell and Molecular Biology, Karolinska 
Institute, Stockholm, Sweden). 
4.5.1 Tissue obtainment 
Mice were killed upon ethical procedures by decapitation. The spinal cord was 
fluxed from the vertebral column employing sterile physiological solution (0.9% 
NaCl) and sectioned into the cervical, thoracic and lumbar segments; the 
samples were immediately frozen on dry-ice and stored at -80°C. 
4.5.2 Protein extraction 
Frozen spinal cord tissues were thawed on ice and homogenized in 500 III of 
ice-cold homogenization buffer (20 mM Hepes pH 7.4, 100 mM NaCI, 10 mM 
NaF, 1% Triton X-IOO, I mM orthovanadate and 10 mM EDTA) containing 
freshly added 20 mM NEM (N-methy1 d-aspartate) to block deubiquitination 
enzymes, and complete mini-protease inhibitor cocktail (Roche). 
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Homogenisation was carried out by sonication (30 pulses of 1 sec at 15% 
intensity) on a Bandelin Sonopuls ultrasonic homogenizer, and samples were 
centrifuged at 10,000 g for 10 min at 4DC; supernatants were transferred to a 
fresh tube and stored on ice. Protein concentration was determined by BCA 
Proteain Assay (Pierce Biotechnology, Rockford, IL, USA) against BSA 
standards and homogenates were adjusted to equal protein concentration in 
homogenization buffer. 
4.5.3 SDS-poly-acrylamide gel elecrophoresis (SDS-PAGE) 
Prior to electrophoresis, aliquots of homogenate were boiled in SDS sample 
buffer (1.2% SDS, 5% j3-mercaptoethanol, 5% glycerol, 25.5 mM Tris/HCI 
pH6.8, 0.6% glycine) at 95-100DC for 10 min Equal amounts of total protein 
(30 J.1g) were separated on 12% Tris-glycine polyacrylamide gels and 
electroblotted onto 0.2 J.1M nitrocellulose membranes, 100V for Ih using a 
BioRad mini-transfer system. To check for even protein loading and transfer, 
membranes were briefly immersed in Ponceau-S stain (0.2% Ponceau-S in 3% 
trichloro-acetic acid) and rinsed in water. Membranes were then placed 
between plastic sheets and scanned for later analysis. 
4.5.4 Immunoblotting 
Membranes were rinsed in PBS to remove Ponceau-S stain and immersed in 
blocking buffer (5% non-fat milk in PBS pH 7.4, 0.1% Tween). Membranes 
were then probed with the primary antibody diluted in blocking buffer, washed 
4 times in PBST, and incubated with HRP-conjugated secondary antibody (GE 
Helathcare, UK) 1:4000 for Ih at RT. Membranes were washed 4 times in 
PBST for 10 min and the signal detected by enhanced chemioluminescence 
(ECL) using Fuji Super RX f11m for various exposure times to obtain signal 
within the linear range. Films were scanned on a CanoScan 5200F scanner 
(Canon) and band intensities measured using Image J (public domain 
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software). The obtained values were normalized to Ponceau staining quantity 
and expressed as percentage of the basal value registered in the control 
samples (i.e. single transgenic tissues). Mean values were used for statistical 
analysis by Student's t-test. The statistical analysis was done using Prism 4 
for Windows, version 4.03. 
4.6 REAL TIME peR 
4.6.1 Tissue obtainment 
The analysis of mRNA expression was performed on total RNA extracted from 
fresh tissues. Mice were killed upon ethical procedures by decapitation. The 
spinal cord was fluxed from the vertebral column employing sterile 
physiological solution (0.9% NaCI) and sectioned in the cervical, thoracic and 
lumbar tracts. The brain was sectioned, isolating the hippocampus, the 
cerebellum and the cortex. The samples were immediately frozen on dry-ice to 
avoid endogenous RNases to degrade the RNA and stored at -80°C. 
4.6.2 RNA extraction 
Total RNA was extracted using the Trizol method (Invitrogen), purified 
according to the manufacturers' recommendation and resuspended in sterile 
water. 
RNA was quantified by spectrophotometer. Moreover, to check its quality, 2 pg 
of each sample were loaded in electrophoresis gel and 18S and 28S ribosomial 
bands were considered as indicators of RNA integrity. 
4.6.3 DNase I treatment 
Prior to retrotranscription, RNA samples were treated with DNasel 
(Deoxyribonuclease I Amplification Grade, Invitrogen) in order to minimized 
genomic DNA contamination. 
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DNase I treatment was performed upon the manufacturer's instructions: 2 pg 
of total RNA were added to the mix containing IX DNase I reaction buffer and 
2U of DNAse I, in a total volume of 10 pl. The mixture was incubated for 15 
min at RT, then DNase I was inactivated by adding EDTA (pH 8.0) to a fmal 
concentration of 2.5 mM, and heating the sample at 65°C for 10 min. To 
assure that the treatment with DNAse I was efficient, a portion of each sample 
was tested with a qualitative PCR in order to verify possible DNA 
contaminants; this was obtained using the standard conditions described 
above (paragraph 4.1.4) and a set of primers able to amplify the genomic 
sequence of murine SOD2 gene (primer sequences in table 4.2). 
4.6.4 Synthesis of eDNA 
I. eDNA for SYBR Green experiments 
The cDNA used for real time PCR experiments with the SYBR Green chemistry 
was obtained by reverse transcription of total RNA with a Moloney murine 
leukaemia virus reverse transcriptase (MuLV RT) from Gene Amplification RNA 
PCR-core kit (Applied Biosystems, Foster City, CA, USA). It was decided to 
employ oligo d(T)16 to allow retro-transcription of any messenger harbouring 
the polyA tail. Practically, 2 pg of DNase-treated RNA from each sample were 
used as a substrate for cDNA synthesis in a mix containing IX PCR Buffer, 
MuLV reverse transcriptase (2.5 U/pl), RNAsi inhibitor (IU/pl) oligo dT (2.5 
pM), and deoxyNTP (1 mM each) in a fmal volume of 40 )Jl. 
The mixture was stored at RT for 10 min, then incubation was performed in 
the thermocyc1er at 42°C for 15 min, at 99°C for 5 min, and at 4°C for at least 
5 min. 
D. eDNA for TaqMan experiments 
For real-time quantification using the TaqMan technology, it was decided to 
modify the conditions of retro-transcription in order to accomplish the 
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guidelines of the manufacturers for this kind of experiments. Reverse 
transcription was therefore carried out using the High Capacity reverse 
transcription kit (Applied Biosystems): 2 llg of DNase-treated RNA from each 
sample were added in a mix containing IX RT Buffer, Multiscribe MuLV 
reverse transcriptase (1.25 U jp.1), RNAsi inhibitor (1 U jp.1) Random Primers IX, 
and 4 mM deoxyNTP mix in a [mal volume of 40 ~l. 
The mixture was incubated in the thermocyc1er at 25°C for 10 min, at 37°C for 
120 min, and at 85°C for 5 sec. 
III. cDNA quality control 
The quality of the obtained cDNA was tested with qualitative PCR using 
primers able to recognize the transcript of murine SOD2 (sequence in table 
4.2) 
T 
Gene Forward (5 '->3 ') Reverse (5' 3 ') 
annealing 
SOD2 
GGCAGCAGGTGCAGGAGAG GATATCCAAGGGGTCAGGGAG 60°C 
DNA 
SOD2 
TGCACTGAAGTTCAATGGTGG TAGAGCAGGCAGCAATCTGT 56°C 
cDNA 
Table 4.2 Primer sequences for the gene and the transcript of SOD2 
4.6.5 Real time peR with SYBR Green 
For the majority of the transcripts analyzed, the levels of expression of mRNAs 
were determined by real time quantitative PCR, performed with 7300 Real time 
PCR system (Applied Biosystems), exploiting SYBR Green as fluorescent dye. 
In order to reach high efficiency rate of amplification, the steps to optimize the 
reaction of amplification were accomplished according to the manufacturer of 
the real-time PCR instrument. Indeed, amplicon and primer design were 
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achieved by Primer Express software (Applied Biosystems) set with default 
parameters. Thus, the annealing temperature of each primer was restricted to 
58-60°C, which corresponds to the optimal working conditions for the used 
DNA polymerase enzyme (AmpliTaq Gold, Applied Biosystems). 
The specificity of SYBR Green dye for a certain DNA target is entirely 
determined by primers, since this dye binds any double stranded nucleotide 
sequence; for this reason, a dissociation curve analysis (analysis of melting 
temperature profiles) was performed upon completion of each PCR run. 
Moreover, agarose gel analysis was done to further verify the lack of any 
spurious band due to non-specific amplification. 
Real time PCR on cDNA specimens, standards and not-template control (in 
triplicate) was performed in a 25-].11 reaction mixture containing 25 ng of cDNA 
template, IX SYBR Green PCR master mix and specific primers (0.3 IlM each). 
The quantification of the samples was done using the standard scale method; 
the efficiency and reproducibility of the peR were assessed evaluating the 
slope and correlation coefficient of the standard curve. 
The thermocycling proflle used for the amplification is reported below: 
1. 95°C for 10 min 
2. 95°C for 5 sec 
60°C for 1 min 
For 40 cycles 
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4.6.6 Real time peR with TaqMan 
For some transcripts, the evaluation of their levels was done in real time peR 
using the TaqMan technology. The principle of TaqMan reaction is based on 
the use of flu orogenic probes designed to hybridize to the gene target sequence 
of two peR primers. Each probe contains a 5' fluorescent reporter dye and a 3' 
quencher dye; in the intact probe, the presence of the 3' quencher inhibits the 
5' reporter emission. During the extension phase of peR cycling, the annealed 
probe is cleaved by the 5'-3' exonuclease activity of Taq polymerase, thus 
producing an increase in the fluorescence emission of the reporter dye. This 
event occurs in each peR cycle and leads to an increase of fluorescence 
proportional to the initial concentration of target sequences in the sample. 
Real time PeR on cDNA specimens, standards and not-template control (in 
triplicate) was performed in a 20-pl reaction mixture containing 50 ng of cDNA 
template, IX Universal peR master mix and IX mix containing specific 
primers and probe (TaqMan Gene expression assays, Applied Biosystems). The 
quantification of the samples was done using the standard scale method; the 
efficiency and reproducibility of the peR were assessed evaluating the slope 
and correlation coefficient of the standard curve. 
The thermocycling proflle used for the amplification is the same reported 
above for SYBR Green experiments. 
4.6.7 Statistical analysis 
The quantity of the measured transcript was normalized to p-actin quantity 
and expressed as percentage of the basal value registered in the control 
samples (i.e. NTg or single transgenic tissues). Mean values were used for 
statistical analysis by Student's t-test. The statistical analysis was done using 
Prism 4 for Windows, version 4.03. 
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4.7 IN SITU HYBRIDIZATION 
4.7.1 Tissue obtainment 
Mice were killed using ethical procedures by decapitation and brain and spinal 
cord rapidly removed. Tissues were immediately frozen in 2-methylbutane at -
45°C and conserved at -80° until the experiments. 
4.7.2 Slide preparation and pre-hybridization procedure 
Frozen lumbar spinal cords were cut on a cryostat at -20°C and sections (14 
J,lm) mounted on poly-L-Iysine coated microscope slides. Sections were then 
fIxed in 4% para-formaldehyde for 15 min followed by two 10 min incubations 
in PBS, acetylated (0.1 M triethanolamine and 0.25% acetic anhydride in 0.9% 
NaCI), dehydrated through a graded series of ethanol, delipidated for 5 min in 
chloroform, air dried and stored frozen at -SO°C. 
4.7.3 In vitro transcription 
35S-labelled RNA probes were obtained by in vitro transcription (Bendotti et al., 
1990). 
The reaction mixture for the in vitro transcription contained: 1 J,lg of DNA, IX 
transcription buffer, 10 mM dithiothreitol (OTT), 15 U of RNA polymerase, 15 U 
of RNase inhibitor, 0.5 mM ATP, 0.5 mM GTP, 0.5 mM CTP, 10 /lM UTP (all the 
reagent were purchased from Promega) and 2.5 /lM 35S-UTP (1000 Ci/mM; 
Amersham Biosciences, Little Chalfont, Buckinghamshire, UK). Mter 90 min 
incubation at 37°C for T7 or at 40°C for SP6 , the templates were digested with 
1 U of DNase I - RNase free (Promega) for 15 min at 37°C. 
The templates were hydrolysed in mild alkaline buffer (80 mM NaHC03 and 
120 mM Na2HC03) at 60°C to obtain fragments of about 200 base pairs in 
length. The mixtures were neutralized and the 35S-labelled riboprobes were 
purifIed by G-50 Sephadex Quick Spin Columns (Roche, Basel, Switzerland). 
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Probes were diluted to 4000 cpm/I.d with hybridization buffer containing 50% 
formamide, 2X sodium saline citrate buffer (SSC), 10 mM Tris/HCI pH 7.5, IX 
Denhart's solution, dextran sulfate 10%, 0.2% SDS, 100 mM OTT, 500 Jlg/ml 
double-strand Salmon Sperm DNA (Roche). 
4.7.4 Hybridization and post-hybridization procedures 
On the day of the experiment, the slides were brought to room temperature 
and hybridized with the 35S-labelled RNA probes. Sections were incubated 
overnight at 55°C in sealed humidified chambers using Parafllm coverslips. 
Mter hybridization, coverslips were removed and sections were incubated in 
IX SSC for 10 min at RT. Sections were then washed for 30 min at 37°C in 20 
J,lg/J,ll of RNase A in RNase buffer (0.5 M NaCl, 1 mM EDTA and 10 mM 
Tris/HCl, pH 8.0) followed by 30 min at 37°C in RNase buffer alone. Sections 
were then washed in IX SSC for 30 min at RT, O.SX SSC for 30 min at 65°C 
and O.SX SSC for 10 min at RT before dehydrating through a graded series of 
ethanol. The slides were exposed to Beta-max fllm (Amersham Biosciences) for 
7 days, dipped in photographic emulsion (Ilford KS diluted 1: 1 with 0.1% 
Tween 20) and exposed for 15 days at 4°C. Sections were then developed, 
counterstained with cresyl violet and examined by light and dark field 
microscope before the quantitative analysis of the grain density. The specificity 
of the in situ hybridisation for the transcript was verified by the absence of the 
signal using sense radiolabelled probes. 
4.7.5 Image analysis 
Grain density in single cell was quantitatively evaluated using AnaliSYS 
software (Soft Imaging Systems, ver. 3.2). 
Cresyl violet stained cells were used to defme the circular frame outlining the 
cell and the grain density over a single cell was expressed as number of 
grains/Jlm2 cell area. At least two sections from each animal were analyzed 
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and the cells were subdivided on the basis of their size. Mean values of grain 
density for each size category in each animal were used for statistical analysis 
by Student's T -test. The statistical analysis was done using Prism 4 for 
Windows, version 4.03. 
4.8 MATERIAL 
Unless otherwise stated, the reagents used for the experiments were obtained 
from Sigma-Aldrich (Poole, U.K.). 
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CHAPTER V 
EVALUATION OF THE FUNCTIONALITY 
OF THE UBIQUITIN-PROTEASOME PATHWAY 
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5.1 INTRODUCTION 
As already discussed in the second chapter, altered functionality of UPP as a 
pathogenetic event has been proposed in various neurodegenerative diseases. 
Also in the field of ALS research, several studies have evaluated this 
hypothesis. 
5.1.1 Clearance of mutant SOOl by the ubiquitin-proteasome 
pathway 
In a recent study carried out by our group, it was established that the 
accumulation of mutant SOD1 observed in the spinal cord of G93A mice 
during disease progression did not involve changes in the transcription of the 
transgene: mRNA levels were unchanged at ages in which the amount of 
protein was already markedly increased and were even reduced at the final 
stage of the disease, although the protein was still at high levels (Cheroni et 
al., 2005). For this reason, we hypothesised that the accumulation of SODI 
was due to an inhibition of its degradation. Additionally, in agreement to other 
data (Shinder et al., 2001), we found that increased levels of mutant SOD1 
correlated with a decrease of its solubility and with the presence of high 
molecular weight forms. It is known that in vivo the propensity of mutant 
SOD 1 to aggregate is linked to the rate of turnover of native and misfolded 
species by the protein degradation machinery. 
All these data pointed out a possible involvement of alterations of UPP 
functionality in the processes of accumulation and aggregation of mutant 
SOD I. 
Indeed, studying cell lines stable transfected with wild type or mutant SOD 1, 
Hoffman and colleagues verified that the mutation increases the rate of protein 
turnover; however, the half-life of mutant SOD1 could be prolonged by 
blocking the UPP, demonstrating that the mutant protein is degraded by the 
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proteasome (Hoffman et al., 1996; Johnston et al., 2000). These fmdings were 
conf1IlIled also by Urushitani and co-workers (Urushitani et al., 2002), who 
showed that mutant SOD 1 was degraded by the UPP in cultured cells and that 
oxidative damage increased the degree of ubiquitination of the mutant but not 
of the wild type protein. 
Partial inhibition of the proteasome is sufficient to provoke the formation of 
large aggregates in cultured cells that express SOD1 mutants (Johnston et al., 
2000; Hyun et al., 2003), thus suggesting that proteasome activity is limiting 
and its decrease prevents the appropriate removal of the mutant protein 
and/or of other components. In addition, the presence of mutated SOD1 
enhances the vulnerability to proteasome dysfunction: exposure to proteasome 
inhibitors resulted in increased cell death in cell lines expressing mutant 
SODI (Aquilano et al., 2003; Hyun et al., 2003) and, in primary cultures, 
caused the selective death of motor neurons (Urushitani et al., 2002). 
These data are supported by studies carried out in organotypic cultures from 
G93A mice, which demonstrated that the ubiquitin-proteasome system is 
critically involved in the generation of SOD I-positive complexes. In fact, 
treatment of G93A spinal cord slices with proteasome inhibitor induced the 
formation of high molecular weight SOD 1 complexes identical to those 
observed in spinal cord homogenates from symptomatic G93A mice 
(Puttaparthi et al., 2003). This was proved to be a reversible phenomenon, 
given that aggregates could be eliminated after the removal of the proteasome 
inhibitor. From these experiments, proteasomal processing of mutant SOD1 
appeared to be fmely tuned, since also modest perturbations of its activity 
were able to generate aggregates in a short period. 
In a similar experimental paradigm, selective damage and death of motor 
neurons were reported after a short-term exposure (36 and 72 hours) to 
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proteasome inhibitor (Tsuji et al., 2005); however, a longer term treatment 
determined the degeneration of motor neurons and intemeurons in a similar 
amount (Vlug and Jaarsma, 2004). 
Besides the degradation pathway by the 26S complex, it has been shown that, 
at least in vitro, purified SOD 1 in its metal-free form can be degraded directly 
by the 20S proteasome without requiring ATP or ubiquitin; for mutant SOD1, 
the susceptibility to degradation through the 20S particle correlates with the 
amount of structural perturbation caused by the mutation (Di Noto et al., 
2005). Moreover, in a recent work, the use of specific inhibitors has permitted 
to reveal that wild type and mutant SOD 1 are degraded both by the UPP and 
macroautophagy in a comparable percentage (Kabuta et al., 2006). 
In vivo, 20S proteasome activity measured by tluorogenic peptides is reduced 
in adult mouse spinal cord compared to other tissue types, maybe 
contributing to the propensity of SOD 1 to accumulate and form aggregates in 
this region (Puttaparthi et al., 2003). Furthermore, proteasome activity in the 
spinal cord decreases with age (Keller et al., 2000b). 
5.1.2 Interaction of mutant SODI with UPP components 
In ALS patients and mouse models, proteinaceous inclusions are often labelled 
with antibodies that recognize members of the UPP, pointing out their 
potential involvement in ALS. The possible interactions of mutant SOD1 with 
some of these molecules have been investigated more in detail. 
I. DorfiD 
The RING fmger-type E3 ligase dorfm was found localized in inclusion bodies 
in familial and sporadic ALS cases. In cell cultures, dorfm was demonstrated 
to be able to selectively interact with mutant SOD I, promoting its poly-
ubiquitination and degradation and protecting cells against the toxic effects of 
the mutant protein (Niwa et al., 2002). Interestingly, dorfm expression is 
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increased in the spinal cord of sporadic ALS patients (Ishigaki et al., 2002); 
this may suggest an attempt to enhance the clearance of altered proteins. 
U. REDL-l 
NEDL-1 is an HECT-type E3, preferentially expressed in the CNS, that 
physiologically interacts with Trapo, a component of the ER system. In 
neuroblastoma cells, mutant SOD1, but not the wild type enzyme, interacts 
with the NEDL1-Trapo complex, that mediates SOOl ubiquitination. NEOL-1 
is contained in inclusion bodies in the motor neurons of fALS patients and 
SOD1 mutant mice (Miyazaki et al., 2004). 
m. CHIP 
Also the E4 protein CHIP (carboxyl terminus of Hsc-70 interacting protein) is 
localized in the proteinaceous inclusions of G93A mouse spinal cord 
(Urushitani et al., 2004). CHIP is a chaperone-dependent E4 that ubiquitinates 
unfolded proteins, thus representing a link between the chaperone system and 
UPP (Meacham et al., 2001). In cell line paradigms, CHIP, together with 
Hsp/Hsc 70, is able to selectively bind mutant SOD1 and to promote its 
degradation. CHIP over-expression modulates the ubiquitination pattern of 
SOD1, surprisingly increasing the species linked with short ubiquitin chains 
(Choi et al., 2004). Probably, the augmented clearance of SOD1 is mediated by 
the poly-ubiquitination of Hsp/Hsc70 rather than of mutant SOD1 itself 
(Urushitani et aI., 2004). 
IV. SUllO 
SUMO (small ubiquitin-like modifier) is a family of ubiquitin-like proteins; the 
link of SUMO on a lysine residue of the target protein blocks the 
ubiquitination of the same site, resulting in the inhibition of protein 
degradation and in the alteration of its function (Desterro et al., 1998; Huang 
et aI., 2003; Steffan et aI., 2004). Human SOD1 is a substrate of SUMO-I, that 
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modifies the protein on Lys75; SUMO-1 modification of SOD 1 enhances its 
stability and its steady-state level. Furthermore, in a cell culture paradigm, 
over-expressed SUMO-1 increases the aggregation of SOD1 and co-localizes 
onto SOD1 aggregates (Fei et al., 2006). 
V. UCHLI 
Although the interaction of this protein with mutant SOD 1 has not been 
studied so far, depletion of the transcript of the deubiquitinating enzyme 
UCHL1 was found in the motor cortex of patients affected by sporadic AL8 
(Lederer et al., 2007). 
5.1.3 Levels of constitutive proteasome subunits 
In a recent published study, analysing by western blot the spinal cord of G93A 
mice, we found reduced levels of the three constitutive catalytic subunits /31, 
/32 and /35 at the late stage of disease progression. Immunohistochemical 
experiments highlighted a decrease of 20S immunostaining selectively in some 
spinal motor neurons of pre-symptomatic G93A mice; with disease 
progression, a more diffuse and marked decrease of both 208 and 198 was 
observed in ventral and intermediate zones of spinal cord sections and 
correlated with the accumulation of mutant SOD 1 and ubiquitin (Cheroni et 
al., 2005). In line with these [mdings, Kabashi's study reported a decrease of 
20S proteasome (l subunit in motor neurons of symptomatic G93A mice 
(Kabashi et al., 2004). However, some inclusions moderately labelled by the 
antibody recognizing 208 proteasome were reported in the spinal cord of G93A 
and G85R mice (Watanabe et al., 2001). As regards to sporadic human 
samples, the results are contradictory: no inclusions were found 
immunoreactive for proteasome in two studies (Ii et al., 1997; Watanabe et al., 
2001) while Mendoca and colleagues highlighted, in some neurons and 
astrocytes, the presence of areas of intense focal 20S staining, in which the 
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proteasome could be co-localized with aggregates (Mendonca et al., 2006). 
Finally, the proteasome complex was found down-regulated in a microarray 
study on the motor cortex of sALS patients (Lederer et al., 2007). 
5.1.4 Proteasomal activity in in vitro and in vivo models of ALS 
Various studies have tried to analyze the activity of the ubiquitin- proteasome 
pathway in in vitro and in vivo models of amyotrophic lateral sclerosis. 
However, the complex nature of UPP renders the evaluation of its functionality 
a difficult task; in the last years, various methods have been developed to try 
to accomplish it. 
I. Methods for measuring the activity of the ubiquitiD-proteuome 
pathway 
Two are the major approaches that have been used to analyze the activity of 
the UPP: 
1. Small flu orogenic peptides: 
The individual activities of purified proteasome can be quantified with the 
use of synthetic peptide substrates linked to a flu orogenic group, that 
measure the ability of the proteasome present in the tissue extract to 
catabolize an additional substrate load (the flu orogenic peptide). This assay 
is simple and reliable, but it has certain limitations. First, it provides 
information only about the proteolytic process and does not take into 
account upstream events such as ubiquitination, deubiquitination and 
unfolding. Second, flu orogenic substrates cannot be used for the study of 
qualitative variations, such as changes in the subcellular distribution of 
components of the UPP. Finally, this assay does not provide information of 
the functional impairment in vivo or on cell type differences. 
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2. Fluorescent reporter proteins: 
To overcome the above reported limits, several groups have developed 
assays that allow the functional analysis of UPP in vivo. All these reporter 
substrates are based on the targeting of a fluorescent protein for 
proteasomal degradation by the introduction of constitutive degradation 
signals; the latter are defmed as motifs that recruit specific E3s, resulting 
in the ubiquitination and proteasome degradation of the target protein. 
Kopito's group coupled green fluorescent protein (OFP) to the short degron 
CL1, generating the OFPU reporter (Bence et al., 2005). Oantuma's group 
has designed different substrates, among which the Ubo76v-GFP, that is 
constitutively degraded by the ubiquitin-fusion degradation (UFO) pathway 
(Salomons et al., 2005). UFO signal is characterized by the presence of an 
N-terminal ubiquitin moiety that, due to the 076V substitution, cannot be 
cleaved by OUBs; in these circumstances, ubiquitin is recognized as a 
degradation signal, leading to poly-ubiquitination and degradation of the 
UFO-containing protein (Johnson et al., 1992; Johnson et al., 1995). The 
use of fluorescent reporter proteins offers the great advantage to permit the 
evaluation of the global activity of the UPP in vivo and at the cellular level. 
However, also this methodology has its own limitations: frrst, only 
ubiquitin-dependent proteolysis is monitored; moreover, high level 
inhibition of proteasome activity is required to observe a substantial 
increase of OFP fluorescence. Fluorescent reporter proteins have been used 
also for the generation of animal models that allow the study of UPP in the 
contest of different diseases; Ubo76v-OFP mice, that were used in this 
study, have been already described in the method section of this thesis 
(4.1.2). 
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II. The activity of the ubiquitiD-proteasome pathway in models of 
ALa 
Several studies measured the total proteasomal proteolytic activity by 
analysing the hydrolysis of flu orogenic peptides in cell lines transfected with 
mutant SOD1. The results obtained, however, are controversial, since total 
proteasomal activity was found decreased by some investigators (Urushitani et 
al., 2002; Allen et al., 2003; Hyun et al., 2003) and increased by others 
(Casciati et al., 2002; Aquilano et al., 2003). 
Our group used the same technical approach with the purpose to analyse the 
proteasomal catalytic activity in homogenates from the spinal cord of G93A 
mice compared to NTg littermates; the results showed no change of the three 
proteolytical activities (Cheroni et al., 2005). Analysing the spinal cord of late 
onset G93A mice at advanced stage of disease progression, an increase of 
chymotripsin-like and caspase-like activities of the proteasome has been 
revealed (Puttaparthi and Elliott, 2005); similar data were described in G93A 
rats (Ahtoniemi et al., 2007). Conversely, Durham and colleagues reported in 
the lumbar spinal cord of G93A mice a significant decrease in proteasome 
activity already at a pre-symptomatic stage (Kabashi et al., 2004); the 
discrepancy with the other data may rely on the fact that these authors 
focused on the lumbar region of the spinal cord. 
Two recent studies have taken advantage of the reporter proteins for UPP 
activity to analyze the functionality of the entire ubiquitin-proteasome system 
in cell cultures expressing mutant SOD1. Matsumoto and colleagues reported 
increased level of Ubi-YFP reporter in cells containing G85R or G93A 
aggregates (Matsumoto et al., 2005); similarly, the presence of mutant SODI 
in NSC34 cells determined a strong accumulation of the YFPU reporter (Sau et 
al.,2007). 
112 
C!itzpter ~ ~wliuttion of tIie fonctimudity of tlie u6i.quitin-protustmU patfrway 
5.1.5 Link between ER stress and UPP functionality 
The endoplasmic reticulum is the main site of the synthesis of secreted 
proteins. Given the substantial protein load in the ER, it is of great importance 
to promptly eliminate abnormal and potentially hazardous proteins that 
accumulate in this organelle (Bachmair et al., 1986). In fact, there is a tight 
connection between the protein quality control in the ER and the ubiquitin-
proteasome pathway (Aviel et al., 2000): in a process known as ER-associated 
degradation (ERAD), proteins that fail the ER quality control are transported 
back to the cytosol where they are rapidly destroyed by the UPP (Aviel et al., 
2000). Under conditions that negatively affect the environment in the ER, the 
pool of aberrant proteins rapidly increases, resulting in the induction of the 
unfolded protein response (UPR). The UPR is a cellular program which involves 
at least three different mechanisms to re-establish the homeostasis: 
attenuation of protein synthesis, optimization of chaperone-assisted protein 
folding and augmentation of protein degradation (Bachmair et al., 1986). 
Stimulation of translocation of aberrant ER proteins to the cytosol followed by 
UPP-dependent degradation is an integrated part of the UPR and it is 
necessary to relieve the burden of abnormal proteins in the ER (Bachmair et 
al., 1986; Bachmair and Varshavsky, 1989); cells that fail to restore a proper 
ER homeostasis will eventually be eliminated by ER stress-induced cell death 
(Baumeister et al., 1998; Bebok et al., 1998). CHOP, also named GADDI53, is 
a stress transcription factor linked to cell death and controls the transition 
from pro-survival to pro-apoptotic signalling during ER stress (Rutkowski and 
Kaufman, 2004), but its mode of action and its downstream pathways are still 
essentially obscure. With unknown mechanisms, CHOP is able to decrease 
Bcl-2 levels and to provoke glutathione depletion (Oyadomari and Mori, 2004). 
Its regulation is essentially transcriptional: in physiological situations, the 
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protein is expressed at very low levels and localizes in the cytosol; during ER 
stress, CHOP is strongly inducted and accumulates in the nucleus (Oyadomari 
and Mori, 2004). Phosphorylation of CHOP by p38 MAPK is able to enhance its 
transcriptional activity (Wang and Ron, 1996). p38 is a member of a large 
family of serine/threonine kinases that has been implicated in the responses 
to a variety of cellular stresses, including pro-inflammatory cytokines and 
excitotoxicity. A selective accumulation and activation of p38 has recently 
been demonstrated by our group in the spinal motor neurons of G93A mice at 
an early stage of the disease; this effect persisted until the end stage, 
becoming prominent in the reactive glial cells (Tortarolo et al., 2003). 
A recent study has pointed out a subtle effect ofER stress on the functionality 
of UPP (Menendez-Benito et al., 2005). In fact, the administration in cell 
cultures of drugs that act as ER stressor provoked a robust induction of 
CHOP; this phenomenon was accompanied by a modest accumulation of 
Ubo76v-GFP reporter protein for UPP functionality. The effect was about 10% of 
that accomplished by a full obstruction of the pathway, but it could be 
important to detennine an increased sensitivity of the system to other stresses 
(Menendez-Benito et al., 2005). These data suggest that the pressure to keep 
the ER operative while facing large amounts of aberrant proteins may alter the 
UPP functionality, causing a chronic imbalance between generation and 
clearance of misfolded proteins. 
5.1.6 ER stress in ALS 
SOD 1 is an essentially cytosolic protein that lacks organelle targeting 
sequences and is synthesized by free ribosomes (Hirano et al., 1985). 
Nonetheless, recent and surprising data have revealed that both mutant and 
wild type SOD 1 are present also in the ER compartment. It has been shown 
that SOD1 co-localizes with ER markers in COS7 and neuro2A cells (Tobisawa 
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et al., 2003; Urushitani et al., 2006); furthermore, in mice spinal cord, both 
wild type SOD 1 and mutant ones have been identified in the ER, where the 
mutant proteins accumulate during disease progression and form high 
molecular weight species (Kikuchi et al., 2006). How SOD1 is post-
translationally imported within the ER compartment remains enigmatic; also 
the reasons of the physiological presence of SOD 1 in the ER is unclear, 
although one possibility is to form native disulfide bonds before transit to 
other locations. Indeed, the disulfide status of the proteins is largely regulated 
by ER stress-inducible enzymes. Protein-disulfide isomerase (POI) is an ER 
chaperone that catalyzes the formation and rearrangement of intra- and inter-
molecular disulfide bonds (Roth and Koshland, 1981; Turano et aI., 2002). PDI 
was found in association with SOD1 in cellular and animal models of fALS; 
furthermore, the pharmacological inhibition of POI triggered the formation of 
SODI inclusions (Atkin et al., 2006). 
Another important issue regards the consequences of the presence of the 
mutated protein in the endoplasmic reticulum. ER abnormalities have been 
reported in human ALS patients and transgenic mice (Dal Canto and Gurney, 
1995; Engelhardt et aI., 1997); moreover, in the spinal cord of SODI mutant 
mice, UPR-induced chaperones, stress sensor kinases and apoptotic effectors 
are up-regulated. For instance, in low expressor G93A mice, induction of ATF-
3 has been highlighted in the motor neurons at a relatively early stage of 
disease progression (Vlug et aI., 2005); another study, in early onset G93A 
mice, reported an increase of ATF -6 and IRE-l at the symptomatic stage 
(Kikuchi et al., 2006). 
As regards to CHOP, contrary results come from studies on G93A mice, in 
which its expression has been reported both as unchanged (Wootz et aI., 2004) 
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or up-regulated at disease onset in low expressor line (Vlug et al., 2005) and at 
symptomatic stage in high expressor line (Atkin et al., 2006). 
Given these results, it seems possible that, over the course of the disease, 
motor neurons expressing ALS-linked SODI mutants undergo a UPR aimed at 
improving their capacity to withstand the ER accumulation of misfolded 
mutant SOD1; therefore, ER stress may play a role in SODI mediated 
neurodegeneration. 
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5.2 AIMS 
As just discussed, an eminent literature has been produced regarding the 
possible involvement of alterations of the ubiquitin-proteasome pathway in the 
events that lead to motor neuron loss in ALS. However, the obtained data are 
contradictory and neither prove nor exclude a pathogenic role of UPP in the 
disease. 
The first aim of this section was to analyze by immunohistochemistry the time 
course of the accumulation of ubiquitinated proteins in the spinal cord of 
G93A mice during disease progression. Mterwards, I evaluated the activity of 
UPP in the same animal model. To achieve this goal, I took advantage from the 
UbG76v-GFP mouse model, that expresses a reporter protein for UPP activity; in 
this way, it was possible to study the overall functionality of UPP in vivo and at 
the cellular level in G93A mice, thus overcoming the limitations typical of the 
flu orogenic in vitro assays used so far on SOD 1 mutant mice. 
In order to characterize the expression of the reporter protein in the area of 
interest, the fIrst investigations were focussed on the analysis of UbG76v-GFP 
basal levels in the spinal cord of UbG76V_GFP mice and on the confrrmation of 
its accumulation in the motor neurons in response to the administration of 
proteasome inhibitors. Then, the breeding between G93A and UbG76v-GFP mice 
permitted to obtain double transgenic mice; since the presence of UbG76V_GFP 
in the spinal cord of G93A mice may have been a further element of stress for 
motor neurons, the disease progression in double transgenic mice was 
evaluated. Finally, UPP functionality was studied in double transgenic 
GFPG93A mice by assessing the levels of the reporter protein both in the 
homogenate and in the cell populations of the spinal cord. 
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5.3 METHODS 
5.3.1 VVestern blot 
Western blot experiments were conducted in collaboration with Dr. C. 
Maynard and Dr. N. Dantuma (Dept. Cell and Molecular Biology, Karolinska 
Institute, Stockholm, Sweden), according to the general procedures described 
in the paragraph 4.5. 
For the detection of OFP protein, membranes were probed overnight at 4°C 
with an anti-GFP mixed-mouse monoclonal antibody (Roche) diluted 1 :2000 in 
blocking buffer. 
5.3.2 Immunohistochemistry 
I. Experiments of co-localization with ubiquitiD 
Following the general procedures described in the paragraph 4.2, the sections 
were first labelled for ubiquitin (polyclonal antibody from DAKO - Ely, 
Cambridgeshire, UK - diluted 1:750 and incubated for 30' at RT) and the 
signal revealed with the tyramide amplification. Then, the sections were 
incubated with the following primary antibodies: anti-human SOD 1 rabbit 
polyclonal antibody, 1 :2000 dilution (Upstate Biotechnology, Temecula, CA, 
USA); anti-GFAP mouse monoclonal antibody, 1 :2500 dilution (Chemicon 
International, Harrow, UK) to stain the glial fibrillary acidic protein (GFAP); 
anti-CDl1f3 rat monoclonal antibody, 1:1000 dilution (The Chemical Society) 
to label activated microglial cells; anti-choline acetyl transferase (ChAT) mouse 
monoclonal antibody, 1:200 dilution (Chemicon) for co-localization with the 
motor neuronal popUlation. Anti-mouse, anti-rabbit or anti-rat secondary 
fluorescent antibodies were used as described (paragraph 4.2.3). 
If not differently specified, primary antibodies were incubated overnight at 4°C. 
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D. DAB ataiaing of GFP 
The staining was performed as described in the section 4.2.2 using an anti-
GFP rabbit polyclonal antibody (Molecular Probes) diluted 1 :3500. 
m. DAB atalaiag of CHOP 
The staining was performed as described in the section 4.2.2 using anti-CHOP 
rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
diluted 1:200. 
IV. Experiments of co-localization with GFP 
Free-floating sections were first labelled for GFP (rabbit polyclonal antibody 
from Molecular Probes, diluted 1:1000 and incubated for 2 h at 4°C) and the 
signal was revealed by tyramide amplification; then, they were incubated with 
the following primary antibodies: anti-SMI-32 mouse monoclonal antibody, 
1:200 dilution, or anti-SMI-31 mouse monoclonal antibody, 1:5000 (both from 
Sternberger) for co-localization with non-phosphorylated or phosphorylated 
neurofllaments antigens, respectively; anti-GFAP mouse monoclonal antibody, 
1:2500 dilution (Chemicon); anti-CDlll3 rat monoclonal antibody, 1:1000 
dilution (The Chemical Society); anti-calretinin rabbit polyc1onal antibody, 
1: 1000 dilution (Swant, Bellinzona, Switzerland) for co-localization with 
interneurons; anti-NeuN mouse monoclonal antibody (diluted 1:250, 
Chemicon) to stain the neuronal population; anti-ubiquitin rabbit polyclonal 
antibody (form DAKO, diluted 1:100 and incubated for 45 min at RT). Anti-
mouse, anti-rabbit or anti-rat secondary fluorescent antibodies were used as 
already described (section 4.2.3). 
If not differently specified, primary antibodies were incubated overnight at 4°C. 
V. Experiments of co-localization with CHOP 
Free-floating sections were first labelled for CHOP (polyc1onal antibody from 
Santa Cruz, diluted 1 :300) and the signal revealed by tyramide amplification; 
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subsequently, sections were incubated with the following primary antibodies: 
anti-NeuN mouse monoclonal antibody (1:250, Chemicon) to stain the 
neuronal population; anti-GFP rabbit polyclonal antibody (from Molecular 
Probes, diluted 1:500 and incubated for I h. at RT). Anti-mouse or anti-rabbit 
secondary fluorescent antibodies were used as already described (section 
4.2.3). 
If not differently specified, primary antibodies were incubated overnight at 4 D C. 
5.3.3 Real time peR 
Real time PCR for GFP transcript was done exploiting SYBR Green as 
fluorescent dye, as described in the paragraph 4.4, and using ~-actin as 
internal standard. 
In table 5.1 are reported the primer sequences. 
5.3.4 In situ hybridization 
In situ hybridization (ISH) experiments were conducted following the method 
described in section 4.7. Primers specific for GFP (sequence in table 5.2) were 
employed to amplify a 514 bp fragment from GFP mouse cDNA, following the 
standard procedures already illustrated (paragraph 4.1.4). The fragment was 
subcloned in pCDNA3 plasmid. 
The plasmid was linearized with Not I for the antisense and with BamHI for 
the sense and purified. Radiolabelled cRNA were synthesized in vitro from 
linearized plasmid (paragraph 4.5.3), using RNA polymerase T7 for the sense 
and SP6 for the antisense. 
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I Gene II Accession n ° II Forward (5'~ 3') I Reverse (5'~ 3') 
(3-actin (Actb) NM_OO7393 GCCCTGAGGCTCTTIITCCAG TGCCACAGGATTCCATACCC 
GFP M62654 CATGCCCGAAGGCTACGT GCTTGTGCCCCAGGATGT 
Table 5 . 1 Primer sequences for real-time peR experiments 
Gene I Forward (5'~ 3') Reverse (5'~ 3') 
GFP I GCCGGATCCCTTGTACAGCTCGTCCATGC AAGGAAGGCGCGCCCCATGAAGCAGCACGACT . 
Table 5.2 Primer sequences for ISH experiments 
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5.4 RESULTS 
5.4.1 Ubiquitin accumulation in G93A spinal cord during 
disease progression 
The presence of ubiquitinated inclusions is a well-known phenomenon that 
occurs in the spinal cord of SOD1 mutant mice. By immunohistochemical 
techniques, the extension of this phenomenon was analyzed in our mouse 
model during the progression of the disease. In Fig. 5.1 is displayed the 
immunolabelling for ubiquitin and the neuronal marker NeuN in the lumbar 
spinal cord of NTg and G93A mice. In NTg mice, a weak ubiquitin staining 
appears homogenously distributed in the neurons of the ventral horns. In 
G93A sections, rare ubiquitin-positive spots are visible at the pre-symptomatic 
stage in large neurons of the ventral horns and become more numerous as the 
motor impairment aggravates; fmally, at the end stage, a massive increase of 
ubiquitin is found both inside neuronal cells and as large spots spread 
throughout the grey matter. In some cases, neurons with high ubiquitin 
accumulation are characterized by a weak NeuN staining. 
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Figure 5.1 Laser scanning confocal microphotographs of NeuN and ubiquitin labelling in the ventral horn lumbar spinal cord of NTg (A-D) and G93A mice at the pre-symptomatic (E-H), 
symptomatic (I-L) and end stage (M-P) of disease progression. Scale bar 50 ~m (A-C, E-G, I-K, M-O) and 20 ~m (0, H, L, P). In NTg sections, ubiquitin staining is weak and uniform in 
NeuN-positive neurons. In G93A speciments, ubiquitin-positive spots are rarely visible at the pre-symptomatic stage (arrowheads in H) and become more frequent during the progression of 
the disease both in the grey matter (arrows in L, P) and inside neuronal cells (arrowheads in L, P). 
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In order to examine the cellular distribution of ubiquitin and its possible co-
localization with mutant SOD1, triple immunostaining experiments were 
performed in lumbar spinal cord sections of end stage G93A mice in 
comparison to mice that over-express wild type human SOD1 (WT SOD1). 
In WT SOD1 mice, both SOD1 and ubiquitin labelling resulted low and 
uniformly distributed in the neurons of the spinal cord, including the ChAT-
immuno-positive motor neurons (Fig. 5.2 A-E). Conversely, particularly intense 
labelling for SOD 1 was detected in G93A mice at the edge of the vacuoles 
characteristic of the ventral and intermediate regions of spinal cord grey 
matter (Fig. 5.2 arrows in I and M) and in some degenerating motor neurons 
(Fig 5.2 arrowheads in I and L). In the same sections of G93A mice, the 
ubiquitin immunoreactivity showed a pattern of distribution characterised by 
large spots of ubiquitin-positive accumulation scattered throughout the grey 
matter (Fig. 5.2 H-M), which did not co-localise with SOD1, except for very few 
cases. Focussing on ChAT-positive motor neurons of G93A mice, it was 
observed that only occasionally ubiquitin-positive spots were localized in 
vacuolized motor neurons where SOD1 was highly expressed (Fig 5.2 I-M). 
The analysis of SOD1 and ubiquitin in GFAP labelled astrocytes of G93A mice 
showed that hypertrophic astrocytes do not accumulate SOD1; however, some 
GFAP-positive cells characterized by a round morphology display high levels of 
ubiquitin signal (Fig 5.2 N-S). 
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Figure 5.2 Laser scanning confocal microphotographs of S001 , ChAT, GFAP and ubiquitin labelling in the 
ventral hom lumbar spinal cord of WT S001 (A-E) and G93A (F-S) mice at the end stage of disease 
progression. Scale bars 40 11m (A-O, F-I and N-Q) and 20 11m (E, L, M, Rand S). In WT S001 mice, S001 and 
ubiquitin labelling are low and uniformly distributed in ChAT-positive motor neurons (A-E). In G93A sections, 
S001 accumulation is particularly visible on the edge of vacuoles in the grey matter (arrows in I, M) and in some 
motor neurons (arrowheads in I, L), with scarce co-localization with ubiquitin-positive spots. No accumulation of 
S001 occurs in GFAP-positive astrocytes (N-S), while some of them show high ubiquitin levels (O-R). 
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5.4.2. Immunohistochemical analysis of 
distribution in the spinal cord of UbG76v_GFP mice 
UbG76V_GFP 
Both GFP! and GFP2 lines of UbG76v-GFP mice were characterized for the 
presence of the reporter protein in the spinal cord, in order to establish the 
basal levels of UbG76v-GFP in this area. 
Examining the sections from the lumbar spinal cord of GFP! and GFP2 mice, 
no GFP intrinsic fluorescence was detected. Therefore, the analysis of the two 
transgenic lines was conducted by immunohistochemistry using an anti-GFP 
antibody and amplifying the immunostaining by the avidin/biotin 
diaminobenzidine system or the tyramide system for the immunofluorescence. 
The diaminobenzidine labelling revealed differences in the basal level of the 
reporter protein between the two transgenic lines: while in GFP2 mice GFP 
remained undetectable, in GFP! sections the signal was higher and 
distributed in various cell populations in the ventral and dorsal horns of the 
spinal cord; the staining resulted being particularly evident in the motor 
neurons (Fig. 5.3). No differences with age progression were found in both 
GFP! and GFP2 lines. No staining was visible in non-transgenic (NTg) mice. 
Since in GFP2 mice the background level of the reporter protein is lower, this 
line was considered more appropriate to detected possible increases in 
neuronal UbG76v-GFP. However, before using it for the majority of the 
experiments, the accumulation of the reported protein was tested in response 
to UPP inhibition in spinal cord neurons by in vitro studies. 
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Figure 5.3 Microphotographs of GFP labelling in the dorsal and ventral horns of the lumbar spinal cord of NTg (A, B), GFP1 (C-H) and GFP2 (I-N) mice (w = weeks of age). Scale bar 100 
!-1m. No staining is visible in NTg and GFP2 sections, while in GFP1 speciments the signal is visible in various cell populations both of the dorsal and the ventral horns. No changes are 
detectable with age progression in both GFP1 and GFP2 mice. 
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5.4.3 Proteasome inhibition in UbG76v_GFP primary cultures 
Primary cultures were obtained from the spinal cord of NTg and GFP2 embryos 
(14 days), treated with the proteasome inhibitor MG132 0.5, 1.5 or 4.5 J.lM for 
6 h and labelled for SMI-32 and GFP as described in the method section. 
The results achieved showed that, in GFP2 neurons, the administration of 
MG132 was able to determine an increase in the levels of the reporter protein. 
The accumulation of Ub076V_GFP was clearly visible also in neurons 
characterized by intense SMI-32 labelling, large cell body and prominent 
neuritic arborisation, identified as motor neurons (Fig 5.4). 
In conclusion, these experiments have demonstrated that the administration 
of a proteasome inhibitor is able to determine the accumulation of the reporter 
protein in the motor neuronal population of GFP2 embryos. Therefore, the 
GFP2 mouse line was used for the majority of the experiments, although the 
key fmdings were confirmed also in GFPlline. 
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Figure 5.4 Laser scanning microphotographs of GFP and SMI-32 in spinal primary cultures from NTg (A-C) or 
GFP2 (0-0) embryos treated with vehicle (D-F) or the proteasome inhibitor MG132 0.5 !-1M (A-C, G-I), 1.5 !-1M 
(J-L) or 4.5 !-1M (M-O). Scale bar 50 !-1m, insets 20 !-1m. In GFP2 cultures, the inhibition of the proteasome is able 
to provoke an increase of GFP levels; the phenomenon is noticeable also in neurons characterized by an 
intense SMI-32 labelling (arrows in G-O and insets). 
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5.4.4 Cross-breeding of UbG76v_GFP and G93A mice 
Double transgenic GFPIG93A and GFP2G93A lines were established 
according with the procedures reported in the method section (4.1.3). 
The offspring was genotypized for both the transgenes by peR analysis. 
Figure 5.5: Percentage of offspring genotypes in GFP1 G93A (n=300) and GFP2G93A (n=386) lines. 
As shown in Fig. 5.5, the percentage of double transgenic IDlce in both 
GFPIG93A and GFP2G93A lines is lower than the expected 25%. However, the 
statistical analysis by x-square test revealed that the difference was not 
significant (p>O.05). 
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5.4.5 Behavioural analysis of double transgenic mice 
The presence of a transgene coding for a protein that is degraded by UPP could 
represent an additional burden for a system already facing large amounts of 
unfolded proteins; therefore, the expression of UbG76V_GFP in G93A mice may 
be able to modify the disease progression. To investigate this possibility, the 
motor behaviour of double transgenic mice was analyzed. Since GFPl mice 
express higher levels of the reporter protein, this line was selected for the 
behavioural tests. 
Initially, to verify that the solely expression of UbG76v-GFP was not able to 
influence the motor behaviour of the mice, I evaluated GFPl mice in respect to 
NTg littermates (8 animals for each group). As described in the section 4.4, 
starting from 84 days of age, the body weight of the mice was recorded once a 
week; moreover, the motor function of the animals was evaluated using the 
grid test. 
As shown in Fig 5.6 and 5.7, no differences in the body weight nor in the grid 
test were found between NTg and GFPl mice. 
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Figure 5.6 Body weight of NTg (n=8) compared to GFP1 (n=8). Each point represents the mean ± S.E. 
Statistical analysis was done by N-Io-way AN OVA for repeated measures; no significant interaction was found. 
GRID TEST 
100 
90 
80 
70 
iii 
"C 
c: 
60 
0 
u 
~ 50 
-.l-NTg 
-It- CTP1 
CD 40 E 
i= 
3D 
20 
10 
80 90 100 110 120 130 140 150 160 170 180 190 200 
Age (Days) 
Figure 5.7 Grid test of NTg (n=8) compared to GFP1 (n=8). Each point represents the mean ± S.E. Statistical 
analysis was done by N-Io-way ANOVA for repeated measures; no significant interaction was found. 
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Then, with the same approach, GFP1G93A mice (n=13) were evaluated in 
respect to G93A mice (n=13). The decline of the body weight (Fig. 5.8) and of 
the motor function (Fig 5 .9) was not different between G93A and GFP1G93A 
mice; also the survival was unchanged (Fig. 5.10). It can therefore be 
concluded that the progression of the disease in G93A and GFP 1 G93A mice is 
contemporaneous. 
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Figure 5.8 Body weight of G93A (n=13) compared to GFP1 G93A (n=13). Each point represents the mean ± 
S.E. Statistical analysis was done by two-way ANOVA for repeated measures; no significant interaction was 
found. 
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Figure 5.9 Grid test of G93A (n=13) compared to GFP1G93A (n=13). Each point represents the mean ± S.E. 
Statistical analysis was done by rND-way ANOVA for repeated measures; no significant interaction was found. 
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Figure 5.10 Comparison of the survival curves for G93A and GFP1G93A mice. Log-rank analysis of 
probabilities showed no significant difference. 
134 
clUtpter V. ~wUwttion of tIie futJCtimul&ty of tIie u6iquitin-proteasome patnway 
5.4.6 Western blot analysis of UbG76v_GFP in the lumbar spinal 
cord of double transgenic mice 
By western blot, the total levels of the reporter protein were evaluated in the 
lumbar spinal cord of GFPG93A mice in comparison to GFP littermates. 
Western blot experiments were conducted in collaboration with Dr. Maynard 
and Dr. Dantuma (Dept. Cell and Molecular Biology, Karolinska Institute, 
Stockholm, Sweden). 
Regarding the GFP2 line, the levels of the reporter protein were under the 
threshold of detection both in GFP2 and GFP2G93A mice. 
Conversely, in the lumbar spinal cord of both GFPl and GFPIG93A at the 
symptomatic phase, a band corresponding to Ubo76v-GFP was detectable (Fig 
5.11). The quantification of the optical density (Fig. 5.12) revealed an 1.2-fold 
increase in GFPl G93A samples compared to GFPl ones, although the data did 
not reach the statistical significance (p=O.058). 
Therefore, it can be concluded that the presence of mutant SOD 1 does not 
determine obvious changes in the global levels of the reporter protein, thus 
excluding major and generalized alterations of UPP functionality. However, the 
trend to an augment of Ub076V_GFP in double transgenic mice put forward the 
possibility of a dysfunction of UPP occurring selectively in some cell 
populations. 
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Figure 5.11 Representative immunoblot for UbG76V-GFP in the lumbar spinal cord of GFP1 and GFP1 G93A mice 
at the symptomatic stage. 
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Figure 5.12 Quantitative analysis of the immunoblot. The optical density was evaluated for each 
autoradiographic band and values for GFP1 G93A were normalized to GFP1 after correction for protein loading. 
Each histogram shows the mean ± S.E. of at least four mice. Data were analyzed by Student's t-test. A tendency 
to an increase is visible in GFP1 G93A samples, but it does not reach the statistic significance. 
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5.4.7 Immunohistochemical analysis of UbG76V_GFP in the 
lumbar spinal cord of pre-symptomatic GFP2G93A mice 
Western blot data suggest that UPP functionality may be altered selectively in 
particular cell types of the spinal cord. For this reason, immunohistochemical 
experiments were performed on the lumbar spinal cord of double transgenic 
mice at various stages of disease progression. 
In sections from pre-symptomatic G93A mice, an unspecific background signal 
is visible; in GFP2 specimens, the reporter protein remains undetectable, as 
already shown in Fig. 5.3. In pre-symptomatic GFP2G93A, only sporadic cells 
with a mild increase of Ubo76v-GFP, difficult to distinguish from the 
background signal found in G93A sections, are noticeable (Fig. 5.13). 
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Figure 5.13 Microphotographs of GFP labelling in the lumbar spinal cord of pre-symptomatic GFP2 (A, 8), G93A (C, D) and GFP2G93A (E, F) mice. Scale bar 100 11m. No clear 
accumulation of GFP is noticeable in the neurons of double transgenic mice. 
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5.4.8 Immunohistochemical analysis UbG76V_GFP in the spinal 
cord of symptomatic double transgenic mice 
To evaluate whether a dysfunction of UPP could be more evident at later 
phases of disease progression, also symptomatic and end stage double 
transgenic mice were analyzed. 
5.4.8.1 Immunohistochemical analysis of UbG76V -GFP in the lumbar spinal 
cord of symptomatic GFP1G93A and GFP2G93A mice 
Immunohistochemical experiments were performed on the lumbar spinal cord 
of symptomatic GFP2G93A mice in comparison to GFP2 and G93A littermates 
(Fig. 5.14). As already shown, no specific GFP staining is visible in G93A and 
GFP2 sections. On the contrary, in GFP2G93A mice a small number of cells 
with a clear accumulation of the reporter protein is detectable in the grey 
matter; the majority of them are localized in the ventral horns and some show 
morphological alterations such as vacuolization. 
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Figure 5.14 Microphotographs of GFP labelling in the dorsal and ventral horns of the lumbar spinal cord of GFP2 (A, B), G93A (C, D) and GFP2G93A (E-I) mice at the symptomaUc stage 
of disease progression. Scale bar 100 11m (A-F) and 20 11m (G-I). While in GFP2 and G93A secUons no specific staining is visible (A-D), rare cells from GFP2G93A sections display high 
levels of GFP (arrows in F-I). 
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To verify if the observed phenomenon was replicable also in line 1, 
symptomatic GFP1G93A mice were studied in comparison to GFPl and G93A 
littermates. As already highlighted (Fig. 5.3) and shown in Fig. 5.15, in GFP1 
sections the reporter protein is visible in various cell populations of the lumbar 
spinal cord. In GFPl G93A, a stronger GFP signal is noticeable in large cells of 
the ventral horns, similarly to what observed in GFP2G93A line. 
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Figure 5.15 Microphotographs of GFP labelling in the dorsal and ventral horns of the lumbar spinal cord of GFP1 (A, B), G93A (C, D) and GFP1G93A (E-H) mice at the symptomatic 
stage of disease progression. Scale bar 100 IJlll (A-F) and 20 J.lm (G, H). G93A sections display no specific GFP staining, while in GFP1 speciments the reporter protein is localized in 
various cell populations of both the dorsal and the ventral horns. In the ventral horns of GFP1 G93A sections some large neurons with an intense GFP staining are observable (arrows in F-
H). 
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S.4.B.2 Co-localization between UbG76v-GFP staining and neuropathological 
markers in the lumbar spinal cord of symptomatic GFP2G93A mice 
I. GFP and SMI-31 double staining 
With the aim to obtain an estimation of the number of damaged neurons that 
accumulate Ubo76v-GFP, double immunostaining for GFP and SMI-31 was 
performed on serial sections from symptomatic GFP2G93A lumbar spinal cord 
as described in the paragraph 4.2.5. SMI-31 antibody specifically labels 
phosphorylated epitopes of the neurofllaments, whose accumulation in the 
neuronal cell body is considered as a pathological hallmark. Neuronal cells 
were identified by the NeuN marker. 
The co-localization between NeuN, SMI-31 and GFP is shown in Fig. 5.16. In 
sections from GFP2 mice, SMI-31 labelling was never found in the neuronal 
population stained by NeuN; on the contrary, in the ventral horns of both 
G93A and GFP2G93A spinal cord, some neuronal cells resulted stained with 
SMI-31 (arrows in Fig. 5.16). In double transgenic mice, a significant fraction 
of SMI-31-positive cells also displayed an accumulation of Ubo76v-GFP. 
The number of the cells stained only for GFP or double stained for GFP and 
SMI-31 was recorded; the great majority of GFP-positive cells were localized in 
the ventral horns. In table 5.17 A are reported the data obtained analysing the 
ventral horns of 10 sections for each animal (5 GFP2G93A mice examined). As 
visible in the graph, about one third of GFP-positive cells is also SMI-31 
positive. 
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Figure 5.16 Laser scanning confocal microphotographs of NeuN, GFP and SMI-31 in the ventral horn lumbar spinal cord of GFP2 (A-D), G93A (E-H) and GFP2G93A (1-0) mice at the 
symptomatic stage. Scale bar 100!lm (A-L) and 20!lm (M-O). In G93A, but not in GFP2 sections, SMI-31-positive neurons are detectable (arrow in G). In GFP2G93A sections, some GFP-
positive neurons are noticeable (arrow and arrowhead in J); some of these display also SMI-31 accumulation in the cell body (arrows in K-O). 
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Figure 5.17 Quantitative analysis of SMI-31 labelling in the GFP-positive population of the ventral horns of 
symptomatic GFP2G93A lumbar spinal cord. In the table A, the mean represents the total count of positive 
cells in 10 sections for each sample (5 mice analyzed). The graphic B represents, expressed as percentage, 
the total population of GFP-positive cells (green bar, mean ± S.E. of five mice) and the fraction that is also 
SMI-31 positive (orange bar, mean ± S.E. of five mice). 
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II. GFP and ubiquitin double staining 
The same approach was applied also for the co-localization between UbG76V-
GFP and ubiquitin (Fig 5.18). In GFP2 mice, the staining for ubiquitin resulted 
low and uniformly distributed in the neurons of the ventral horns, while in 
symptomatic G93A mice ubiquitin-positive spots were noticeable. In 
GFP2G93A mice, GFP-positive cells frequently displayed also ubiquitin 
accumulation. 
The number of cells stained only for GFP or double stained for GFP and 
ubiquitin was recorded. In Fig. 5.19 A are reported the data obtained 
analysing the ventral horns of 10 sections for each sample (5 GFP2G93A mice 
examined). As shown in the graph (Fig 5.19 B), about a half of GFP-positive 
cells showed also intense ubiquitin staining. 
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Figure 5.18 Laser scanning confocal microphotographs of NeuN, GFP and ubiquitin in the ventral horn lumbar spinal cord of GFP2 (A-D), G93A (E-H) and GFP2G93A (1-0) mice at the 
symptomatic stage. Scale bar 100 flm (A-L) and 20 flm (M-O). Ubiquitin-positive spots are noticeable in G93A and GFP2G93A sections (G, K) , while are absent in GFP2 speciments (C). 
In GFP2G93A samples, GFP-positive cells frequenUy display an intense ubiquitin staining (arrows K-O). 
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Figure 5.19 Quantitative analysis of ubiquitin labelling in the GFP-positive population of the ventral horns of 
symptomatic GFP2G93A lumbar spinal cord. In the table A, the mean represents the total count of positive celis 
in 10 sections for each sample (5 mice analyzed). The graphic B represents, expressed as percentage, the total 
population of GFP-positive cells (green bar, mean ± S.E. of five mice) and the fraction that is also ubiquitin-
positive (orange bar, mean ± S.E. offive mice). 
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S.4.B.3. Analysis of CHOP staining in the spinal cord of G93A and double 
transgenic mice 
As reported in the introduction, it has been shown that a situation of ER 
stress can determine subtle alterations in UPP functionality. For this reason, it 
was assessed if the accumulation of UbG76v-GFP in the spinal cord of 
symptomatic double transgenic mice correlated with the up-regulation of 
CHOP, a marker ofER stress. 
I. Immunohistochemical analysis or CHOP distribution in the 
lumbar spinal cord or G93A mice during disease progreuion 
Initially, the induction of CHOP was analyzed in the spinal cord of G93A mice 
at the pre-symptomatic, symptomatic and end stage. As shown in Fig. 5.20, 
CHOP expression is very low in NTg mice. On the contrary, in G93A mice, 
already at the pre-symptomatic phase is evident the presence of large celis, 
localized in the ventral horns, with intense CHOP staining in the nucleus. 
CHOP-positive cells with similar features are found more frequently in 
symptomatic mice; [mally, at the end stage, also some smaller cells of the 
dorsal horns display CHOP-positive nucleus. 
The results of the DAB staining were confrrmed with the immunofluorescence 
techniques (Fig 5.21), that highlighted an intense CHOP labelling in the 
nucleus of large NeuN-positive cells localized in the ventral horns of G93A 
sections. 
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Figure 5.20 Microphotographs of CHOP labelling in the dorsal and ventral horns of the lumbar spinal cord of NTg (A, B) and G93A mice at the pre-symptomatic (C, 0), symptomatic (E, F) 
and end stage (G, H) of the disease. Scale bar 100 f.lm, insets 20 f.lm. CHOP labelling is weak in the neurons ofNTg sections, while an intense staining is visible in the nucieous of ventral 
hom neurons in pre-symptomatic and symptomatic G93A samples (arrows in 0, F). At the end stage, CHOP-positive cells are noticeable both in the ventral andf dorsal horns (arrows in G, 
H). 
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Figure 5.21 Laser scanning confocal microphotographs of NeuN and CHOP in the ventral hom lumbar spinal cord of NT g (A-D) and G93A mice at the pre-symptomatic (E-H), 
symptomatic (I-L) and end stage (M-P) of the disease. Scale bar 100 11m (A-C, E-G, I-K, M-O) and 20 11m (0, H, L, P). Some large neurons in the ventral hom of G93A mice at various 
stages of disease progression present an intense CHOP staining in the nucleous (arrows in E-P). 
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II. Co-localization between CHOP and UbG76V_GFP in the lumbar 
spinal cord of symptomatic GFPIG93A mice 
Double staining for GFP and CHOP was performed on the lumbar spinal cord 
of symptomatic GFPIG93A mice in order to understand if the accumulation of 
the reporter protein correlates with signs of ER stress. For this experiment, 
GFPl line was chosen for a technical reason, that is the possibility to detect 
UbG76v-GFP signal using a secondary fluorescent antibody; this permitted to 
reveal the CHOP signal using the tyramide amplification. 
As shown in the Fig. 5.22, in GFPIG93A sections the majority of CHOP-
positive cells does not present increased levels of UbG76v-GFP and, reciprocally, 
the cells with augmented GFP are not CHOP-positive. 
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Figure 5.22 Laser scanning confocal microphotographs of GFP and CHOP in the ventral hom lumbar spinal cord of GFP1 (A-C), G93A (D-F) and GFP1 G93A (G-I) mice at the 
symptomatic stage. Scale bar 100 11m. In the ventral homs of both G93A and GFP1 G93A spinal cord, some cells with an intense CHOP-positive nucleous are noticeable (arrows in E, 
H). In double transgenic sections, CHOP and GFP stainings do not co-localize (arrows and arrowheads in I). 
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5.4.9 Immunohistochemical analysis of the spinal cord of end 
stage double transgenic mice 
The levels of the reporter protein were examined by immunohistochemistry 
also in sections from end stage double transgenic mice. 
5.4.9.1. Immunohistochemical analysis of UbG76V -GFP in end stage 
GFP1G93A and GFP2G93A lumbar spinal cord 
DAB staining for OFP was performed on sections from the lumbar spinal cord 
of end stage OFP2093A mice and OFP2 and 093A littermates. Some cells with 
stronger OFP labelling were detected in double transgenic mice; these cells 
were localized in the grey matter of the dorsal and the ventral horns and 
showed a neuronal-like morphology, with a size that, in the majority of cases, 
seemed lower than motor neurons (Fig. 5.23). 
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Figure 5.23 Microphotographs of GFP labelling in the dorsal and ventral homs of the lumbar spinal cord of GFP2 (A, 8), G93A (C. 0) and GFP2G93A (E-I) mice at the end stage of 
disease progression. Scale bar 100 f-lm (A-F), and 20 f-lm (G-I). GFP2 and G93A sections do not present GFP-positive cells. On the contrary, GFP2G93A samples reveal high levels of 
GFP in neuronal-like cells of the ventral and intermediate region of the gray matter (arrows in F-I). 
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To prove if the observed phenomenon was present also in the other transgenic 
line, the lumbar spinal cord of end stage GFPIG93A mice was also analyzed in 
comparison to age-matched GFPl and G93A mice. Like in GFP2G93A mice, 
also in GFPIG93A ones cells with increased levels of UbG76v-GFP were found; 
the morphology of these cells was similar to those observed in GFP2G93A mice 
(Fig. 5.24). 
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Figure 5.24 Microphotographs of GFP labelling in the dorsal and ventral horns of the lumbar spinal cord of GFP1 (A-C), G93A (0, E) and GFP1 G93A (F-I) mice at the end stage of 
disease progression. Scale bar 100 ~m (A, B, 0, E, F, G) and 20 ~m (e, H, I). G93A sections display no GFP staining, while in GFP1 speciments the reporter protein is present in the 
neuronal population of the spinal cord. In GFP1 G93A sections, some small cells with an intense GFP labelling are localized both in the ventral and the dorsal horns (arrows in F-I). 
157 
Cliapter tV, tEwfuation of the functimudity of the u6iquitin-proteasome patmvay 
5.4.9.2. Analysis of the distribution of UbG76v_GFP in the cell populations of 
the lumbar spinal cord of end stage GFP2G93A mice 
In order to describe better the cell types showing the rise of Ubo76v-GFP, 
double immunofluorescence experiments followed by confocal microscopy 
analysis were performed in the spinal cord of end stage GFP2G93A mice. 
I. GI'P and ChAT double atalniDg 
To examine the levels of the reporter protein in the vulnerable cell population, 
a double staining for GFP and the motor neuronal marker choline acetyl 
transferase (ChAT) was performed. As shown in Fig. 5.25, the motor neurons 
display differential levels of UbG76v-GFP, with only rare cells showing high 
quantities of the reporter protein. The majority of GFP-positive cells are not 
ChAT-positive, indicating that, among the cells with accumulation of UbG76V-
GFP, only few motor neurons are present. 
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Figure 5.25 Laser scanning confocal microphotographs of ChAT and GFP in the ventral hom lumbar spinal cord of GFP2 (A-C), G93A (D-F) and GFP2G93A (G-I) mice at the end stage of 
disease progression. Scale bar 100 J..lm. GFP staining is not visible in the ChAT -positive population of GFP2 and G93A sections. In GFP2G93A samples, GFP accumulation occurs in 
some ChAT-positive motor neurons (arrows in G-I). 
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II. GFP and calretbdn double staining 
In order to verify if increased levels of UbG76v-GFP are detectable in other 
neuronal populations besides motor neurons, a double staining for GFP and 
calretinin was performed. Calretinin is a calcium-binding protein that 
specifically labels a sub-population of spinal interneurons. 
As visible in Fig. 5.26, UbG76v-GFP accumulation occurs in some calretinin-
positive interneurons; however, some GFP-positive cells do not co-localize with 
the calretinin staining. 
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Figure 5.26 Laser scanning confocal microphotographs of calretinin and GFP in the ventral horn lumbar spinal cord of GFP2 (A-C), G93A (D-F) and GFP2G93A (G-I) mice at the end 
stage of disease progression. Scale bar 50 flm. Differentially from GFP2 and G93A samples, in GFP2 sections some calretinin-positive neurons display high levels of GFP staining (arrows 
in G-.I). 
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III. GFP and GFAP double staining 
Since in G93A mice at the advanced stage of motor neuron degeneration both 
astrocytes and microglial cells are strongly activated, the levels of UbG76v-GFP 
were examined also in the glial population. Fig. 5.27 shows the 
immunofluorescent staining for GFP and for the glial fibrillary acidic protein 
(GFAP) , which specifically labels the astrocytes. In the spinal cord of GFP2 
mice, GFAP immunoreactivity is weak, while in G93A and GFP2G93A mice 
astrocytes become hypertrophic and intensely immunostained, a sign of their 
activation. However, no co-localization between GFP and GFAP was observed. 
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Figure 5.27: Laser scanning confocal microphotographs of GFAP and GFP in ventral hom lumbar spinal cord of GFP2 (A-C), G93A (D-F) and GFP2G93A (G-L) mice althe end stage of 
disease progression. Scale bar 50 ~m (A-I) and 20 ~m (J-L). GFP labelling reveals the proliferation and hypertrophy of the astrocytic population in the spinal cord of G93A and 
GFP2G93A mice (E, F. H, I). In GFP2G93A sections some neuronal-like GFP-positive celis are noticeable (arrows in G, I, J-L) while no co-localization between GFP and GFAP is 
observed (I-L). 
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IV. GFP and CDlll3 double staining 
A remarkable increase of reactive microglial cells detected by the anti-CDllp 
antibody was also found in the sections from end stage G93A and GFP2G93A 
mice, but GFP immunoreactivity was never localised inside this cell population 
(Fig. 5.28). 
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Figure 5.28 Laser scanning confocal microphotographs of CD11 p and GFP in the ventral hom lumbar spinal cord of GFP2 (A-C). G93A (D-F) and GFP2G93A (G-L) mice at the end 
stage of disease progression. Scale bar 50 flm (A-I) and 20 ~ (J-L). CD11 P labelling reveals a strong activation of the microglial population in G93A (E-F) and GFP2G93A (H-I) 
samples. In GFP2G93A sections. GFP staining is localized inside small neuronal-like cells (arrows in G. I. J-L) and does not co-localize with CD11 p. 
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v. GFP and ubiquitin double staining 
To verify whether the cells with increased UbG76v-GFP undergo a general 
accumulation of ubiquitinated proteins, a double labelling for ubiquitin and 
GFP was performed. Large spots of ubiquitin deposits are noticeable in the 
sections of G93A and GFP2G93A samples (Fig. 5.29). In double transgenic 
mice, most of the GFP-positive cells display high levels of ubiquitin. 
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Figure 5.29 Laser scanning confocal microphotographs of GFP and ubiquitin in the ventral hom lumbar spinal cord of GFP2 (A-C) , G93A (O-F) and GFP2G93A (G-I) mice at the 
end stage of disease progression. Scale bar 50 ~m (A-I) and 20 ~m (J-L). Ubiquitin-positive spots are easily noticeable in G93A and GFP2G93A sections (E, F, H-L). In double 
transQenic samples, ubiquitin accumulation is visible in GFP-positive cells (arrows in G-L). 
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5.4.10 Immunohistochemical analysis of UbG76v_GFP in the 
brain of GFP2G93A mice 
To evaluate whether the accumulation of the reporter protein was restricted to 
the lumbar spinal cord or involved also other areas of the eNS, the brain of 
double transgenic mice was analyzed at various phases of disease progression. 
I. Pre-symptomatic GFP2G93A mice 
DAB staining for GFP in the brain of pre-symptomatic GFP2G93A did not 
reveal any difference in comparison to GFP2 or G93A mice. 
U. Symptomatic GFP2G93A mice 
Also in the brain of symptomatic GFP2G93A mice, no GFP signal was revealed 
(Fig. 5.30). Only in one sample out of five, rare GFP-positive cells were found 
in the brainstem. 
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Figure 5.30: Microphotographs of GFP labelling in the brain of GFP2 (A-D), G93A (E-H) and GFP2G93A (I-L) mice at the symptomatic stage of the disease. Scale bar 500 flm. No 
specific GFP staining is visible in GFP2, G93A and GFP2G93A brain sections. 
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UI. End stage GFP2G93A mice 
Analyzing the brain of GFP2G93A mice at the end stage of disease progression, 
the levels of the reporter protein were found undetectable in most of the 
regions. However, a stronger signal was clearly visible in the brain stem, where 
it was particularly evident in neuronal-like small cells of the nuclei trigemini 
and facialis (Fig. 5.31). 
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Figure 5.31: Microphotographs of GFP labelling in the brain of GFP2 (A-D), G93A (E-H) and GFP2G93A (I-N) mice at the end stage of disease progression. Scale bar 500 11m (A-
L) and 20 11m (M, N). The GFP signal is not detectable in the brain of GFP2 and G93A mice, while GFP-positive cells are present in the brainstem of GFP2G93A sections (arrows 
in L-N). 
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5.4.11 Measurement of UbG76v _GFP transcript in double 
transgenic mice 
5.4.11.1 Rea/-time peR experiments 
For changes in Ub G76v-GFP protein levels to be an accurate measure of UPP 
activity, alterations in protein production must be minimal relative to those in 
protein degradation; for this reason, experiments were performed in order to 
evaluate the levels of UbG76V_ GFP transcript by real time PCR. Real-time PCR 
data on the lumbar spinal cord and hippocampus of GFPG93A mice in 
comparison with GFP littermates are reported in Fig. 5.32. 
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Figure 5.32 Real-time peR for UbG76V-GFP transcript in the lumbar spinal cord and hippocampus of GFPG93A 
mice and GFP littermates at the symptomatic or end stage of disease progression. Data were normalized versus 
J3-actin and expressed as percentage of the value of the GFP. Each histogram shows the mean ± S.E. of at 
least five mice. Data were analyzed by Student's t-test (** p<O.01 compared to GFP). 
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At the symptomatic stage, no differences were detected between GFP and 
double transgenic mice in both GFPl and GFP2 line; on the contrary, at the 
end stage in the spinal cord of both GFP2G93A and GFPIG93A mice, UbG76V-
GFP transcript resulted significantly increased in respect to GFP littermates. 
The phenomenon was restricted to the pathological area, since no changes 
were detected in the hippocampus. 
5.4.11.2 In situ hybridization experiments 
Real time peR revealed an increase of UbG76V_GFP mRNA in double transgenic 
mice at the end stage and no changes at the symptomatic phase. However, in 
order to evaluate the quantity of the transcript at the cellular level, an in situ 
hybridization approach was employed. 
In Fig. 5.33 are shown representative images of sections from NTg, GFP2 and 
GFP2G93A mice in which the in situ hybridization for GFP was performed. A 
clear accumulation of grains, higher than the background signal visible in 
NTg, is noticeable in the cells of GFP2 and GFP2G93A samples, indicating the 
specificity of the probe for the UbG76V_GFP mRNA. 
The graph (Fig. 5.34) reports the levels of UbG76V_GFP transcript, quantify as 
grain density, localized in small (100-250 J.IlIl2 of area) and large cells (>250 
J.l.ml of area, that could be in part considered as large motor neurons) of the 
ventral horn in the lumbar spinal cord of GFP2G93A mice compared with 
GFP2 littermates. At the symptomatic phase, no significant rise of the 
transcript was noticeable in the large cells of GFP2G93A mice, while 
augmented levels were detected in the small cells. At the end stage, the density 
of silver grains resulted significantly increased in both small and large cells; 
moreover, it was registered a relevant increase in the number of small cells, 
probably glia, with a signal higher than the background. 
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Figure 5.33 Microphotographs of ISH for UbG71iV-GFP on sections from the lumbar spinal cord of NTg (A). GFP2 
(8) and GFP2G93A mice at the symptomatic (e) or end stage (D) of the disease. 
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Figure 5.34 Quantification of the grain density in cells from the ventral horn lumbar spinal cord of GFP2 and 
GFP2G93A mice at the symptomatic or end stage of the disease, Each histogram shows the mean ± S,E, of five 
mice. Data were analyzed by Studenfs t-test (* p<O.05, ** p<O.01 . *** p<O.001 compared to GFP). 
To visualize better the population of cells in respect to the measured grain 
density, the data are represented also as frequency of cells with increasing 
values of grain density (Fig. 5.35, 5.36, 5.37, 5.38) . At the end stage, as well as 
for small cells at the symptomatic stage, a shift toward higher values is clearly 
visible in double transgenic mice for a consistent fraction of cells. On the 
contrary, for symptomatic motor neurons, only very sporadic GFP2G93A cells 
with a mild increase of UbG76V_GFP mRNA are detectable in one sample out of 
the five analyzed. 
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Figure 5.35 Frequency of 1 00-250 ~m2-l arge cells with various levels of grain density in the lumbar spinal cord 
of symptomatic GFP2G93A mice compared to GFP2 littermates, 
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Figure 5.36 Frequency of >250 ~m 2-large cells with various levels of grain density in the lumbar spinal cord of 
symptomatic GFP2G93A mice compared to GFP21ittermates, 
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Figure 5.37 Frequency of 100-250 11m 2..large cells with various levels of grain density in the lumbar spinal cord 
of end stage GFP2G93A mice compared to GFP2 littermates, 
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Figure 5.38 Frequency of >250 11m2-large cells with various levels of grain density in the lumbar spinal cord of 
end stage GFP2G93A mice compared to GFP2 littermates, 
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5.5 DISCUSSION 
As described in the introduction of this chapter, the presence of inclusion 
bodies of aggregated and ubiquitinated proteins is a well known feature of the 
motor neurons of ALS patients and murine model of the disease; moreover, it 
is known that both mutant SODI and ubiquitin accumulate in the spinal cord 
of G93A mice during disease progression (Cheroni et al., 2005). 
Analysing by immunohistochemistry the lumbar spinal cord of G93A mice, I 
observed increasing amounts of ubiquitin-positive deposits as the motor 
dysfunction progresses, with massive presence of inclusions of ubiquitinated 
proteins scattered throughout the grey matter at the end stage. It was noticed 
that, sometimes, the neurons with higher ubiquitin accumulation showed a 
weak labelling of the neuronal marker NeuN. In fact, it has been reported that 
NeuN staining can be decreased (for a reduction of its levels or loss of 
antigenicity) in stressful conditions such as cerebral ischemia (Unal-Cevik et 
al., 2004) and axotomy (McPhail et al., 2004); therefore, its loss can be 
considered a sign of cellular suffering. As a consequence, it could be possible 
that the accumulation of ubiquitin in the neuronal population was 
underestimated for the lack of NeuN immunostaining. 
With the purpose to verify the possible co-localization between ubiquitin and 
mutant SOD 1, triple immunostaining experiments for SOD 1, ubiquitin and 
ChAT or GFAP were done at the end stage of disease progression. However, 
only sporadically the signals of SODI and ubiquitin appeared to be overlapped 
in motor neuronal cells; in astrocytes, in which ubiquitin inclusions were 
occasionally detected, SOD 1 levels were not found increased (Basso et al., 
2006). Proteomic analysis carried out in collaboration with the Proteomic Unit 
of our institute on the detergent insoluble portion of G93A end stage spinal 
cord demonstrated that mutant SOD 1 is partially mono- and oligo-
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ubiquitinated (Basso et aI., 2006); on the contrary, poly-ubiquitinated mutant 
SOD 1 does not accumulate in the insoluble portion. It is possible that poly-
ubiquitinated SOD 1 is instead present in the soluble fraction, or that, when 
the mutant protein reaches the poly-ubiquitinated state, it is rapidly degraded 
by the proteasome. On the other hand, it has been demonstrated that 
proteasome degradation of mutant SOD I can occur, at least in part, 
independently from direct poly-ubiquitination: for example, CHIP has been 
reported to mediate the degradation of mutant SOD 1 by the ubiquitination of 
associated Hsp/Hsc 70 (Choi et aI., 2004; Urushitani et aI., 2004). 
Even if the mutant SOD1 does not accumulate in a poly-ubiqitinated insoluble 
form, the formation of deposits of ubiquitinated proteins is a clear hallmark of 
the pathology in SOD1 mutant mice. The most probable reason that could 
explain such phenomenon is an aItered functionality of the ubiquitin-
proteasome pathway. 
Various studies have tried to anaIyze the activity of the ubiquitin-proteasome 
pathway in in vitro and in vivo models of ALS. So far, contradictory results 
have been obtained probing the homogenates of G93A spinaI cord with 
flu orogenic peptides, that, as already discussed, can give information only on 
the proteolytic activity of the 208 proteasome (Kabashi et aI., 2004; Cheroni et 
al., 2005; Puttaparthi and Elliott, 2005; Ahtoniemi et aI., 2007). For this 
reason, we decided to face the problem with a more direct approach, and 
particularly using Ubo76v-GFP mouse model, that allow an in vivo evaIuation of 
the overall functionality of the ubiquitin-proteasome system, after the cross-
breeding with G93A mice. Ubo76v-GFP model has already been used to 
demonstrate that proteasome impairment does not contribute to the 
neurodegeneration in a mouse model of 8CA7 (Bowman et aI., 2005) and to 
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detect a functional UPP dysfunction in prion-infected mice (Kristiansen et al., 
2007). 
Immunohistochemical analysis of the basal levels of the reporter protein in 
GFPi and GFP2 spinal cord revealed differences between the two lines; GFP2 
mice were considered more appropriate to detect possible increases of the 
reporter protein, so this line was used for the majority of the analyses. 
Experiments on GFP2 primary cultures confirmed the accumulation of the 
reporter protein in response to proteasome inhibition in the spinal motor 
neurons. 
The analysis of body weight, motor function impairment and survival in 
GFP1G93A mice compared to G93A did not show any differences. Therefore, 
the presence of a transgene coding for a protein that must be degraded by the 
'UPP does not modify the time course of the motor decline in the G93A model. 
Since disease progression is contemporaneous in G93A and GFPG93A mice, 
the levels of the reporter protein in double transgenic samples were analyzed 
at the same end points established for G93A. 
Western blot measure of UbG76v-GFP in the lumbar spinal cord of double 
transgenic mice did not reveal substantial changes of the reporter protein at 
the symptomatic stage of the disease, thus excluding a major and generalized 
impairment of UPP functionality. However, a trend to an increase was detected 
in double transgenic mice, suggesting that a UPP dysfunction may occur 
selectively in specific cell populations. 
In fact, while in sections from the lumbar spinal cord of double transgenic 
mice at the pre-symptomatic stage there was not a clear increase of the 
reporter protein, at the symptomatic stage a few GFP-positive cells were found 
and were identified prevalently as large neurons of the ventral horns. These 
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data were confirmed both in GFP! G93A and GFP2G93A mice, thus excluding 
a possible line-specific effect. 
Interestingly, co-localization studies on serial sections demonstrated a partial 
association between the presence of the reporter protein and markers of 
neurodegeneration, such as ubiquitin deposits and perikaryal accumulation of 
phosphorylated neurofllaments. The connection between increased levels of 
the reporter protein and accumulation of ubiquitin strengthen the hypothesis 
of UPP alterations in these cells. In addition, it was observed that sometimes 
cells with high levels of Ubo76v-GFP were characterized by a weak NeuN 
staining. All these indications point out that the accumulation of the reporter 
protein occurs prevalently in damaged cells. 
At the end stage of the disease, GFP-positive cells were more numerous and 
localized both in the ventral and dorsal horns. Co-localization experiments 
revealed increased levels of Ub076V_GFP in neuronal but not in glial cells, in 
association with the presence of ubiquitin deposits; however, only few motor 
neurons resulted GFP-positive. 
In the brain, an augment of Ub076V_GFP was detected only at the end stage in 
the motor nuclei of the brainstem, thus further demonstrating the association 
with the pathology. As already noticed at the same stage for the spinal cord, 
also in the brain stem GFP staining was noticeable prevalently in small 
neuronal-like cells. 
To assure that the increased levels of Ubo76v-GFP were due to an inhibition of 
its degradation and not to a change in its production, the transcription of the 
transgene was monitored. Real-time peR experiments in the lumbar spinal 
cord of GFPG93A mice highlighted no changes at the symptomatic stage, while 
augmented mRNA levels were detected at the end stage selectively in the 
lumbar spinal cord. When mRNA levels were measured at the cellular level by 
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in situ hybridization experiments, a clear increase of UbG76v-GFP mRNA was 
registered in both small cells and motor neurons of the ventral horns from end 
stage mice. The transcriptional induction of the transgene renders it difficult 
to evaluate if this is the only phenomenon that determines the increase of the 
reporter protein or if an alteration of the degradation contributes to it. 
Conversely, at the symptomatic stage, motor neuronal cells did not show 
significant increase of UbG76V_GFP mRNA, demonstrating that the augmented 
levels of the reporter protein detected in these cells are due to an inhibition of 
its degradation. 
At the end stage, the rise of UbG76v-GFP transcript observed in double 
transgenic mice appears to be a phenomenon strictly related to the pathology, 
since it occurs selectively in the lumbar spinal cord and not in the 
hippocampus. It could be speculated that this event reflects generalized 
pathological changes in the transcriptional machinery; however, in the motor 
neuronal population, at the end stage of the disease a marked degree of 
transcriptional repression has been found (Ferraiuolo et al., 2007). On the 
other hand, it could not be excluded a selective induction of the transgene due 
to the action of cytokines or other signalling pathways activated during the 
disease progression. In fact, the CMV promoter, whose enhancer is present in 
UbG76V-GFP construct, could be induced by TNFa through NFkB transcription 
factor (Ramanathan et al., 2005). 
At the symptomatic and, even more evidently, at the end stage of the disease, 
an increase in UbG76v-GFP mRNA was noticed in a consistent number of small 
cells, among which probably glia. However, UbG76v-GFP protein was never 
found increased in astrocytes and microglia, thus suggesting that, 
differentially from neurons, they are able to get rid of even large amounts of 
proteasome substrates. 
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Stage of disease 
progression 
Symptomatic 
stage 
End stage 
-: no co-localization 
+: rare co-localization 
++: frequent co-localization 
Marker 
Ubiquitin 
SMI-31 
CHOP 
ChAT 
Calretinin 
GFAP 
CDllb 
Ubiquitin 
+++: very frequent co-localization 
Co-Iocaliza tion 
with UbG76V_GFP 
+++ 
++ 
-
+ 
+ 
-
-
+++ 
Table 5.3: Co-localization of UbG76V_GFP with various markers in the spinal 
cord of GFPG93A mice at the symptomatic or end stage of disease progression. 
Table 5.3 recapitulates the co-localization studies carried on on double 
transgenic mice. In summary, the analysis of the protein and mRNA levels of 
UbG76v-GFP reporter points out a subtle dysfunction of the ubiquitin 
proteasome pathway in the lumbar spinal cord of double transgenic 
symptomatic mice. This rmding is in agreement with what observed by Sau 
and colleagues, that described increased levels of the YFPu reporter for UPP 
functionality in NSC34 cel1lines expressing mutant SOD1 (Sau et al. , 2007). 
Even if high levels of UbG76v-GFP were noticeable only in a fraction of the 
vulnerable cell population, this phenomenon could be relevant in the context 
of a chronic neurodegenerative disease, in which the pathological changes and 
the loss of the motor neurons are dispersed in a long time span. 
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The detection of GFP staining required the use of amplification techniques, 
indicating that the accumulation of the reporter protein was not massive; this 
moderate rise of UbG76v-GFP suggests a mild dysfunction of UPP rather than a 
complete block of the system. However, even subtle perturbations of UPP could 
alter the appropriate protein turnover, especially in cells dealing with mutant 
and aggregation-prone proteins or exposed to other stresses. Indeed, it has 
been demonstrated that the presence of mutant SOD 1 increases the 
vulnerability to proteasome dysfunction (Aquilano et ai., 2003; Hyun et ai., 
2003). Moreover, a partial inhibition of the proteasome is sufficient to provoke 
the accumulation and aggregation of mutant SOD1 in cell cultures (Johnston 
et al., 2000; Hyun et al., 2003) and in organotypic slices from G93A spinal 
cord (Puttaparthi et al., 2003). 
The dysfunction of the ubiquitin-proteasome pathway may be due to a 
decrease of 20S levels or catalytic activity. In support to this hypothesis, a 
marked decline of constitutive 20S staining was observed in the motor 
neurons of G93A mice during disease progression (Kabashi et al., 2004; 
Cheroni et al., 2005). Also the catalytic activity of 208 proteasome was found 
diminished in lumbar spinal cord homogenates of the same model (Kabashi et 
ai., 2004). However, it is important to remind that UbG76v-GFP requires to be 
poly-ubiquitinated and recognized by the 268 complex to be degraded. 
Therefore, a failure in other steps of this process, like the availability of free 
ubiquitin, the action of ubiquitinating enzymes, the delivery of the substrate to 
the proteasome and the functionaiity of 198 subunit may be involved. 
The decline of UPP activity probably contributes to the accumulation and 
aggregation of mutant 80D 1 and ubiquitinated proteins that occurs during 
disease progression (Cheroni et al., 2005). Moreover, since it is known that 
UPP functionality can be impaired by protein aggregates (Bence et ai., 2001), a 
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negative feed-back mechanism could arise. Given the fundamental role of the 
ubiquitin-proteasome system in the regulation of the cells homeostasis, its 
dysfunction could have profound consequences on cell physiology, altering the 
levels of a variety of proteins, such as chaperones, transcription factors and 
key regulatory proteins. 
The selectivity of the involvement of the spinal cord in the described 
phenomenon could be related to the reduction of 20S catalytic activity found 
in this region as compared to other disctrlcts (Puttaparthi et al., 2003). 
Furthennore, in organotypic cultures, motor neurons are more sensitive to a 
short tenn proteasome inhibition than the other cell types (Tsuji et al., 2005). 
It has been demonstrated that mild alterations of UPP function could be linked 
to ER stress (Menendez-Benito et al., 2005). CHOP-positive large neurons were 
visible in the ventral horns of G93A spinal cord already at the pre-
symptomatic stage and their number increased with the worsening of the 
motor dysfunction. Nevertheless, at the symptomatic stage, no co-localization 
between CHOP and GFP was found. Therefore, ER stress maybe an early event 
in the processes of motor neuron degeneration produced by mutant SOD 1. In 
fact, it has been demonstrated that mutant SOD 1 could accumulate and 
aggregate in the ER (Kikuchi et al., 2006) and ER abnonnalities have been 
reported in human patients and in the murine model (Dal Canto and Gurney, 
1995; Engelhardt et al., 1997). Furthennore, various studies have reported the 
presence of markers of ER stress in SODI mutant mice (Vlug et al., 2005; 
Atkin et aI., 2006; Kikuchi et al., 2006). Nonetheless, the induction of CHOP 
and the dysfunction of the UPP, detectable as UbG76v-GFP accumulation, 
appear not to be contemporaneous events. 
In conclusion, this is the fIrst study that demonstrates in vivo an impainnent 
of the ubiquitin-proteasome pathway in a mouse model of ALS. Even if subtle, 
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this dysfunction could contribute in the events that determine the motor 
neuron degeneration in G93A mice. While the motor neurons may suffer from 
an impairment of UPP activity, the glial cells appear able to eliminate large 
amounts of proteasome substrate. 
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CHAPTER VI 
ROLE OF THE INDUCTION 
OF THE IMMUNOPROTEASOME 
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6.1 INTRODUCTION 
In a recent study, analyzing by western blot the levels of proteasome subunits 
in the spinal cord of end stage G93A mice, we observed that the decrease of 
20S constitutive catalytic subunits ~1, ~2 and ~5 was mirrored by an increase 
in their inducible counterparts LMP2, LMPI0 and LMP7 (Cheroni et al., 2005). 
These fmdings were confirmed by Puttaparthi and colleagues in G93A low 
expressor mice (Puttaparthi and Elliott, 2005) and Ahtoniemi and colleagues 
in G93A rats (Ahtoniemi et al., 2007). 
While constitutive proteasomes are typical of tissues and cell types with a low 
immunological activity (Rock et al., 1994), immunoproteasomes are especially 
expressed in lymphoid organs (Eleuteri et al., 1997; Cascio et al., 2001). As 
regards to the CNS, in physiological situations constitutive proteasome is 
predominant; however, immunoproteasome can be up-regulated in activated 
microglia (Stohwasser et al., 2000). Moreover, although the levels of MHC class 
I and II are very low in the normal CNS parenchyma, neuronal injury leads to 
a massive increase of these molecules on the activated microglia (McGeer et 
al., 1989; Kaur and Ling, 1992), which can serve as competent antigen-
presenting cells (Ford et al., 1996; Dangond et al., 1997). Traditionally, it was 
thought that neurons did not express MHC class I molecules and were unable 
of presenting antigens to CD8+ T-cells (Joly and Oldstone, 1992); however, 
more recent studies in developing CNS have revealed a functional and highly 
ordered expression of MHC I, suggesting a role in brain development and 
neuronal plasticity (Corriveau et al., 1998; Huh et al., 2000; Oliveira et al., 
2004). Furthermore, MHC I expression is reported increased in motor neurons 
and glia of aged rat spinal cords (Edstrom et al., 2004). 
A rise of LMP2 and LMP7 was found in cortical pyramidal neurons of a 
conditional mouse model of Huntington's disease (Diaz-Hernandez et aI., 
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2003). The authors suggested that this may be a common feature of 
degenerative processes characterized by the accumulation of protein 
aggregates, as a compensatory mechanism of the affected neurons trying to 
counteract the decreased clearance of proteins, or alternatively as a response 
to pro-inflammatory cytokines released by activated glia. However, it is still 
unknown whether the capacity of the inducible proteasome to degrade 
disease-related aggregates is distinct from the constitutive proteasome, as well 
as it is unclear the effect of the substitution of constitutive with inducible 
subunits on the CNS physiology. 
As regards to ALS, immunohistochemical studies in the spinal cord of animal 
models revealed that the augmented signal for LMP7 co-localizes with 
astrocytic and microglial markers (Ahtoniemi et al., 2007; Puttaparthi et al., 
2007). In NSC-34 cells expressing mutant SOD1, a decrease of LMP7 (but not 
LMP2) and increase of 135 protein levels was found; moreover, RT-PCR in both 
NSC-34 cells and motor neurons from human fALS samples confirmed the 
LMP7 decline (Allen et al., 2003). In another cell model (PCI2 cells), LMP2 co-
expressed with G85R mutant resulted sequestered into SOD 1 aggregates 
(Matsumoto et al., 2005). 
Various experiments have been done to try to explain the mechanisms 
involved in the induction of immunoproteasome levels and its importance 
during the progression of motor dysfunction in SODI mutant mice. In 
organotypic spinal cord slice cultures from both G93A and NTg mice, the 
administration of TNFa. or IFNy was able to induce LMP2 and LMP7 , 
suggesting an important role played by cytokines. Indeed, IFNy treatment has 
been demonstrated to induce the immunoproteasome in microglia (Stohwasser 
et al., 2000). Dysregulation in various cytokines, among which TNFa. and IFNy, 
has been found in G93A spinal cord (Hensley et al., 2002). 
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The treatment of G93A rats with the anti-inflammatory drug pyrrolidine 
dithiocarbamate determined an earlier onset of the disease and a decrease of 
the survival (by 15%) in the treated group. This effect was accompanied by 
increased levels of ubiquitinated proteins and by the prevention of the 
induction of LMP7 during disease progression (Ahtoniemi et al., 2007). 
However, largely due to the non-specificity of the drug, this study did not 
provide a definitive answer to the importance of immunoproteasome induction 
on disease course. Using a genetic approach, Puttaparthi and colleagues 
cross-bred G93A mice (low expressor line) with LMP2 knock out mice. Knock 
out mice lacking LMP2, LMPIO or LMP7 subunits are viable, show modest 
reduction in proteasome activity as well as in immunological function but do 
not manifest neurological deficits (Van Kaer et al., 1994; Stohwasser et al., 
2000; Martin et al., 2004). The loss of LMP2 in G93A mice determined a mild 
decrease in proteasome function in spinal cord and a compensatory induction 
of LMP7, but did not significantly impact motor function or survival 
(Puttaparthi et al., 2007). 
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6.2 AIM 
The aim of this section of experiments was the investigation of the role of the 
shift from constitutive proteasome to immunoproteasome in G93A mice. 
In order to evaluate a possible transcriptional regulation, the levels of the 
transcripts for constitutive and inducible J3 catalytic 208 subunits, as well as 
an u non catalytic subunit, were examined in the spinal cord of G93A mice at 
different stages of disease progression. To complete the information about the 
entire 268 complex, I analyzed also components of the 198 and 118 particles 
and the proteasome maturation protein POMP, whose presence is important 
for the correct assembly of the proteasome complex. 
It is known that the increment of immunoproteasome occurs following 
changes in the cytokine network, which may result from glia activation. 
Therefore, I measured the transcript levels of TNFu and of markers of the glial 
population (GFAP for astrocytes and CD68 for phagocytic cells). Finally, since 
immunoproteasome is involved in the antigenic presentation, I investigated the 
presence of CD8+ lymphocytes. 
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6.3 METHODS 
Real time peR experiments were perfonned exploiting SYBR Green as 
fluorescent dye or using TaqMan assays, as described in the paragraphs 4.4.5 
and 4.4.6. 
In table 6.1 are reported the primer sequences used in SYBR Green 
experiments or the number of the chosen TaqMan Gene Expression Assays. 
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Gene II Accession n ° II Forward (5'~ 3') II Reverse (5'~ 3') 
~-actin (Actb) NM_OO7393 GCCCTGAGGCTcrnTCCAG TGCCACAGGATTCCATACCC 
~1 subunit of 20S (Psmb1) NM_Oll185 TAATTGGCTGCAGTGGTTTCC AAGCGCCGTGAGTACAGGAT 
~2 subunit of 20S (Psmb2) NM_01l970 GATGAAGGACGATCATGACAAGAT TGGGAGACAATTCATATCCATTCC 
~5 subunit of 20S (Psmb5) NM_Ol1186 CGCAGCAGCCTCCAAACT GAAGGCGGTCCCAGAGATC 
LMP2 subunit of 20S (Psmb9) NM_013585 TAGCTGACATGGCCGCCTA TGGTCCCAGCCAGCTACTATG 
LMP7 subunit of 20S (Psmb8) NM_010724 AAGGATGAACAAAGTGATCGAGATT TGCTGCAGACACGGAGATG 
LMPI0 subunit of 20S (Pmsbl0) NM_013640 GGAACCCACAGGAGGCTTCT GTCCGCTCCCAGGATGACT 
a 5 subunit of 20S (Psma5) NM_Ol1967 AGTCCTCGCTCATCATCCTCA ACGGCTCCTTCTTAAATGTCCTT 
S 1 subunit of 19S (Psmd 1) NM_027357 TGTTGGATAATCCAGCACGAGT GGTTCCACGAGTTCTTCAACGT 
a Subunit of lIS (Psme1) NM_011189 GGCTTCCACACGCAGATCTC TCTCCATGACCATCAGACGG 
POMP NM_025624 GTGTGCTCAGCATAGTTGCCTG AGCTTTGCTATAACCTCAGAACCAC 
CD8 a chain (Cd8a) NM_OO108111O CTATTCAAACCACTGCCGCAG CCGAGGTTCGACCTGACATTAC 
I Gene II Accession n ° II TaqMan Gene expression assay n ° I 
~-actin (Actb) NM_OO7393 4352341E 
GFAP NM_010277 Mm00546086_ID 1 
CD68 NM_OO9853 MmOO839636~1 
TNF a NM_013693 Mm00546086_ffi 1 
Table 6 . 1: Primer sequences and TaqMan Gene Expression Assay number for real-time peR experiments 
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6.4 RESULTS 
6.4.1 Measure of the transcript levels of 265 proteasome 
components 
To obtain information about the rate of transcription of various components of 
the 26S complex in G93A mice during disease progression, the following 
transcripts were measured: constitutive catalytic (31, (32 and (35 subunits of 
20S particle; inducible catalytic LMP2, LMP10 and LMP7 subunits of 20S 
particle; non-catalytic 0.5 subunit of 20S particle; non-ATPAse S 1 subunit of 
the base of 19S complex (homolog of S. Cerevisiae Rnp2); a. subunit of lIS 
complex; POMP protein. 
I. Pre-symptomatic stage 
In the lumbar spinal cord of G93A mice prior to symptom onset, no changes 
were found for the catalytic subunits of the 20S proteasome (Fig. 6.1 and 6.2), 
nor for the non-catalytic 0.5. However, both Sl subunit of 19S and a. subunit 
of 11S resulted significantly decreased (Fig. 6.3). 
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Figure 6.1 : Real-time peR for (35, (31 and (32 transcripts in the lumbar spinal cord of pre-symptomatic G93A 
mice and NTg littermates. Data were normalized versus (3-actin and expressed as percentage of the value of the 
NTg. Each histogram shows the mean ± S.E. of at least four mice. Data were analyzed by Student's t-test. 
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Figure 6.2: Real-time peR for LMP7, LMP2 and LMP10 transcripts in the lumbar spinal cord of pre-symptomatic 
G93A mice and NT 9 littermates. Data were normalized versus f3-actin and expressed as percentage of the 
value of the NTg. Each histogram shows the mean ± S.E. of at least four mice. Data were analyzed by Student's 
t-test. 
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Figure 6.3: Real-time peR for as subunit of 20S, S1 subunit of 19S, a subunit of 11 S and POMP transcripts in 
the lumbar spinal cord of pre-symptomatic G93A mice and NTg littermates. Data were normalized versus 13-
actin and expressed as percentage of the value of the NTg. Each histogram shows the mean ± S.E. of at least 
four mice. Data were analyzed by Student's t-test (* p<O.OS compared to NTg). 
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II. Symptomatic stage 
At the symptomatic stage, the mRNA levels of catalytic constitutive 20S 
proteasome subunits were not different between the lumbar spinal cord of 
G93A and NTg littermates (Fig. 6.4). On the contrary, LMP7 and LMPIO 
transcripts were found significantly up-regulated in G93A (Fig 6.5), while the 
non-catalytic a. subunit was decreased (Fig 6.6). 
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Figure 6.4: Real-time peR for [35, [31 and [32 transcripts in the lumbar spinal cord of symptomatic G93A mice 
and NT g littennates. Data were nonnalized versus [3-actin and expressed as percentage of the value of the 
NTg. Each histogram shows the mean ± S.E. of at least four mice. Data were analyzed by Student's t-test. 
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Figure 6.5: Real-time PCR for LMP7, LMP2 and LMP10 transcripts in the lumbar spinal cord of symptomatic 
G93A mice and NT g littermates. Data were normalized versus l3-actin and expressed as percentage of the 
value of the NTg. Each histogram shows the mean ± S.E. of at least four mice. Data were analyzed by Studenfs 
t-test (** p<0.01 compared to NTg). 
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Figure 6.6: Real-time PCR for as subunit of 20S, S1 subunit of 19S, a subunit of 11 S and POMP transcripts in 
the lumbar spinal cord of symptomatic G93A mice and NTg littermates. Data were normalized versus l3-actin 
and expressed as percentage of the value of the NTg. Each histogram shows the mean ± S.E. of at least four 
mice. Data were analyzed by Student's t-test (* p<O.OS compared to NTg). 
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III. End stage 
The analysis of the transcript levels in the lumbar spinal cord of G93A mice at 
the end stage of disease progression in comparison to NTg littermates revealed 
a general tendency to a decrease of the constitutive subunits and to an 
increase of the inducible counterparts. The data reached the statistical 
significance for pS, PI and LMP7 transcripts (Fig 6.7 and 6.8) . Also the levels 
of 19S and POMP were decreased (Fig 6.9) . 
These changes were restricted to the pathological area, since no alterations 
were detected in the hippocampus (PS , LMP7, as and 19S tested). 
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Figure 6.7: Real-time peR for P5, P1 and P2 transcripts in the lumbar spinal cord and hippocampus of end 
stage G93A mice and NTg littermates. Data were normalized versus p- actin and expressed as percentage of 
the value of the NTg. Each histogram shows the mean ± S.E. of at least four mice. Data were analyzed by 
Studenfs t-test (** p<O.01 compared to NTg) 
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Figure 6.8: Real-time PCR for LMP7, LMP2 and LMP10 transcripts in the lumbar spinal cord and hippocampus 
of end stage G93A mice and NTg littermates. Data were normalized versus p-actin and expressed as 
percentage of the value of the NTg. Each histogram shows the mean ± S.E. of at least four mice. Data were 
analyzed by Student's t-test (* p<0.05 compared to NTg). 
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Figure 6.9: Real-time PCR for a5 subunit of 20S, S1 subunit of 19S, a subunit of 11 S and POMP transcripts in 
the lumbar spinal cord and hippocampus of end stage G93A mice and NT g littermates. Data were normalized 
versus p-actin and expressed as percentage of the value of the NTg. Each histogram shows the mean ± S.E. of 
at least four mice. Data were analyzed by Student's t-test (* p<0.05 compared to NTg). 
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6.4.2 Measure of the transcript levels of glia and 
immunological markers 
To investigate whether the induction of immunoproteasome correlates with 
alterations of the immuno-inflammatory sys tem, the levels of the pro-
inflammatory cytokine TNFa were measured in the lumbar spinal cord of 
G93A mice. The presence of astrocytic cells (evaluated by GF AP marker), of 
phagocytic cells (CD68-positive cells) and of T lymphocytes (evaluated by CD8 
marker) was also investigated. 
The results showed that, already at the pre-symptomatic stage, TNFa, CD68 
and GFAP were up-regulated in transgenic mice (Fig. 6.10). The phenomenon 
became remarkably prominent with the progression of the disease (Fig. 6 .11, 
6.12). On the contrary, changes of CD8 level were never found (Fig 6. 10, 6.11, 
6 .12). 
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Figure 6.10: Real-time PCR for TNFa, GFAP, CD6B and COB transcripts in the lumbar spinal cord of pre-
symptomatic G93A mice and NTg littennates. Data were nonnalized versus fJ-actin and expressed as 
percentage of the value of the NTg. Each histogram shows the mean ± S.E. of at least five mice. Data were 
analyzed by Studenfs t-test (* p<O.05 compared to NTg). 
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Figure 6.11: Real-time PCR for TNFu, GFAP, CD68 and CD8 transcripts in the lumbar spinal cord of 
symptomatic G93A mice and NTg littennates. Data were nonnalized versus l3-aclin and expressed as 
percentage of the value of the NTg. Each histogram shows the mean ± S.E. of at least five mice. Data were 
analyzed by Studenfs t-test (** p<O.01 , *** p<O.001 compared to NTg). 
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Figure 6.12: Real-time PCR for TNFu, GFAP, CD68 and COB transcripts in the lumbar spinal cord of end stage 
G93A mice and NTg littennates. Data were normalized versus l3-actin and expressed as percentage of the 
value of the NT g. Each histogram shows the mean ± S.E. of at least five mice. Data were analyzed by Student's 
I-test (*** p<O.001 compared to NTg). 
201 
clUtpter 'J/J: qu,fe of tlie indUction of tIie immunoprote4some 
6.5 DISCUSSION 
Real-time PCR experiments on the lumbar spinal cord of G93A mice compared 
to NTg littermates revealed no changes in the levels of 20S proteasome 
catalytic constitutive subunits UH, ~2 and ~5) at the pre-symptomatic and 
symptomatic stage of the disease, while a decrease was detected at the end 
stage. These data are in agreement to what found in a recent study for the 
protein levels (Cheroni, 2005). The reduction of constitutive proteasome could 
not be only ascribed to the loss of motor neurons, that is relevant already in 
the symptomatic phase. Indeed, a decline of the immunolabelling for 208 
constitutive proteasome was registered in the spinal motor neurons of G93A 
with the progression of the motor dysfunction (Cheroni et al., 2005). 
Unlike for the constitutive subunits, a significant up-regulation of LMP7 and 
LMP10 is present already at the symptomatic stage in the lumbar spinal cord 
but not in a non-vulnerable area such as the hippocampus. Since mutant 
SOD1 is over-expressed both in the spinal cord and the hippocampus, it 
appears clear that this effect is strictly associated with pathological features. 
Moreover, these data, for the fIrst time, permit to conclude that the changes in 
the protein levels of constitutive and inducible 20S catalytic subunits revealed 
by our and other groups (Cheroni et al., 2005; Puttaparthi and Elliott, 2005; 
Ahtoniemi et al., 2007) are regulated at transcriptional level. 
The mechanisms that control the transcription of constitutive subunits of 20S 
proteasome are poorly understood; it is believed that the various subunits are 
transcripted in a coordinated fashion and that can be induced in stress 
situations through the antioxidant response element (Kwak et al., 2003a; 
Kwak et al., 2003b). On the other hand, it is well known that inducible 
proteasome can be up-regulated in response to inflammatory cytokines 
(Bochtler et al., 1999). Among the inducible subunits, LMP7 showed the 
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strongest induction, with a 2.5-fold increase in the lumbar spinal cord of 
symptomatic and end stage G93A mice compared to NTg littermates. Since the 
induction of the other subunits was more limited, it is possible that mixed 20S 
particles formed. In fact, the presence in the CNS not only of homogeneous 
immunoproteasome, but also of heterogeneous particles incorporating LMP7 
but not LMP2 and LMP10 has been reported (Griffm et al., 1998; Piccinini et 
al., 2003). However, at the moment, the specific properties and biological 
functions of heterogeneous immunoproteasome are not known. 
As regards to the non-catalytic a5 subunit, a modest decrease was observed in 
all the disease stages analyzed, and reached the statistical significance at the 
symptomatic phase. Since the various 20S subunits must assembly in 
stochiometric amounts, it is possible that the scarcity of non catalytic 
subunits is limiting in the process of building new proteasome particles, even 
when the rate of transcription of catalytic subunits is not affected. Moreover, 
at the end stage, also POMP results diminished of about 20% in respect to NTg 
littermates; given its role in the biogenesis of 20S proteasome, the decrease in 
its levels could be a further element that contributes to reduce the availability 
of assembled proteasomes. 
The S1 non-ATPase subunit of 19S and the a subunit of lIS resulted mild 
diminished already at the pre-symptomatic phase, being the first detectable 
change. The decrease in 19S correlated with immunohistochemical data 
(Cheroni et al., 2005), which revealed reduced levels in the ventral horns of 
G93A spinal cord. Since 19S is necessary for the physiological degradation of 
ubiquitinated proteins, its reduction could have consequences on UPP 
functionality; however, it has been reported that a minority of proteins could 
be degraded directly by 20S proteasome (Orlowski and Wilk, 2003). More 
puzzling appears to be the change in 11 S, that behaved differentially from the 
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other inducible components of the UPP. Although 118 is known to enhance 
the ability of 208 to hydrolyze small peptides in vitro (Ma et al., 1992), its in 
vivo function has not been unravelled yet. 
In parallel with the up-regulation of LMP7, I have found an increase of TNFa 
already at the pre-symptomatic stage; the induction became prominent during 
disease progression (6-fold increase compared to NTg littermates). These data 
are in line with other studies (Elliott, 2001; Ishigaki et al., 2002). It is known 
that TFNa is able to determine an up-regulation of LMP7 in the astrocytes and 
microglia of both NTg and G93A spinal cord slices (Cheroni et al., 2005; 
Puttaparthi and Elliott, 2005; Ahtoniemi et al., 2007); therefore, the increase 
of TNFa is probably contributing to the induction of the immunoproteasome in 
G93A spinal cord. 
GFAP and CD68 were found increased in transgenic mice already at the pre-
symptomatic stage, when proliferation of glia is difficult to reveal by 
immunohistochemistry. CD68 is a Lamp protein expressed on phagocytic cells 
and could be considered as a marker of monocytes, macrophages, activated 
microglia and dendritic cells; its rise is the most relevant, since at the end 
stage a 12-fold increase in its levels could be detected. These data confrrmed 
the increase of C68 transcription revealed both in SOD1 mutant mice (Henkel 
et al., 2006) and in ALS patients (Henkel et al., 2004); in the latter case, 
CD68-positive cells were found to densely infiltrate both the white and the 
grey matter regions of the spinal cord (Graves et al., 2004). 
Since there is a strong correlation between LMP7 up-regulation and massive 
increase of glial markers in a phase of disease in which the motor neurons are 
dying, it appears highly probable that, differently of what has been reported for 
Huntington's disease (Diaz-Hernandez et al., 2003), in mutant SOD1 model 
the induction of immunoproteasome takes place in the glial popUlation. The 
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literature confirms this view for LMP7 (Puttaparthi and Elliott, 2005; 
Ahtoniemi et al., 2007), while no data are to date available for the other two 
subunits; therefore, at the moment, the localization of LMPI0 and LMP2 is not 
known and it is not possible to totally exclude an involvement of the motor 
neuronal population. 
As antigen-presenting cells, microglia is known to normally express 
immunoproteasome and to further up-regulate its subunits after activation 
(Stohwasser et al., 2000); for this reason, it is possible that these cells are 
involved in starting an immune response against modified proteins. This 
scenario would require the influx of CD8+ T-Iymphocytes specific for the 
antigens presented on the surface of the microglia; however, by real time PCR, 
no changes of CDB transcript were found in the spinal cord of G93A mice. 
In ALS patients, the influx of peripheral lymphocytes is a rare event only 
associated with end stage of the disease (Kawamata et al., 1992; Graves et al., 
2004; Zhang et al., 2005). The presence of CDB+ cytotoxic T cells has never 
been investigated before in the mouse model; immunohistochemical studies 
performed by Alexianu and colleagues (Alexianu et al., 2001) revealed the 
sporadic presence of a small number of CD3+ T cells only at the end stage. 
Therefore, even if it is not possible to exclude the infiltration of rare cells not 
detectable by real time PCR due to sensitivity limitations, it can be concluded 
that, unlike macrophagic cells, CD8+ lymphocytes seems not to playa relevant 
role in immune-inflammatory reaction observed in SOD 1 mutant mice. 
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CHAPTER VII 
CONCLUSIONS 
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The main focus of this thesis was to unravel the role of the ubiquitin-
proteasome pathway in the mechanisms that lead to motor neuron 
degeneration in the G93A mouse model of ALS. 
The expression of UbG76V_GFP reporter of UPP functionality made it possible to 
identify subtle alterations of the ubiquitin-proteasome system in the spinal 
cord of G93A mice in the symptomatic phase, mainly in the motor neuronal 
population. Even if a generalized and total impairment of the UPP was never 
observed, it is important to consider that a not completely efficient UPP could 
represent a critical weakness for cells that are dealing with large amounts of 
misfolded and aggregation-prone proteins. 
Accumulation of the reporter protein was never detected in the glial 
population, even in presence of augmented mRNA levels. It is possible that the 
capability of the glial cells to preserve a full functioning UPP is related to their 
capacity to induce the immunoproteasome. In fact, the measure of transcript 
levels revealed a decrease of constitutive proteasome subunits and an increase 
of their inducible counterparts in the lumbar spinal cord of G93A mice during 
disease progression; the changes in proteasome composition were 
accompanied by a substantial increase of glial markers and TNFa. 
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